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Summary
Carbon monoxide (CO) is an important signalling messenger in mammalian cells 
as it participates in a variety of physiological processes including vessel tone 
regulation. Dr. Motterlini’s group has discovered a new class of molecules which 
have the ability to carry and deliver CO to physiological systems. These 
molecules were termed CO-releasing molecules (CO-RMs) and they are an 
excellent tool to investigate the biological role of CO in the vasculature and other 
systems.
The major focus of the research presented in this report was to evaluate the effects 
of different water soluble CO-RMs on vascular tone. For this purpose, an aortic 
ring preparation model was used to assess the vasodilatory properties of CORM-3 
and CORM-A1, the first two water-soluble CO-RMs to be identified, and the 
cellular targets involved in this effect. CORM-3 is a transition metal carbonyl that 
liberates CO very rapidly (t^=l-5 min) in physiological solutions, whereas 
CORM-A1 is a boron-containing carbonate with a much slower rate of CO release 
(b*=21 min at pH=7.4). In the current studies CORM-3 induced a rapid 
endothelium-dependent vasorelaxation, whereas CORM-A1 elicited gradual 
endothelium-independent vasorelaxation. The inactive form of both CO-RMs, in 
which CO has been deliberately depleted, did not exert vasorelaxation indicating a 
direct involvement of CO liberated from the compounds in the observed 
vasorelaxation. The vasorelaxation induced by both molecules was enhanced and 
attenuated by an activator and inhibitor of guanylate cyclase (sGC), respectively. 
CORM-3-mediated vasorelaxation was completely abolished by non-selective 
inhibitors of potassium channels (K+), and partially attenuated by inhibition of 
ATP dependant ( K a t p )  potassium channels. In contrast, CORM-A1-mediated
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vasorelaxation was partially attenuated by non selective inhibition of K+ and by 
inhibition of voltage dependent (Ky) potassium channels. Even at concentrations 
higher than that used to induce significant vasorelaxation, both CO-RMs had no 
noticeable effect on the viability of rat aortic smooth muscle cells (A7r5) in vitro. 
CORM-319, a new water soluble iron containing CO-RM, also induced 
significant vasorelaxation and was relatively safe to cultured SMCs compared to 
other non-water soluble iron containing CO-RMs that were extremely toxic. In 
summary, our data reveal that the CO-RMs examined in this project are promising 
CO carriers that could be further modified for optimal therapeutic applications. In 
addition, our data demonstrate the significant effect imposed by the chemical 
structure and kinetics of CO release on the pharmacological activity of various 
CO-RMs.
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KC1: potassium chloride
Kiri inward rectifier K+ channels
Kv: voltage sensitive K+ channels
L-NAME: A^-nitro-L-arginine-methyl ester
NANC: neurally evoked nonadrenergic noncholenergic relaxation
NO: nitric oxide
NOS: nitric oxide synthase
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ORD: oxygen radical disease
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PDGF: platelet derived growth factor
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1 Introduction
1.1 Historical background on carbon monoxide: old enemy or new friend?
Carbon monoxide (CO), a gas with a bad reputation, has been known for a very 
long time. Aristotle is attributed with the first recognition of CO toxicity in the 
third century BC when he described it as “Coal fumes lead to heavy head and 
death” (Morse and Sethi, 2002). In the 19th century a French physician, Leblanc, 
established Aristotle’s observation by identifying CO as the toxic molecule in coal 
gas (Morse and Sethi, 2002). The formation of CO in the body was demonstrated 
in 1952 by Sjostrand, who reported that decomposition of haemoglobin in vivo led 
to CO production (Sjostrand 1952; Marks et al, 2002 a). In 1968 haem oxygenase 
(HO), the enzymatic source of CO was identified (Tenhunen et al., 1968), and 
later on two isoforms of the haem oxygenase enzyme (HO-1 and HO-2) were 
purified and identified in rat liver (Maines et al., 1986). Haem oxygenase-1 (HO- 
1), the inducible form, and haem oxygenase-2 (HO-2), the constitutive form, 
cleave and oxidize the a-methene bridge of the haem molecule giving rise to 
equimolar amounts of biliverdin, CO and iron (Maines et a l ., 1997).
CO is a tasteless, colourless, odourless gas; some physical characteristics of this 
gas are shown in Table 1.1 (Piantadosi et al., 2002; Ryter and Otterbein, 2004). 
CO is usually generated by the incomplete combustion of organic matter such as 
propane, coal, natural gas, wood and gasoline (Ryter and Otterbein, 2004). The 
average global levels of CO in the atmosphere are estimated to be 0.19 parts per 
million (ppm). 90% of this gas comes from natural sources including ocean 
microorganism generation and the remaining part is produced by human activity 
(Motterlini et al., 2002b).
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Physical properties of CO
Molecular Weight 28.01
Boiling Point -191.5 °C
Melting Point -205 °C
Solubility (H20) 3.3 ml 100 m l1 @0°C
2.3 ml 100 m l'1 @ 20 °C
Density (vapour) 0.968 air = 1
1.250 g L 1 @0°C
1 ppm = 1.25 mg m 3 at 25 °C
Specific Gravity
Conversion Factor
T ab le  1.1: Physical properties of CO (adapted from Ryter and Otterbein. 2004).
Carbon monoxide has been considered as the most common lethal poison in every 
community yet studied, and accounts for more morbidities than all other non­
prescribed poisons combined (Raub et al. 2000.; Gorman et al., 2003). The 
toxicity of CO is attributed to its high affinity for haemoglobin as the affinity of 
haemoglobin to CO is 240 times that for O2  (Morse and Sethi, 2002; Omaye,
2002). In addition, the CO haemoglobin ligand on any one of the four oxygen 
binding sites of the haemoglobin molecule prevents oxygen at other sites of 
haemoglobin from being easily released to peripheral body tissues (Morse and 
Sethi, 2002; Omaye 2002). As a consequence the haemoglobin dissociation curve 
is shifted to the left and tissue hypoxia is further exacerbated. CO also binds to 
and inhibits the activities of other haemoproteins such as cytochrome c oxidase, 
cytochrome P450 and myoglobin, although this inhibitory effect would be likely 
to occur at very high levels of CO exposure (Morse and Sethi 2002; Ryter and
18
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Otterbein, 2004).
Interestingly, over the last few years evidence has accumulated showing that HO 
enzymes and their by-products, particularly CO, are important factors in cellular 
metabolism. Thirteen years ago after tracking the story of CO and comparing it to 
nitric oxide (NO) gas, Barinaga predicted that CO would provide a research 
interest to fully occupy laboraties in future (Barinaga et al., 1993). If the interest 
of the scientific community can be estimated by the number of publications 
dealing with a particular subject, then the prediction of Barinaga surely turned out 
to be true (Morse and Choi 2002) (Figure 1.1).
0 ) 0 ) 0 ) Q > 0 ) 0 > 0 ) 0 ) 0 ) 0 ) O O O O O Oo> o> o> o> o> o> o  o> o> o> &  &  &  &  &N K K K K K N N N . K  C\j ( y  ( y  <y ( y
Year
Figure 1.1. Number of publications concerning HO-1 catalogued by PubMed 
from 1990 to 2005 (adapted from Morse and Choi 2002).
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1.2 The Haem Molecule
The haem molecule plays many crucial biological functions (Wagener et al., 
2003). It interacts with various inactive apo-haem proteins yeilding 
functional haem proteins such as haemoglobin, myoglobin, cytochromes, 
catalases and peroxidases enzymes. Additionally, haem itself may influence 
the expression of many genes and regulates differentiation and proliferation 
of various cell types (Wagener et al., 2003). On the other hand, excess of 
free haem molecule can cause cell damage and tissue injury since haem 
catalyzes the formation of reactive oxygen species (ROS), which cause 
oxidative stress. Therefore, the HO system is a crucial defence mechanism 
against free haem-mediated oxidative stress (Wagener et al., 2003).
A brief review of the structure of the haem molecule will provide the basis 
to understand the nature of HO enzyme (Figure 1.2). The term haem refers 
to a complex of metal ions (e.g, Fe, Mg, Zn, Cr, and Ag) chelated in a 
porphyrin ring; the porphyrin ring is protoporphyrin IX (Maines et al., 
1988). However, the term haem is used to refer to the iron complex of such 
chelates. Porphyrins, in which a metal ion is chelated, are cyclic 
tetrapyrroles in which the four pyrrole rings are attached through four meso 
(methane) bridges labelled a, (3, y, and 8. The capacity of chelated metal 
ions to undergo a reversible change in the oxidation state (e.g., Fe2+±T Fe3+) 
makes haem compounds effective biological catalysts (Maines et al., 1988). 
Several types of haem which differ in the composition of the side chains of 
the pyrrole rings have been identified in nature. Haem type b identified in 
higher animals is the most ubiquitous and comprises the prosthetic moiety 
of all haem-proteins except cytochromes type a and c. Haem a and c form
20
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the prosthetic moiety of cytochromes a and c respectively (Maines et 
al, 1988).
1 2
5 3F e ' » 7/
4 3
Haem Molecule
Figure 1.2 Structure of protoporphyrin IX (Haem b). (adapted from Maines 
et al.91997)
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1.3 The Haem Oxygenase System
HO is the rate limiting enzyme in the catabolism of haem (Maines et al, 1988). It 
breaks down the porphyrin ring to yield equimolar amounts of biliverdin, free iron 
(Fe2+) and CO (Figure 1.3). Biliverdin is then rapidly converted into bilirubin by 
biliverdin reductase (Maines et al, 1988). The HO system requires the activity of 
microsomal NADPH-cytochrome P450 reductase, which transfers an electron 
from NADPH to haem, and utilizes molecular oxygen for cleavage of haem. HO 
specifically cleaves the a-methene bridge of the haem b molecule (Maines et al, 
1988; Maines et al, 1992).
HAEM
M V o 2 H *0
M
<8>
HAEM
P M
B iliv erd in
H H H
NADPH♦ H’
^ilirubirx
m v mi_ p p m m v
D J J l l T i
O N  N  s  '  N N OM H H H
Figure 1.3. Products of haem degradation by haem oxygenase enzyme 
(adapted from Durante et al., 2003).
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In mammals three isoforms of HO proteins have been identified. The first 
isoform, now known as HO-1, was first described in 1969 (Tenhunen et al., 
1968). Later on, the second isoform, now known as HO-2, was purified and 
identified (Maines et al., 1986; Trakshel et al., 1986). The third isoform (HO-3), 
was identified around eight years ago (McCoubrey et al., 1997). HO-3 has been 
found only in rats and it has been proposed that it could have originated from 
retrotransposition of the HO-2 gene (Scapagnini et a.,. 2002). In contrast to other 
two HO isoenzymes, HO-3 is a poor haem catalyst and it is unlikely to work as 
haem degrading enzyme but it might be involved in haem binding (McCoubrey et 
al., 1997). Because HO-3 has no reported biological activities and it is not 
expressed in humans (Abraham and Kappas. 2005), the general referral to “HO 
system” in the current project will be addressed to the HO-1 and HO-2 isoforms. 
The two isozymes, HO-1 and HO-2, are exclusively localised in the endoplasmic 
reticulum and they are mainly positioned in the smooth endoplasmic reticulum 
(Maines et al., 1992). To express their activity they require the concerted activity 
of NADPH-cytochrome P-450 reductase. The two isozymes represent different 
gene products and share little similarity in either amino acid sequences, 
composition, transcript number or size (Cruse and Maines, 1988; Maines et al., 
1997). HO-2, the larger of the two, has a molecular weight -36,000 whereas HO- 
1, also known as stress protein HSP32, has a molecular weight of -30,000-33,000 
(Table 1.2). Although HO-1 and HO-2 share similar mechanisms as haem 
catalysts, substrate specificity and coenzymes requirement, major differences have 
been found between the two isozymes (Maines et al., 1988; Maines et al., 1992; 
Maines et al., 1997). HO-1 and HO-2 are different in their gene structure and 
organisation, in chromosomal localisation, regulatory mechanisms and tissue
23
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distribution. Both HO-2 and HO-1 are single-copy genes but HO-2 is encoded by 
two transcripts (-1.3 and -  1.9 kb) whereas the HO-1 protein is the transcription 
product of a single message of -1.8 kb (Maines et al, 1997). A 24-amino acid- 
long segment of HO-1 and HO-2 is conserved among all haem oxygenases. The 
24-amino acid segment forms a hydrophobic pocket (haem pocket) that binds 
haem pyrrole rings. A part of this segment is now recognised as the HO signature 
(Maines etal., 1997).
1.3.1 Regulation and distribution of haem oxygenase nzymes
In fact HO is expressed in almost all life forms from prokaryotic bacteria and 
fungi to plants and human (Wagener et al, 2003). When the HO-1 and HO-2 
isozymes are evaluated by assessing their protein and message levels they show 
different patterns of distribution and development (Maines et al, 1997). Most 
cells, under normal physiological conditions, express low or undetectable levels of 
HO-1 protein, while HO-2 protein is constitutively expressed (Wagener et al,
2003). The only exception is spleen in which under normal, unstressed conditions, 
HO-1 is the predominant form (Maines et al, 1997). Although it is not 
constitutively expressed in most tissues under normal physiological conditions, 
HO-1 transcription is up-regulated by a huge number of stimuli such as oxidative 
stress, growth factors, disease states, hormones, dietary antioxidants and some 
physiological changes (Table 1.3) (Maines et al, 1997; Kim et al, 2005). There 
is no harmony among HO-1 inducers, which have diverse chemical structures 
varying from proteins to small organic compounds to a gas molecule (NO). 
Actually, there is no enzyme identified to date that is induced by so numerous 
stimuli of diverse nature as is HO-1 (Maines et al, 1997). Unlike HO-1, the 
inducers of HO-2 are very limited and include adrenal glucocorticoids,
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developemental factors, opiates and possibly nitric oxide (NO) (Maines and 
Panahian, 2001). The activity of HO-1 is high even at low concentrations of haem 
and it increases with rise of haem concentrations within physiological limits 
(Wagener et al., 2003). On the other hand, HO-2 has a low level of activity at low 
haem concentrations and even its maximum activity is limited to less than 10 % 
that of HO-1. Specific activity of HO, which reflects the activity of both HO-1 
and HO-2, varies greatly in different organs; the highest HO activity has been 
reported in the spleen, brain and testes (Maines et al., 1988; Maines et al., 1997).
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TABLE 1.2; Summary of various functions of HO isoforms, their distribution and 
gene regulation (adapted from Wagener et al 2003; Yachie et al, 2002).
HO-1 (hsp32) Isoform HO-2 Isoform HO-3 Isoform
Molecular weight -32 kD ~36kD ~33kD
Physiological role Haem degradation 
Modulation of 
vascular tone and 
liver perfusion 
Neural signaling 
Anti-inflammatory 
action
Down-modulation of 
adhesion molecule 
expression
Haem degradation 
Haem binding 
Maintenance of 
vascular tone 
Neural signaling
Haem binding
Constitutive tissue Spleen, liver Most tissues e.g., brain, 
retina, liver, spleen, 
testis, lungs, vascular
Most tissues
Inducers of 
expression
Very diverse, e.g., 
oxidative stress, 
cytokines, heavy 
metals, hypoxia, 
nitric oxide, heat 
shock, haem and UV
Adrenal corticoid, 
opiates
Unknown
Enzyme activity Km = 0.24 pM 
Vmax= 3.4 pmol/mg/h
Km = 0.67 pM 
Vmax = 0.24 pmol/mg/h
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TABLE 1.3; Various stimuli induce HO-1 production (adapted from Kim et al.,
2005)
Disease state Oxidative stress
Ischaemia reperfusion Endoplasmic reticulum stress
Inflammation Heavy metals
Immune dysfunction Oxidized LDL
Transplantation Hydroperoxide
Myocardial infraction Dieldrin
Atherosclerosis Cigarette smoke extract
Hypertension Alcohol
Vascular restenosis 
Glomerulonephritis
Asthma Dietary antioxidant/natural product
Alzheimer’s disease Synthetic terpenoid
Hormone Quercetin/flavonoid
Estrogen Mycotoxin
Prolactin Ferulic acid/ethyl ferulic acid
Adrenocorticotrophin Zerumbone
Atrial natriuretic peptide Selegiline
Angiotension Turpentine oil
Progesterone 3-0-caffeoyl-methyl quinic acid
Glucocorticoid Diallyl sulphide
Medicines/chemicals Chalcone/rosolic acid
Immunosuppressant/anti-inflammatory Taurine
IL-10 Curcumin
Aspirin/salicylic acid Cafestol/kahweol
Rapamycin Avicins
Antioxidant Resveratrol
VitE Physiological changes
Miscellaneous Hypertonic saline
Dopamine Transient glucose deprivation
Nicotine Acidosis
Cysteamine Nitric oxide
UV irradiation Cytokine
Co-protoporphyrin Mechanical shear stress
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1.4 Haem Oxygenase Metabolites
Over a long time, HO has been thought to be only involved in the breakdown of 
haem from senescent red blood cells or denatured haem-proteins and the 
degradation products free iron, biliverdin/bilirubin, and CO were considered 
“toxic waste” materials (Johnson et al., 1999; Morse and Choi, 2002). However, 
the attitude toward HO metabolites has changed dramatically over the last two 
decades and hundreds of studies investigating the biological roles of these 
compounds, especially CO, have published every year. The biological roles of 
bilirubin and iron will be briefly described in the following two sections, and then 
a detailed study of the beneficial role of CO in biological systems will be 
presented.
1.4.1 Bilirubin
Bilirubin is formed from the catalysis of biliverdin by the cytosolic enzyme 
biliverdin reductase (Kutty and Maines 1981; Maines et al, 1988). This enzyme 
is considred as one of the most unique proteins in the animal kingdom because it 
has two pH optima, 7.0 and 8.7 (Maines et al, 1988). At pH 7.0, biliverdin 
reductase has clear preference for the NADH cofactor whereas at pH 8.7 it has 
preference for the NADPH cofactor. At pH 7.4, biliverdin reductase has low 
activity with either factor (Kutty and Maines 1981; Maines et al, 1988). The daily 
generation of bilirubin in adult humans is around 300 mg and because it is 
sparingly soluble in water it is tightly bound to albumin in the circulation (Stocker 
et al., 1990). The physiological concentration of plasma bilirubin is between 5 and 
20 pM, practically all of which is unconjugated pigments bound to albumin. 
Circulating bilirubin is taken up by hepatocytes where it is transformed into water 
soluble conjugated bilirubin. The concentration of conjugated bilirubin in the liver
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ranges from 20 to 40 pM and becomes more concentrated (0.35 to 4 mM) after 
excretion into bile. Concentrated conjugated bilirubin is excreted into small 
intestine where it is transformed into urobilinogens which are then either 
reabsorbed or excreted in the faeces (Stocker et al., 1990).
Bilirubin has been shown to have antioxidant effects (Stocker et al, 1987; Stocker 
et al, 1987; Neuzil and Stocker 1993). Bilirubin efficiently scavenges peroxyl 
radicals and when the experimental concentration of oxygen is < 2 %, the 
antioxidant activity of bilirubin is more effective than alpha-tocopherol, which has 
long been regarded as the best antioxidant of lipid peroxidation (Stocker et al, 
1987). In one clinical study, 25 preterm infants who have oxygen-radical disease 
(ORD) (e.g., bronchopulmonary dysplasia, necrotizing enterocolitis, 
intraventricular hemorrhage and retinopathy of prematurity) were shown to have 
lower bilirubin levels compared to 57 control infants who did not have disorders 
related to ORD (Hegyi et al, 1994). Bilirubin and biliverdin were also reported to 
have cytoprotective antioxidant effects in hepatocytes (Wu et al, 1991a).
In addition to its antioxidant effect, bilirubin plays a protective role against some 
cardiovascular disorders (Wu et al, 1991b; Wu et al, 1994; Hopkins et al, 1996; 
Clark et al, 2000). It was reported that bilirubin, whether endogenously produced 
from haem degradation or exogenously administrated, significantly ameliorated 
myocardial functions and minimized both infarct size and mitochondrial damage 
on perfusion of isolated hearts (Clark et al, 2000). Furthermore, in another study, 
mildly elevated serum bilirubin was associated with decreased risk of early 
familial coronary artery disease (Hopkins et al, 1996). In yet another larger study, 
where 1741 subjects were screened for carotid plaque, it was found that the serum 
bilirubin level was inversely correlated with the presence of carotid plaque
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(Ishizaka et al, 2001).
Although collective evidence from animal and human studies indicates that 
bilirubin is a significant physiological cytoprotectant, this protective effect of a 
moderate rise of bilirubin does not change the well-established dangers of brain 
damage (kemicterus) associated with a major rise of serum bilirubin (Sedlak and 
Snyder, 2004).
1.4.2 Iron
Unlike CO, very little attention has been devoted to ferrous iron the product of 
haem degradation (Snyder and Baranano, 2001). It has been revealed that cells 
must have protective mechanisms to deal with iron released by HO because 
ferrous iron is extremely toxic even at low concentration (Snyder and Baranano,
2001). It is fundamental to the Fenton reaction that produces hydroxyl free 
radicals, one of the most toxic biological species, which play a major role in 
cellular death in septic shock and strokes (Snyder and Baranano, 2001). However, 
the ferrous iron generated from haem degradation by HO also induces the 
synthesis of ferritin, an intracellular protein present in species ranging from 
bacteria to humans, which binds and stores free iron inside the cell and has well 
known cytoprotective properties (Eisenstein et al., 1991; Balia et al, 1992). In 
addition to promoting the synthesis of ferritin, production of ferrous iron also 
leads to rapid expression of an ATPase pump that may mediate the efflux of 
cellular iron for iron re-utilization, and therefore reduces iron accumulation within 
cells, thus protecting cells under stress (Ferris et al, 1999). The role of ferritin in 
mediating the cytoprotection of HO-1 is still arguable as it sometimes appears to 
substitute for HO-1 cytoprotection and sometimes does not (Otterbein et al, 
2003). It was suggested that in endothelium and perhaps other cell types, HO-1
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serves mainly to degrade haem to free iron which in turn induces the synthesis of 
ferritin, which is likely the proximate protective against oxidative damage (Balia 
et al., 1992). On the other hand, it has been reported that haemoglobin-induced 
protection against the inflammatory consequences of lipopolysaccharide 
administration is dependent on HO-1 not ferritin induction (Otterbein et al,
1997). The respective contributions of ATPase pumps, that pump iron from the 
cell, versus ferritin, which sequesters free iron within the cell, to the overall 
cytoprotective effects of HO are not clear but both mechanisms might be involved 
in a vital way to the overall HO antioxidant effect (Otterbein et al., 2003).
1.5 Carbon monoxide (CO)
Sources and quantification of endogenous CO, beneficial roles of CO in different 
biological systems, particularly blood vessels, interaction with NO in vascular 
tissues, and the development of new CO releasing molecules (CO-RMs) will be 
discussed thoroughly in the following sections.
1.5.1 Sources o f endogenous CO
Under normal physiological conditions there are two sources of endogenous CO 
production, which include either haem or non-haem sources (Figure 1.4) (Vreman 
et al., 2002). The main sources of CO come from haem degradation catalysed by 
HO. The majority of this haem (-79%) comes from senescing red blood cells 
whereas the remaining haem is derived from the turn over of other haem-proteins 
such as myoglobin, cytochromes, catalase and others (Vreman et al., 2002). 
Around 14% of CO produced in the body comes from non-haem processes, such 
as lipid peroxidation, photooxidation, xenobiotic activity in blood and others 
(Vreman et al., 2002).
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Figure 1.4. Sources of endogenous CO (adapted from Vreman et al., 2002)
1.5.2 Measurement of CO formation in biological systems
CO generated endogenously has been measured in various biological systems 
using a diversity of analytical procedures which include laser sensor-infrared 
absorption, gas chromatography-mass spectroscopic detection, and gas 
chromatography-reduction gas detection, and formation of 14CO from 14C-haem 
formed following [2-14C] glycine administration (Marks et al., 2002). Although 
different methods have been used to measure CO generation by different tissues, 
the rate of CO formation varies over a short range from 0.28 nmol/mg of protein/h 
in rat liver perfusate and cultured rat olfactory receptors neurons down to 0.029 
nmol/mg of protein in chronic villi of full term human placenta (Marks et al.,
2002). The high levels of CO production in liver and certain brain areas might 
reflect the high level of HO activity in these organs (Maines et al., 1997; Marks et 
al, 2002)
32
UCL INTRODUCTION
1.6 Biological Roles of CO
1.6.1 CO and the lung
Because lung is an organ that provides communication between the environment 
and the circulation it represents an ideal environment for studying oxidative stress 
(Morse and Choi, 2002). Oxidative stress results from imbalance between 
oxidants and antioxidants which happens either from a rise of oxidants and/or 
decrease in antioxidants (Rahman et al, 1996). The release of reactive nitrogen 
species and oxygen species (RNS and ROS, respectively) from inflammatory 
leukocytes and also from airway epithelial cells is the main source of increased 
oxidant load in inflammatory lung diseases (Horvath et al, 2001). Inhaled 
oxidants in cigarette smoke and air pollutants also contribute to oxidative stress. 
The lung is armed with a number of antioxidant systems which vary in their 
significance in various sites in the respiratory tract (Horvath et al, 2001)
HO-1 is induced in the lung by many stresses and has been involved in the 
preservation of homeostasis against oxidative injury and there is evidence that CO 
released from haem degradation by HO-1 mediates at least some of the protective 
properties of HO-1 in the lung (Morse and Choi, 2002). It has been reported that 
animals exposed to low concentrations of CO showed a noticeable tolerance to 
lethal concentrations of hyperoxia in vivo (Otterbein et al, 1999). In the same 
study exogenous CO totally protected against hyperoxia-induced lung injury in 
rats in whose endogenous HO enzyme activity was inhibited. This result indicates 
the role of CO in mediating HO-1 antioxidant effects in the lung. In another study, 
where the functional role of CO in asthma was assessed using an aeroallergen 
model, the rats exposed to CO for 48 h had lower levels of some proinflamatory 
factors than control rats (Chapman et a l, 2001). These data suggest a putative
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immunoregulatory role for CO in aeroallergen-induced inflammation in mice.
1.6.2 Exhaled CO (E-CO) marker
In humans exhaled CO (E-CO) is formed primarily from both systemic haem 
metabolism, which generates CO in different tissues, and localised (lung) haem 
metabolism which results from the combined action of HO-1 and HO-2 enzymatic 
activity (Slebos et al, 2003). As CO, either endogenously produced or inspired, is 
eliminated exclusively by respiration, E-CO can be used as a marker to monitor 
the increase in exogenous sources of CO such as smoking or air pollution 
(Horvath et al, 2001; Morse and Sethi 2002; Slebos et al, 2003). It can be also 
used to monitor the increase in endogenous CO production resulting from 
systemic and local pulmonary inflammation (Horvath et al, 2001; Morse and 
Sethi, 2002; Slebos et al, 2003).
Indeed E-CO has been reported to increase in a number of systematic and 
pulmonary pathological conditions such as cystic fibrosis, chronic obstructive 
pulmonary disease (COPD), infectious lung disease and diabetes (Antuni et al, 
2000; Horvath et al, 2001; Morse and Sethi, 2002). During exacerbations of 
chronic disease, CO production, estimated by E-CO, may rise over what is already 
an elevated baseline (Antuni et al, 2000; Morse and Sethi, 2002). For example, E- 
CO in patients with cystic fibrosis disease was higher than that in control, but it 
increases further during exacerbation of the disease, and goes back to baseline 
again after seven days of antibiotic treatment (Antuni et al, 2000). Similar to the 
early era of measurement of exhaled NO, a standardization in techniques and 
agreement on background correction need to be achieved for E-CO measurements, 
to draw proper conclusions in this area of investigation (Slebos et al, 2003).
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1.6.3 CO and inflammation
Inflammation is a defence system used by organisms to protect them from 
pathogenic invaders, to remove damaged cells after injury and to prevent further 
damage (Wagener et al., 2003). Despite the essential and beneficial role of this 
inflammatory process, some times it is directed against autologous antigens, or it 
does not diminish after its onset and then escalates into long term persistent 
inflammation (Wagener et al., 2003).
A growing body of evidence has indicated the role of HO-1 in inflammation 
(Otterbein et al., 2002; Sarady et al., 2002; Attuwaybi et al, 2004). It was 
reported that HO over expression or exposure to low concentrations of external 
CO inhibited the production of granulocyte macrophage colony-stimulating factor 
(GM-CSF), which is a potent cytokine produced in response to bacterial 
endotoxins (Sarady et al., 2002). In another study HO-1 played an important role 
in protecting gut against ischaemia reperfusion injury, where HO-1 expression 
suppressed inflammatory responses and lessened mucosal injury (Attuwaybi et 
al., 2004). The anti-inflammatory role of HO-1 was further supported by the 
findings in null mice that lack haem oxygenase enzyme as well as the only 
reported case of human HO-1 deficiency; in both cases there was profound 
inflammation that could not be attributed to infection or external exogenous 
factors (Poss and Tonegawa, 1997; Yachie et al., 1999; Otterbein, 2002). It was 
suggested that CO released via HO-1 works as an antidote for these dysfunctional 
inflammatory conditions (Otterbein et al., 2002). Exogenous administration of 
low concentrations of CO markedly attenuated inflammatory processes in 
different cellular and animal models of inflammation such as asthma, hyperoxia, 
endotoxic shock, xenotransplantation and ischaemia perfusion (Otterbein et al.,
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1999; Chapman et al, 2001; Sato et al, 2001; Attuwaybi et al, 2004; Mazzola et 
al, 2004).
The mechanisms by which CO mediates its anti-inflammatory effects remain 
obscure but they may involve the mitogen-activated protein kinase (MAPK) 
pathway which transduces oxidative stress and inflammatory signalling (Otterbein 
et al, 2000). Although the mechanisms by which CO regulates inflammatory 
responses is not well understood, the conclusion is the same: CO at optimal 
concentrations, concentrations that are well below those that would otherwise be 
toxic, has cytoprotective effect (Otterbein et al, 2002).
1.6.4 CO and the liver
The localization of HO-1 and HO-2 in the liver has distinct topographic 
distribution (Goda et al, 1998). In contrast to HO-1 which was detected only in 
Kupffer cells, HO-2 was observed in parenchymal cells, but not in Kupffer cells. 
Neither HO-1 nor HO-2 was detectable in hepatic satellite cells or sinusoidal 
endothelial cells (Goda et al, 1998). HO-1 seems to play an important role in 
protecting liver against stress (Poss and Tonegawa, 1997; Yachie et al, 1999; 
Morse and Sethi, 2002). Great oxidative damage was reported in the livers of rats 
lacking HO-1 (Poss and Tonegawa, 1997). Iron accumulation in the liver and the 
indications of profound endothelial damage in theone and only reported human 
case of HO-1 deficiency highlight the protective role of HO-1 against hepatic 
injury (Yachie et al, 1999; Morse and Sethi, 2002). In perfused livers of 
endotoxaemic rats, CO generation mediated HO-1 protective effect against 
hepatobiliary dysfunction caused by haem overloading under stress condition 
(Kyokane et al, 2001). Furthermore, CO generated from HO-2 in the 
parenchymal cells and released to the extrasinusoidal space, was suggested to play
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an important role in the maintenance of hepatic perfusion, as haemoglobin, the 
trapping agent of CO, induced marked sinosuidal constriction (Goda et al, 1998). 
This hypothesis was supported by Suematsu and co-workers, who reported that 
the increase in sinosuidal constriction due to HO inhibition, was attenuated by 
external CO administration to isolated perfused rat liver (Suematsu et al., 1995).
1.6.4 CO and the neurological system
The localization of HO-2 mRNA in the brain is essentially the same as that of 
sGC mRNA, and inhibition of HO activity depletes endogenous cGMP (Verma et 
al, 1993). Therefore, it was suggested that like NO, CO might function as a 
neurotransmitter (Verma et al, 1993). Intestinal myenteric plexus neurons also 
express HO-2, and targeted deletion of HO-2 gene diminished neurally evoked 
intestinal relaxation, an effect thought to be mediated by endogenous CO 
production (Zakhary et al, 1997). These results further support the role of CO as 
a neurotransmitter (Zakhary et al, 1997). CO also seems to have a role in 
regulating neuroendocrine functions as it decreased stimulated release of stress 
neuropeptides, such as oxytocin, and vasopressin from rat hypothalamus in vitro 
(Giusti-Paiva et al, 2005). CO seems to have a role in regulating cerebral 
circulation as in vitro, ex vivo, and in vivo studies have demonstrated the ability of 
CO, endogenously produced or externally applied, to induce concentration- 
dependant vasorelaxation of piglet, dog, and porcine cerebral circulation (Leffler 
et al, 1999; Komuro et al, 2001; Jaggar et al, 2002; Winestone et al, 2003; 
Koneru and Leffler, 2004; Leffler et al, 2005). The vasorelaxing properties of CO 
will be discussed in later sections.
1.6.5 CO and gastrointestinal tract
HO-2 is predominantly localised within the cell bodies of rat myenteric ganglia
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and nerve fibres coursing in parallel with intestinal inner circular muscle (Zakhary 
et al, 1997). Targeted gene deletion of HO-2 resulted in diminishing the neurally 
evoked nonadrenergic noncholenergic (NANC) intestinal relaxation in rats. 
Therefore, it was concluded that HO-2 plays a role in mediating NANC 
relaxation. This effect was attributed to HO-2 derived CO (Zakhary et al, 1997). 
Similarly, CO, endogenously produced or externally applied, was shown to have 
inhibitory effects on internal anal sphincter (Rattan and Chakder, 1993). CO 
elicited a concentration-dependant drop in the resting tension of internal anal 
sphincter (IAS). The direct effect of CO on internal anal sphincter was confirmed 
by its relaxing effect on isolated smooth muscle cels. Furthermore, HO inhibition 
suppressed the relaxation induced in internal sphincter by NANC nerve 
stimulation (Rattan and Chakder, 1993).
CO seems to play a major role as an endogenous hyperpolarizing factor in the 
gastrointestinal tract (Farrugia et al, 2003). Targeted gene deletion of HO-2 
resulted in depolarization of smooth muscle cells and abolished membrane 
potential, whereas exogenous CO hyperpolarized membrane potential in the 
canine gastrointestinal tract (Farrugia et al, 2003). Recently, it has been reported 
that brief inhalation of low doses of CO protects swine and rodents from 
postoperative gastrointestinal ileus (Moore et al, 2005). Additionally it protects 
against the development of intestinal inflammation in a model of experimental 
necrotizing enterocolitis (Zuckerbraun et al, 2005). Similarly, HO-1 upregulation 
was reported to protect from several types of gastrointestinal injuries, such as 
colitis and sepsis (Gibbons and Farrugia 2004).
1.6.6 CO and transplantation
Expression of HO-1 by graft vasculature seems to be critical to achieve mouse to
38
INTRODUCTION
rat cardiac transplant survival (Soares et al., 1998; Sato et al.,2001). This 
protective effect of HO-1 was attributed to CO generation. Both HO-1 derived CO 
and exogenous CO suppressed graft rejection and restored long term graft 
survival. The process by which CO exerts this effect might involve inhibition of 
platelet aggregation that facilitates vascular thrombosis and myocardial infarction 
(Sato et al, 2001). Additional mechanism by which CO overcomes mouse to rat 
cardiac graft transplant rejection, might involve its ability to suppress cell 
apoptosis (Sato et al., 2001). CO was also reported to protect against lung 
transplant rejection (Song et al., 2003). This cytoprotective effect of CO was 
attributed to its anti inflammatory and anti-apoptotic properties (Song et al.,
2003). The protective role of CO was not confined to heart and lung, as CO also 
prolonged the survival of liver and small intestinal graft (Ke et al., 2002; Nakao et 
al., 2003a; Kaizu et al., 2005).
1.7 CO and vascular functions
1.7.1 General structure of blood vessels
The general structure of arteries, veins, and arterioles is similar (Orallo et al.,
1996). The blood vessel is an active, integrated organ composed of various cell 
types that are arranged in a complex set of autocrine-paracrine interactions 
(Durante et al., 2002). The vessel wall is organised in three distinct layers (Orallo 
et al., 1996; Durante et al., 2002). The innermost, is a layer of endothelial cells 
(the tunica intima), which lines the internal surface of the vessels and is seated on 
a specialised extracellular matrix known as the basement membrane. The 
underlying media (tunica media) is composed of vascular smooth muscle cells 
(SMCs) (20-60 pm in length and about 4 pm in diameter) that are densely packed 
into an interstitial matrix containing collagen, fibronectin and proteoglycans. Each
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smooth muscle cell extends more or less circularly around the lumen of the vessel, 
so when they contract or relax they cause a decrease or increase in the vessel 
diameter respectively (Orallo et al., 1996; Durante et al., 2002). In veins, VSMs 
can also extend longitudinally. The outer layer (adventitial layer), comprises 
collagen fibres, enfolded around the tunica media. The neural axons that innervate 
blood vessels are usually confined to this layer and rarely penetrate the tunica 
media (Orallo et al., 1996; Durante et al., 2002). .
1.7.2 Endogenous production of CO from vascular tissue 
It seems that HO-2 is the predominant form of haem oxygenase enzymes in the 
endothelium and vascular SMCs under normal conditions (Ewing et al., 1994; 
Grozdanovic and Gossrau, 1996; Zakhary et al, 1996; Maines et al., 1997). It is 
also localised in adventitial nerves of blood vessels and carotid body 
chemoreceptors (Prabhakar et al., 1995; Zakhary et al., 1996) but not in striated 
cardiac musculature (Grozdanovic and Gossrau, 1996). HO-1, which is minimally 
expressed in vascular tissue under physiological conditions, is highly induced in 
vascular endothelium, SMCs and myocytes as response to different stimuli 
(Maines et al., 1997; Foresti et al., 2002). These stimuli include hypoxia (Morita 
et al., 1995), haemorrhagic shock (Moncure et al., 2003) , cAMP (Durante et al.,
1997), nitric oxide (NO) (Motterlini et al., 1996; Hartsfield et al., 1997), 
endotoxins (Yet et al., 1997), mildly oxidized low density lipoproteins (Ishikawa 
et al., 1997) and hemodynamic forces such as shear stress (Wagner et al., 
1995;Wagner et al., 1997).
Many techniques have been introduced to measure the endogenous formation of 
CO in blood vessels (Marks et al., 2002). Among these techniques, measurement 
of CO production using an ultrasensitive laser sensor remains one of the most
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sensitive because it has higher sensitivity to low CO levels and does not require 
chemical mediators (Morimoto et al., 2001; Marks et al., 2002). In this protocol 
quantification of CO generated in cultured rat aortic SMCs was done using an 
ultrasensitive laser sensor without interference from other gases (Morimoto et al.,
2001). The basal CO production was 0.25 ± 0.07 nmol per 107 cells/h and that 
level was not affected by treating the cells with sodium nitroprusside, a nitric 
oxide donor, despite marked elevation of HO-1 protein expression (Morimoto et 
al., 2001). In contrast, treatment of the cells with hemin, the haem oxygenase 
substrate, resulted in around a two times increase in CO production. The hemin- 
induced CO synthesis was attributed to its ability to stimulate higher levels of 
HO-1 protein compared to sodium nitroprusside (Morimoto et al., 2001). In 
addition, hemin provides SMCs with additional substrate for HO-1 metabolism. 
Interestingly, treatment of the cells with a combination of hemin and sodium 
nitroprusside resulted in a further increase of CO production (Morimoto et al.,
2001). In the same study adding tin protoporphyrin-IX (SnPP), which is a potent 
HO inhibitor, to hemin treated cells resulted in almost complete block of 
endogenous CO production.
The facts that CO is generated in blood vessels under physiological conditions and 
that real time endogenous CO formation in vascular tissues is measurable satisfy 
important criteria for a physiological role of CO in blood vessels (Marks et al., 
2002 a).
1.7.3 CO and vascular SMC growth
The effect of HO-1 on cell proliferation is highly variable and seems to be cell 
specific (Durante et al., 2003). In contrast to its proliferative effect on epidermal 
keratinocytes and tumour cells, HO-1 appears to play an anti-proliferative role in
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renal and pulmonary epithelial cell and vascular SMCs (Durante et al, 2003). 
Several studies have demonstrated the anti-proliferative effect of HO-1/ CO 
system on vascular SMCs (Morita et al., 1997; Togane et al., 2000; Peyton et al.,
2002). Vascular SMCs proliferation was inhibited or augmented by HO inducers 
or inhibitor respectively (Togane et al., 2000). Haemoglobin, a reagent trapping 
both NO and CO, but not methaemoglobin, which can capture NO but not CO, 
augmented the proliferative response of rat vascular smooth muscle cells to 
angiotensin II (Togane et al., 2000). Serum was reported to induce HO-1 gene 
expression in vascular SMCs, where HO-1 catalyzed CO formation in a negative 
feedback manner to limit serum-stimulated SMC proliferation (Peyton et al.,
2002). Vascular SMC derived CO has been suggested to play an important role in 
regulating vascular SMC proliferation under hypoxic conditions (Morita et al.,
1997). Inhibition of CO generation or scavenging of CO with haemoglobin, 
enhanced vascular SMCs proliferation in response to serum or mitogens, while 
increasing CO formation or exposing cells to exogenous CO resulted in 
significant suppression of growth response (Morita et al., 1997). In addition to 
direct attenuation of cell proliferation, CO might regulate SMC growth by 
inhibiting the endothelium-released platelet derived growth factor (PDGF) or 
endothelin-1 (ET-1), which promotes SMCs proliferation (Morita and 
Kourembanas, 1996).
The influence of CO on SMC apoptosis is controversial (Durante et al., 2002; Liu 
et al, 2002; Liu et al., 2003). Apoptosis is programmed cell death serving many 
physiological functions (Allen and Agrawal, 1997). In contrast to classic cellular 
swelling and membrane rupture associated with necrosis, apoptotic cells shrink 
and maintain their membrane integrity (Allen and Agrawal, 1997). HO-1 over
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expression in cultured aortic SMCs induced apoptotic cell death, and incubating 
the vascular SMC with haemoglobin, the CO scavenger, or SnPP, the HO 
inhibitor, significantly reduced apoptosis (Durante et al, 2002). On the other hand 
CO, either administered exogenously or formed endogenously, inhibited cultured 
aortic SMCs apoptosis (Liu et al., 2002; Liu et al, 2003). Clearly, more work is 
still needed to explore the role of CO in regulation of vascular SMC apoptosis 
(Durante et al., 2002).
1.8 CO-Induced Vasorelaxation
Although the endogenous production of CO has been known for more than a half 
century, the resurgent interest in the physiological effects of CO has only really 
been highlighted over the last two decades (Zhao, 2002). The purification and 
identification of the two different HO isozymes was a turning point in the history 
of the haem oxygenase-carbon monoxide system (Maines et al, 1986). Over the 
last two decades CO, endogenously produced or externally applied, has been 
shown to attenuate vasoconstriction and induce vasorelaxation of diverse blood 
vessels with different diameters and from different species possibly through 
different mechanisms. The affected vascular tissues include: rat and rabbit aorta 
(Lin and McGrath, 1988; Furchgott and Jothianandan, 1991; Brian et al, 1994; 
Hussain et al, 1997); piglet and rat pulmonary arteries and veins (Villamor et al, 
2000; Ding et al, 2002); lamb ductus arteriosus (Coceani et a l,  1988; Coceani et 
al, 1996); rat, dog and porcine coronary arteries and veins (McFaul and McGrath 
1987; Vedernikov et al, 1989; Graser et al, 1990; Barbe et al, 2002c); hepatic 
vein (Pannen and Bauer 1998); dog femoral and carotid artery (Vedernikov et al, 
1989); rat gracillus muscle arterioles (Kozma et al, 1999); rat and newborn piglet 
mesenteric artery (Villamor et al, 2000; Gonzales and Walker 2002; Naik and
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Walker 2003); piglet, dog and porcine cerebral arteries and arterioles (Leffler et 
al., 1999; Komuro et al., 2001; Jaggar et al., 2002; Winestone et al., 2003; Leffler 
et al., 2005); and human placental blood vessels (Bainbridge et al., 2002). CO has 
the ability to dilate blood vessels contracted by different vasoconstrictors such as 
phenylephrine (adrenoreceptor agonist), U-46619 (thromboxane A2  mimetic), 
methoxamine (alpha agonist), indomethacine, potassium chloride (KC1) and 
prostaglandin F (2 alpha) (Lin and McGrath 1988; Graser et al., 1990; Coceani et 
al., 1996; Wang et al., 1997a; Komuro et al., 2001; Nakao et al., 2003b; Tammaro 
et al., 2005).
As examples of its vascular activity, exogenously applied CO elicited 
endothelium independent vasorelaxation of rat tail arteries precontracted with 
phenylephrine (1 pM) (Wang et al., 1997a). The CO-induced relaxation was 
concentration-dependant with a detectable threshold concentration of 1 pM. At 
300 pM CO induced around 60 % relaxation, and 80% vasorelaxation was 
achieved at 1 mM. The effect of CO was sustained, but reversible upon the 
removal of CO from the system (Wang et al., 1997a). In a model of isolated 
perfused rat heart, coronary flow was increased by exogenously applied CO 
(McFaul and McGrath, 1987). CO-induced vasorelaxation was not the result of 
change of heart rate or decreased oxygen content in the perfusate and was not 
mediated by adenosine, prostaglandin or adrenergic influence (McFaul and 
McGrath, 1987). The vasodilatory effect of CO on coronary vasculature was 
reversible as coronary flow returned to normal once CO was removed from the 
system (McFaul and McGrath, 1987). In an isolated ring preparation, 
endogenously produced CO has been reported to play a major role in regulating 
vascular tone in aortic arteries expressing high levels of HO-1 (Sammut et al.,
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1998). In addition, up regulation of HO-1/CO in aortic rings largely suppressed 
the contractile response to phenylephrine. Exogenously applied CO also induced 
dose dependent, endothelium-independent vasorelaxation of isolated aortic rings 
but this effect was much less potent than that induced by NO (Lin and McGrath, 
1988; Furchgott and Jothianandan, 1991; Brian et al., 1994). In mesenteric 
arteries endogenous CO appears to play a significant role in attenuating the 
vasoconstrictor reactivity after chronic hypoxia (Gonzales and Walker, 2002; 
Naik and Walker, 2003). It was reported that haem-L-lysine (HHL), an HO 
substrate, elicited a dose-dependent vasodilatory response and reduced the 
vasoconstrictor sensitivity to increasing concentrations of phenylephrine in 
mesenteric arteries that were exposed to 48 hr chronic hypoxia (Gonzales and 
Walker, 2002; Naik and Walker, 2003). The effect of HHL was attributed merely 
to CO as the role of free iron and biliverdin as mediators of this effect was ruled 
out. In addition, exogenous CO produced a dose-dependant reduction in vascular 
tone (Gonzales and Walker, 2002; Naik and Walker, 2003).
The role of CO in regulating cerebral circulation was questioned by Brian and 
colleagues who reported that CO even at a high concentration (300 pM) had no 
significant effect on rabbit cerebral arteries whereas it induced vasorelaxation in 
aortic arteries (Brian et al., 1994). In the same study NO elicited 80 % to 100 % 
relaxation of all examined cerebral arteries (Brian et al., 1994). On the other hand, 
Leffler and co-workers reported that CO produced significant dose-dependant 
vasodilatation at concentrations as low as 10 11M in newborn pig small cerebral 
arterioles (<60 pm) and at 10 10 M in large arterioles (>60 pM) with maximal 
dilatation reached by 10 9 M in vessels of both diameters (Leffler et al., 1999). 
The vasorelaxing properties of CO in that study were comparable to those induced
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by the NO donor, sodium nitroprusside (Leffler et al, 1999). These authors cited 
four reasons to explain the discrepancy between their results and that obtained by 
Brian’s group: firstly, the diameters of blood vessels examined were different as 
they used small arterioles compared to major cerebral arteries used by the others. 
Secondly, their study was conducted on intact brain in vivo, whereas the former 
researchers used isolated, precontracted artery rings. Thirdly, they used newborn 
animals in their experiments compared to adults used by Brian and co-workers. 
Finally, different species were used by both studies (Leffler et al, 1999). The 
failure of high concentrations of CO to induce vasorelaxation in large cerebral 
arteries provoked another research group, to re-examine the response of large 
cerebral arteries to CO using a similar experimental model to that used by Brian 
(Komuro et al, 2001). Surprisingly, CO caused a concentration-dependent 
relaxation starting with a concentration of 57 pM. The authors of this study 
attributed the failure of cerebral arteries to respond to CO in the former study to 
the presence of carboxygen (95 % O2 : 5 % CO2 ) in their organic bath which 
might have reduced more than 99 % of CO from the solution so that the amount of 
CO in the solution was less than the investigator expected (Komuro et al, 2001). 
Since this debate started, a growing number of articles have reported the role of 
endogenously produced or externally applied CO in attenuating vasoconstrictor 
responses and inducing vasodilatation in cerebral circulation (Jaggar et al, 2002; 
Winestone et al, 2003; Koneru and Leffler 2004; Leffler et al, 2005)
It is well known that the vasodilatory potency of CO is not universal in all 
vascular tissues and it varies between different tissue types, species, 
developmental age and the diameter of the vessels (Wang et al, 1998; Zhang et 
al, 2001b; Zhao W. 2002). For example, endogenous CO acts to maintain portal
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venous vascular tone but has no effect on hepatic arteries (Pannen and Bauer,
1998). Another example of the tissue specificity of CO was demonstrated by 
experiments conducted on systemic and pulmonary vessels of newborn piglets 
(Villamor et al., 2000). In that study, CO-induced endothelium-independent 
vasorelaxation of pulmonary arteries, pulmonary veins and mesenteric arteries, 
but that relaxation was more marked in pulmonary veins than in pulmonary 
arteries or mesenteric arteries. Furthermore, the vascular potency of CO in piglets 
arteries decreases with age as CO-induced vasorelaxation was greater in 
pulmonary arteries in the 12-24h old than that of 2 week old piglets. In the same 
study, vasorelaxation induced by NO was also greater in pulmonary veins than in 
pulmonary arteries; however, its potency increased with postnatal age (Villamor 
et al, 2000). Similarly, exogenous CO which induced 76 % relaxation of pigs 
urethral preparations and 86 % of lower gastroesophagastric junction, failed to 
induce vasorelaxation of extramural arterial rings in the same study (Werkstrom et 
al., 1997).
Despite a large number of studies demonstrating the vasorelaxing properties of 
CO, it was reported that CO promoted endothelium-dependant constriction of 
isolated gracilis muscle arterioles (Johnson and Johnson, 2003). In addition, CO 
contributed to salt-induced hypertension in Dahl salt sensitive rats (Teran et al., 
2005). In another study conducted on rat isolated gracilis arterioles, CO induced 
both vasodilatation and vasoconstriction (Johnson et al., 1999). In the presence of 
intact endothelium, CO elicited vasoconstriction whereas in endothelium denuded 
arterioles CO elicited vasodilatation. The authors attributed this conflicting effect 
of CO in the same blood vessels to the effect of CO on endothelium NO. They 
suggested that in the presence of intact endothelium, CO might inhibit the
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endogenous production of endothelium NO, which is one of main regulators of 
vascular tone, and as a result induces vasoconstriction. Therefore, in the absence 
of an endothelial layer or in the presence of NO synthase inhibitors, CO was 
devoted to its local vasodilatory action on vascular SMC (Johnson et al., 1999). 
This conclusion contrasts with many studies which have shown that the CO has 
relaxing effects on both endothelium intact and endothelium denuded vessels 
(Wang et al., 1997a; Villamor et al., 2000; Ding et al. 2002; Naik et al., 2003). 
The complex architecture of vascular tissue might explain the diverse effect of CO 
on vascular tone reported in the literature (Archer et al., 1996; Zhao et al., 2002). 
It has been reported that the prevalence of various vascular smooth muscle 
populations differs from segment to segment within a single artery and also may 
vary in the vascular tree of different organs (Archer et al., 1996). Furthermore, the 
composition of arterial media is plastic and changes at different developmental 
stages and in response to injury (Archer et al., 1996). Therefore, it has been 
hypothesised that certain vascular tissues are equipped with different signalling 
mechanisms and the expression of various cellular targets of CO in these tissues 
may have different profiles (Zhao et al., 2002).
1.9 The Mechanisms for CO-induced Vasorelaxation
A number of intracellular pathways have been proposed as mediators of CO- 
induced vasorelaxation; however activation of soluble guanylate cyclase (sGC), 
and potassium (K+) channels, remain the two most popular mechanisms for many 
scientists. Therefore in the following sections detailed analysis of the possible role 
of these pathways in amplifying the biological effect of CO will be presented.
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1.10 Soluble Guanylate Cyclase (sGC)
The intracellular second messengers involved in SMC relaxation are cyclic 
guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) 
(Carvajal et al, 2000). cGMP exerts its action through activation of cGMP- 
dependent protein kinase (PKG) whereas cAMP elicits its action through cAMP- 
dependant protein kinase (PKA). For a long time cAMP was regarded as the 
principal second messenger involved in vasorelaxation but recent evidence points 
towards a primary role of cGMP that exceeds that of cAMP in relaxation of SMC 
by endogenous or exogenous compounds (Carvajal et al., 2000). In smooth 
muscle cells, cGMP is generated from guanosine triphosphate (GTP) by the 
activity of guanylate cyclase (GC) enzyme, and degraded by cyclic nucleotide 
phosphodiestarase (PDE) (Carvajal et al., 2000; Pyriochou and Papapetropoulos, 
2005). There are two isoforms of GC; the cytosolic soluble GC (sGC) and the 
membrane bound particulate GC (pGC) (Figure 1.5). They differ in their 
structure, ligands and subcellular organization (Pyriochou and Papapetropoulos, 
2005). Regardless of whether cGMP is formed by means of the pGC or sGC 
pathway, it elicits its effect by binding and modifying the activity of three types of 
intracellular receptors: cGMP dependant protein kinase (PKG), cGMP-binding 
phosphodiestarases, cGMP-regulated ion channels (Carvajal et al, 2000). PKG 
has been considered the principle mediator of cGMP-induced vasorelaxation 
whereas the role of the other two receptors in cGMP-induced relaxation has not 
been evaluated (Carvajal et al., 2000). There are two mechanisms by which 
cGMP might induce vasorelaxation; either by lowering cytosolic Ca+2 ([Ca+2]0 
levels or reducing the sensitivity of contractile systems to Ca+2 (Carvajal et al., 
2000; Cary and Marietta, 2001). Although the mechanisms by which cGMP
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reduce cytosolic Ca+2 are complex and not well understood, an important role of 
PKG in mediating this action has been proposed (Lincoln et al, 1994; Carvajal et 
al, 2000). PKG has been reported to regulate several pathways that control 
cytosolic Ca+2 levels such as inhibition of inositol triphosphate formation and 
receptor activity, activation of Ca+2 activated K + channels (K ca), and activation of 
Ca+2-ATPase pumps in the sarcoplasmic reticulum and plasma membrane 
(Lincoln et al, 1994; Carvajal et al, 2000; Cary and Marietta, 2001). The 
physiological consequence of a transient fall in cytosolic Ca+2 differs depending 
on cell types, but in SMCs, a decline in cytosolic Ca+2 results in relaxation and a 
rise causes contraction (Cary and Marietta, 2001)
In addition, cGMP, possibly through PKG, reduces the sensitivity of the 
contractile system to Ca+2; as a result SMCs contraction is not triggered even by 
supra-threshold levels of cytosolic Ca+2 (Carvajal et al, 2000).
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Figure 1.5. cGMP generation and action (adapted from Carvajal et al., 2000).
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1.10.1 CO and sGC/cGMP pathway
More than fifteen years ago, the possible role of the sGC/cGMP pathway as a 
mediator for the effect of CO was suggested, but it was in platelets rather than in 
blood vessels (Brune and Ullrich, 1988). Later on, several studies established the 
role of sGC as a mediator of CO-induced vasorelaxation (Wang et al., 1998; 
Morse et al., 2002; Nakatsu et al., 2002; Ndisang et al., 2004). Isolated blood 
vessel preparations were used in some laboratories to assess the vasorelaxing 
effect of CO and measure the effects of sGC pathway inhibitors such as 
methylene blue and lH-[l,2,4]oxadiazole[4,3-a]quinoxaline-l-One (ODQ) on 
CO-induced vasorelaxation. The direct stimulating effect of CO on cGMP 
production in vascular tissue and cultured vascular cells was also investigated. In 
the early1990s, Furchgott and co-workers reported that CO produced endothelium 
independent vasorelaxation of rabbit aortic rings (Furchgott and Jothianandan, 
1991). That CO-induced vasorelaxation was associated with an increase in cGMP 
levels. Therefore, they concluded that CO elicited vasorelaxation as a result of its 
stimulation of sGC (Furchgott and Jothianandan, 1991). It is worth noting that the 
CO-induced vasorelaxation was much lower than that induced by NO. Later on, 
the effect of the sGC inhibitor, ODQ, on relaxation of rabbit aortic rings by CO 
was examined (Hussain et al., 1997). ODQ at a concentration of 10 pM 
completely inhibited the CO-induced vasorelaxation, whereas only partial 
attenuation of NO-induced vasorelaxation was achieved by the same 
concentration of ODQ. The authors concluded that CO-elicited relaxation of 
rabbit aortic artery is mediated by activation of the sGC/cGMP pathway (Hussain 
et al., 1997). In another study, the same concentration of ODQ completely 
inhibited the vasorelaxing effects of both CO and NO on mesenteric artery and
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pulmonary artery and vein of newborn piglets (Villamor et al., 2000). 
Interestingly, the age dependant change in the effect of CO on pulmonary artery, 
mentioned in a previous section (page 47), was attributed to increase in 
phosphodiesterase, the cGMP degrading enzyme, activity during the first days of 
extrauterine life (Villamor et al., 2000). It was reported that CO, endogenously 
generated from HO-1 over expression or exogenously applied, substantially 
increased cGMP production in an aortic ring extract (Sammut et al., 1998). 
Another piece of evidence for the role of cGMP was provided by Motterlini’s 
group, who investigated the effect of HO-1 expression on blood pressure in vivo 
(Motterlini et al., 1998). They observed that infusion of vasoconstrictor agents 
that caused acute and significant elevation in rat blood pressure at five days after 
catheter implantation, failed to induce any change when introduced one day after 
surgery (Motterlini et al., 1998). The suppression of a hypertensive response 
observed one day after surgery was associated with significant expression of HO- 
1 in aorta, liver and heart as well as a rise in CO formation and cGMP levels. Pre­
treatment of the rats with HO inhibitors significantly lowered CO and cGMP 
levels and totally restored the acute hypertensive response (Motterlini et al.,
1998). In another study Morita and co-workers showed that CO derived from 
vascular SMC has paracrine effects on endothelial cells under hypoxic conditions 
(Morita and Kourembanas 1996). It caused a fourfold increase in endothelium 
cGMP formation, and inhibition of HO production or scavenging CO prevented 
the rise in cGMP production (Morita and Kourembanas 1996). Hypoxia, which 
has a profound effect on vessel tone, significantly increased HO-1 expression and 
activity in rat aortic and pulmonary artery smooth muscle cells (Morita et al., 
1995). This rise in HO-1 production was associated with similar elevation of
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cGMP levels and this elevation of cGMP levels was completely inhibited in the 
presence of tin protoporphyrin, an HO inhibitor, or haemoglobin, a scavenger of 
CO. In contrast, NO had no effect on cGMP production. Taken together these 
results show that CO may regulate vascular tone under physiological and 
pathological conditions, such as hypoxia, and this effect is largely mediated 
through cGMP activation (Morita et al., 1995).
On the other hand, Suematsu and colleagues, who studied the role of 
endogenously produced CO in modulating sinusoidal tone in liver perfusate, 
hypothesised that CO-induced vasorelaxation in sinusoids was possibly due to 
cGMP-independent mechanisms (Suematsu et al., 1995). Two main findings 
supported their hypothesis: firstly, the minimum concentration of CO which was 
needed to induce a significant rise in cGMP levels in cultured Ito cells was at least 
100 times higher than that detected in the effluent of the control perfusate liver. 
Secondly, 8-bromo-cGMP, the cGMP analogue, reversed only 60 % of 
vasoconstriction induced by the HO inhibitor Zn PP. Therefore, they suggested a 
possible role of potassium channels (K+) in mediating the vasorelaxing properties 
of CO (Suematsu et al., 1995). Cerebral circulation has provided other examples 
of the controversy about the role of cGMP in mediating the vasorelaxing 
properties of CO. It was reported that piglet’s pial arteriolar dilatation to CO was 
completely reversed by ODQ but CO did not increase cGMP. And because the 
minimal level of cGMP analogue restored the vasorelaxing effect of CO after 
inhibition with ODQ, it was concluded that a certain threshold level of cGMP is 
necessary to allow CO to increase Kq* channel activity to induce dilatation 
(Koneru and Leffler, 2004). In dog cerebral artery segments, the CO-induced 
relaxation was reduced in the presence of ODQ or TEA, the non selective K+
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inhibitor. Neither ODQ nor TEA completely inhibited the vasorelaxing effect of 
CO and there was no additive effect when ODQ and TEA were administered 
together (Komuro et al, 2001). The role of cGMP in mediating the vasorelaxing 
properties of CO in mesenteric arterioles varies according to the source of CO 
(Naik and Walker, 2003). Both HO derived and exogenous CO elicited 
concentration dependent vasorelaxation of chronically hypoxic superior 
mesenteric arterioles. However, endogenous CO-induced vasorelaxation was not 
altered in the presence of ODQ whereas the vasodilatation induced by external 
CO was almost completely reversed by the same concentration of ODQ. 
Therefore it was suggested that the vasodilatory response of superior mesenteric 
arterioles to endogenous CO is possibly mediated by cGMP independent 
mechanisms (Naik and Walker, 2003). Similarly, Coceani and colleagues, who 
investigated the effect of CO on lamb ductus arteriosus concluded that the primary 
action of CO in ductus arteriosus is not mediated by sGC/cGMP pathway and that 
the sGC/cGMP pathway may only have an accessory role in the relaxation to CO 
(Coceani et al, 1996). Instead they emphasized the importance of cytochrome 
P450-based mono-oxygenase reaction as a target for CO activity in the lamb 
ductus arteriosus (Coceani et al, 1996).
In summary, it appears that cGMP plays an important role in mediating the 
vasorelaxing properties of CO on at least some blood vessels (Nakatsu et al,
2002). The correlation between CO and cGMP levels seems to be clearer in larger 
vessels than smaller vessels, which tend to be more independent of cGMP 
(Nakatsu et al, 2002).
1.10.2 Benzyl indazole derivative (YC-1) and CO
The degree of purified sGC enzyme activation in vitro differs significantly in
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response to NO and CO (Stone and Marietta, 1994; Friebe et al, 1996). It has 
been shown that CO induced about a 4-5-fold rise in sGC activity while NO 
induces a 100- 400-fold increase (Stone and Marietta, 1994; Friebe et al., 1996). 
In addition, several studies have documented that CO has lower potency 
compared to NO in relaxing blood vessels (Furchgott and Jothianandan, 1991; 
Brian et al, 1994). Therefore, the hypothesis that endogenous CO can play a role 
similar to that of NO in regulating vascular tone has been questioned (Brian et al, 
1994; Hartsfield et al, 2002; Nakatsu et al, 2002). However, these criticisms 
have been muted by the demonstration that in the presence of YC-1, CO is 
capable of stimulating purified sGC to a degree similar to NO (Friebe et al., 1996; 
Stone and Marietta, 1998). YC-1 is an NO and CO-independent activator of sGC 
activity (Friebe et al, 1996). It induced around 12-fold increase in purified sGC 
activity. In the presence of YC-1, the stimulatory effect of CO was potentiated 
enormously, and CO was capable of stimulating sGC 106-fold which is similar to 
levels induced by NO (Friebe et al, 1996). Consistent with these results, it was 
reported that YC-1 potentiated CO-induced relaxation of rat aortic strips by 
around 10 times (McLaughlin et al, 2000). Therefore McLaughlin and colleagues 
hypothesised that should an endogenous compound exist with similar properties 
to that of YC-1, then the vasoactivity of CO in the presence of this factor would 
be increased, and CO could have a role in the regulation of vascular tone 
comparable to that of NO (McLaughlin et al, 2000). This conclusion has been 
shared by Friebe and colleagues, who proposed that the existence of an 
endogenous YC-1-like substance that is expressed in a cell or tissue specific 
manner might explain the controversy about the role of cGMP in mediating the 
vasorelaxing properties of CO. Depending on the presence or absence of such an
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endogenous modulator, CO would display high or low level sGC-activating 
properties (Friebe et al, 1996).
1.11 CO and K+ Channels
An introduction to potassium (K+) channels physiology will be presented in the 
next section followed by thorough analysis of the interaction between CO and K+ 
channels.
1.11.1 K* channels
K+ channels are groups of integral membrane proteins that selectively transport 
K+ ions across the cell membrane (Kom and Trapani, 2005). They have been 
found in all mammalian cells and have diverse functions in both excitable and non 
excitable cells. In fact K+ channels are more sophisticated than any other ion 
channel super family found in the mammalian cells (Cao et al., 2002). In arterial 
smooth muscle cells almost every physiological vasoconstrictor and vasodilator 
has been shown to modulate one type or another of K+ channels (Standen and 
Quayle, 1998). In general most vasoconstrictors and vasodilators have multiple 
pathways of action and, among these pathways; K+ channels contribute to regulate 
membrane potential and vascular contractile tone (Standen and Quayle, 1998). It 
is well known that activation of K+ channels in arterial smooth muscle cells 
(SMCs) induces vasodilatation and lowers blood pressure, whereas inhibition of 
these channels leads to vasoconstriction (Figure 1.6) (Nelson et al., 1990; Sobey 
et al, 2001). At least four K+ channel subgroups have been identified in vascular 
SMCs (Nelson and Quayle, 1995; Standen and Quayle, 1998; Cao et al, 2002; 
Korovkina and England, 2002b; Jackson et al, 2005): The first one is calcium 
(Ca2+) activated K + channels (K ca) which respond to changes in intracellular Ca2+ 
to regulate intrinsic tone in small arteries (Brayden and Nelson, 1992). It has been
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proposed that any rise in intravascular pressure, through cell membrane 
depolarization and elevation of intracellular Ca activates Kca channels. 
Activation of Kca channels leads to K+ efflux, which counteracts membrane 
depolarization and vasoconstriction (Brayden and Nelson, 1992). Kca channels are 
divided into three groups: big conductance (B K ca), intermediate conductance 
(IK ca) and small conductance (S K ca) channels (Brayden and Nelson, 1992). The 
second K+ channel subgroup is voltage-dependant K+ (Kv) channels which 
respond to depolarization stimuli (Cao et al., 2002). Activation of Kv channels 
causes efflux of K+ ions, which leads to membrane hyperpolarization and 
maintains the resting membrane potential at -40 to - 60 mV under physiological 
conditions (Cao et al., 2002). The third subgroup is inward rectifier K+ (Kir) 
channels which appear to mediate external K+-induced hyper polarization and 
dilatation of resistance arteries (Nelson and Quayle, 1995). Finally the fourth 
subgroup is ATP sensitive K + (K Atp) channels which is sensitive to some 
molecules produced from cellular energy metabolism (Zhuo et al., 2005). Among 
these molecules, adenosine triphosphate (ATP) and adenosine diophosphate 
(ADP) are the most common. The decrease of intracellular ATP leads to opening 
of the K Atp channels, which will induce vasodilatation and increase blood flow 
into organs (Zhuo et al., 2005).
BKca and Kv channels are the most prevalent K+ in vascular SMCs (Korovkina 
and England, 2002a; Korovkina and England, 2002b). In arterial smooth muscle 
cells which contain Kir, Kv, Kca, and K At p  channels, the approximate number of 
channels per cell range from around 100-500 per cell for Kir and K At p , up to 
1000-10000 Kca, and Kv channels per cell (Nelson and Quayle, 1995).
The role of K+ channels in endothelial cells (EC) is not as well understood as that
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in SMCs (Coleman et al, 2 0 0 4 ). Kca, Kv, K Atp and Kir channels have all been 
identified in endothelial cells (Coleman et al, 2 0 0 4 ). In contrast to SMCs, IKca 
and SKca are abundant in EC and it appears that these channels play essential 
roles in production of endothelium-derived hyperpolarizing factor (EDHF) which 
travels through myoendothelial gap junctions to SMCs to induce 
hyperpolarization and vasorelaxation (Coleman et al, 20 0 4 ).
K+ C h a n n e l  K + C h a n n e l
A c t i v a t i o n  I n h i b i t i o n
V a s o d i l a t a t i o n V a s o c o n s t r i c t i o n
Figure 1.6. Schematic illustration of the key events involved in the vascular 
smooth muscle response to K+ channel activation (left) or inhibition (right) 
(adapted from Sobey et al., 2001).
1.11.2 Interaction between CO and IC channels
Ten years ago Suematsu and co-workers, hypothesised that cGMP-independent 
mechanisms might be involved in mediating the CO-induced vasorelaxation in 
hepatic sinusoids (Suematsu et al, 1995). They anticipated that K+channels were 
possible cellular targets for CO in hepatic microcirculation and supported their 
view by a number of studies which demonstrated the interaction between CO and
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K+ in non vascular tissue such as corneal epithelial and intestinal smooth muscle 
cells (Rattan and Chakder, 1993; Rich et al., 1994; Suematsu et al., 1995). Later 
on, several studies have demonstrated the involvement of K+ channels subgroups 
in mediating CO-induced vasorelaxation. Among these subgroups, BKca has been 
considered as the most probable cellular target of CO. The role of each subgroup, 
especially Kca channels, in mediating the vasorelaxing effect of CO will be 
discussed in the following sections.
1.11.3 Modulation o fK c a  channels by CO
In experiments conducted on rat tail artery, CO-induced vasorelaxation of 
precontracted isolated rings was partially inhibited by charybdotoxin, the BKca 
channels inhibitor, or ODQ, the sGC inhibitor (Wang et al., 1997a). In contrast, 
apamine, a SKca channel blocker, failed to alter the vasorelaxing effect of CO. 
When both BKca and sGC were blocked, the CO-induced vasorelaxation was 
completely reversed. Thus, the authors concluded that CO may activate both B K c a 
chnnels and cGMP signalling pathway in the same vascular tissue (Wang et al., 
1997a). In another study, run by the same group, the direct effect of CO on the 
activity of Kca channels in isolated single SMCs of rat tail arteries was examined 
in vitro (Wang et al., 1997b). At 10 pM, CO hyperpolarised isolated SMCs from - 
62 to -84 mV. Additionally, CO (10 pM) enhanced whole-cell outward K + 
channel currents and this was reversed quickly after removal of CO from the 
solution. At the same concentration, CO increased the open probability of B K c a 
channels by around 183 %, and this effect was antagonized by charybdotoxin but 
not apamine (Wang et al., 1997b). Although CO did not increase the resting levels 
of intracellular free calcium concentration ([Ca+2]j), it significantly enhanced the 
calcium sensitivity of single BKca channels in SMCs which correlates with
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increased open probability of these channels (Wang et al., 1997b). The absence of 
GTP and cGMP dependant protein kinase in the recording solutions excluded the 
role of cGMP in mediating the effect of CO on BKca. Therefore it was 
hypothesised that CO can directly affect B K c a by increasing its sensitivity to 
([Ca+2]i) (Wang et al., 1997b). A similar conclusion was reached by another group 
who investigated the effect of CO on Kca channels in newborn porcine cerebral 
arterioles SMCs (Xi et al., 2004).
In addition to systemic circulation, BKca has been shown to mediate CO-induced 
vasorelaxation in pulmonary circulation (Dubuis et al, 2005). Continous 
inhalation of low concentrations of exogenous CO, attenuated the development of 
hypoxic pulmonary artery hypertension in vivo, and increased the sensitivity of 
BKca channels to intracellular Ca2+ in pulmonary artery myocytes in vitro. The 
enhancement of BKca sensitivity to Ca2+ increased the activity of BKca which in 
turn decreased membrane depolarization of pulmonary artery myocytes induced 
by chronic hypoxia (Dubuis et al., 2005). Because a hallmark of pulmonary artery 
hypertension is a sustained pulmonary artery vasoconstriction via depolarization 
of pulmonary artery myocytes, it was suggested that chronic inhalation of low 
concentrations of CO attenuates hypoxic pulmonary artery hypertension 
development presumably through activation of BKca channels (Dubuis et al., 
2005).
Kca channels have been shown not only to mediate exogenously applied CO- 
induced vasorelaxation but also the endogenously produced gas (Naik and Walker
2003). HO-derived CO induced a dose dependant vasodilatory response of 
isolated mesenteric arterioles from chronically hypoxic rats that was nearly 
eliminated in the presence of iberiotoxin, the BKca channels inhibitor, but not by
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the cGMP inhibitor, ODQ (Naik and Walker 2003). In addition, endogenously 
produced CO hyperpolarized vascular SMC membrane potential of mesenteric 
arteriolar strips and this effect was also inhibited by iberiotoxin. Therefore it is 
sensible to conclude that within mesenteric circulation, the vasodilatory response 
to endogenous CO involves cGMP-independent activation of BKca (Naik and 
Walker, 2003).
It has been hypothesised that the gating of BKca is under the influence of different 
amino acid residues, and the interaction between CO and certain amino acid 
residues, such as histidine, might be responsible for the activation of BKca 
channels by CO (Wang and Wu, 1997; Wang et al., 1998; Jaggar et al, 2005). It 
appears that NO and CO act on different amino acid residues of BKca channel 
proteins of vascular SMCs and the interaction between NO and CO might 
determine the functional status of BKca channels (Wang and Wu 2003).
1.11.4 Modulation o fS K c a  and K a t p  channels by CO
Small conductance K + channels (S K ca) and ATP sensitive K + channels ( K a t p )  
have been involved in mediating the coronary vasodilatation in isolated perfused 
hearts of rats exposed to one week of high CO concentration (Barbe et al., 2002c). 
CO induced vasodilatation of coronary arteries was inhibited by apamine, the 
inhibitor of S K c a , and glibenclamide, a K At p  channel blocker, but not by 
methylene blue, an sGG inhibitor. In addition chronic exposure to CO induced 
hyperpolarization of coronary artery rings. Therefore it was concluded that CO- 
induced vasodilatation of coronary arteries is mediated by cGMP independent 
activation of SKca and K At p  (Barbe et al., 2002c).
1.11.5 Modulation of K y  channels by CO
Voltage dependant K + channel (K y )  current was activated in coronary vascular
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SMCs of rats submitted to three weeks of CO exposure (Barbe et al., 2002b). 
Chronic exposure to CO hyperpolarized isolated coronary artery myocytes in vitro 
and enhanced coronary blood flow ex vivo. Although the connection between 
these actions has not been established, these results point toward a possible role of 
Kv channels in mediating CO-induced coronary vasodilatation (Barbe et al., 
2002b).
1.12 Other Possible Mediators of CO-induced Vasorelaxation
Inhibition of the cytochrome P-450 enzyme pathway, which produces a number of 
vasoconstrictor metabolites, has been presumed as one of the mechanisms by 
which CO mediates its vasorelaxing effects particularly in lamb ductus arteriosus 
(Coceani et al., 1984; Coceani et a., 1988; Coceani et al., 1996). However, the 
role of cytochrome P-450 enzymes pathways in mediating CO-induced 
vasorelaxation was ruled out in rat aortic artery (Wang et al., 1997a; Wang et al., 
1998).
In addition to the previous mechanisms, there are other cellular targets which 
might be involved in CO-induced vasorelaxation. These cellular pathways include 
calcium (Ca2+) channels, voltage-gated Na+ channels, Na+/K+ ATPase and cAMP 
pathway (Wang et al., 1998; Zhao et al., 2002). However, the importance of 
these mechanisms in mediating CO-induced vasorelaxation is controversial and 
many studies are needed to extend our understanding of their roles (Wang et al., 
1998; Zhao et al., 2002).
1.13 Comparative Properties of CO and NO
Both NO and CO share similar properties (Hartsfield et al., 2002). As gases, NO 
and CO have similar solubility in water (2.6 mL/lOOmL and 4.7 mL/100 ml at 20
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°C) and molecular mass (28.01 and 30.01) respectively (Foresti and Motterlini, 
1999; Hartsfield et al., 2002). Both NO and CO are generated from the vascular 
wall via the constitutive and inducible forms of NOS or HO enzymes respectively. 
Both induced vasorelaxation and activate sGC (Foresti and Motterlini, 1999; 
Hartsfield et al, 2002). On the other hand, remarkable differences between CO 
and NO do exist. NO is a free radical and can react with oxygen derived radicals 
to produce toxic free radicals (Maines et al., 1997; Marks et al., 2002a). In 
contrast, CO is not a free radical and therefore cannot induce tissue damage 
associated with inflammation or cytotoxicity to invading pathogen that is elicited 
by free radical species (Maines et al., 1997). NO is very labile, with a biological 
half life of seconds, whereas CO is very stable and highly resistant to 
transformation (Johnson et al., 1999). Unlike NO which binds to both ferrous and 
ferric haemoproteins, CO binds only to ferrous haem (Durante and Schafer, 1998). 
Therefore, CO can work as a more stable and selective signalling molecule 
(Durante and Schafer, 1998).
NO, CO, and O2  differ in their relative affinity for haem (Maines et al, 1997). 
CO binds more firmly to haem than O2 and easily displaces it. NO has a much 
higher affinity for haem than CO and replaces CO from its linkage with haem 
(Maines et al., 1997). In addition the dissociation rate of NO from haemoglobin is 
slower than that of CO. Therefore the affinity of NO to haemoglobin is around 
1500 times that of CO (Foresti and Motterlini, 1999). Interestingly, the affinity of 
CO to haem is enhanced by up to 15 times in the presence of NO (Maines et al., 
1997). In general, the capacity of mammalian tissue to produce CO is high, and in 
some organs such as the brain it is much higher than the NO-generating capacity 
(Maines et al., 1997). Therefore CO may compete with NO for haem binding
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(Maines et al., 1997; Wang et al., 1998).
1.13.1 Interaction between CO and NO
Although much is known about the NO and CO production pathways, how these 
systems interact is less understood (Hartsfield et al., 2002). A number of studies 
have reported the inhibitory effect of HO on NO production (White and Marietta, 
1992; Chakder et al., 1996; Turcanuet al., 1998; Cavicchi et al., 2000). HO can 
decrease NO production by different mechanisms (Maines et al., 1997). Firstly, 
because NOS is a haemoprotein, HO may accelerate catabolism of newly 
synthesised haem and impair the production of NOS. Secondly, NOS is a 
haemoprotein of the cytochrome P-450 type, which is a substrate for HO, hence 
any increase in HO activity would be expected to accelerate the turnover rate of 
NOS. Thirdly, both NOS and HO systems require NADPH as cofactor, and 
reduction of biliverdin to bilirubin also utilizes NAPDH, thus the competition 
would favour the HO system (Maines et al., 1997). CO, at high concentration, 
seems to inhibit NOS activity and NO generation whereas at lower concentrations 
it might induce NO release from the intracellular pool (Thorup et al., 1999).
NO has been shown both to reduce and enhance HO activity (Willis et al., 1995; 
Motterlini et al., 1996). It was reported that both NO donors, and NOS activation, 
augmented HO activity of porcine aortic endothelial cells by various degrees 
(Motterlini et al., 1996). These findings have been supported by other studies 
establishing the stimulatory effect of NO and NO donors on HO production 
(Foresti et al., 2002; Hartsfield et al., 2002). On the other hand, NO donor sodium 
nitroprusside has been shown to reduce haem HO activity in rat brain and spleen 
(Willis et al., 1995). Additionally, the NO donor, molsidomine attenuated the 
accumulation of HO-1 mRNA and protein and the rise in HO activity after
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haemorrhagic shock in rat liver (Hoetzel et al., 2001). The mechanisms 
underlying the modulation of HO by NO are still unclear, and it seems that the 
discrepancy between studies depends on the cellular concentration of HO versus 
NOS, which particular HO isoforms are present, and distinct characteristics of the 
various NO donors used in these studies (Hartsfield et al., 2002).
1.13.2 NO and CO and regulation of vascular tone
To date there is no unifying hypothesis explaining the role played by these two 
gases in regulating vascular tone. For example Morita and colleagues has 
hypothesised that, in normal vasculature, the basal production of CO might be 
lower than NO, and CO is a less potent vasodilator than NO (Morita and 
Kourembanas, 1996). Therefore NO, not CO, might be the predominant regulator 
of vascular integrity under based conditions. However, once endothelial NO 
production is impaired for any reasons, such as hypoxia, vascular SMC-derived 
CO may take over as the important regulator of vascular tone (Morita and 
Kourembanas, 1996). This hypothesis does not fit with the speculations of 
Wang’s group who attempted to explain the coordination between NO and CO in 
vascular tissue differently (Wang et al., 1998). They have hypothesised that 
endothelium derived NO relaxes vascular SMC in a transient and fast reacting 
way, while SMC-derived CO exerts an autocrine and (or) paracrine vascular effect 
to provide long lasting effects. They have assumed that under certain 
physiological or pathophysiological conditions, both gases may cooperate 
together to coordinate the fine tuning of vascular tone. The long acting CO might 
set a basal level of vascular tone, which can be transiently amplified by a brief 
surge of NO. However under other conditions, such as hypoxia, one gas may 
prevail over the other (Wang et al., 1998).
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Foresti and co-workers have brought together these hypothesises by presuming 
that HO/CO and NOS/NO cooperation to maintain cellular haemostasis depends 
on the localization and the physiological or pathophysiological condition being 
considered (Foresti and Motterlini, 1999). Importantly, under certain situations, 
one enzymatic pathway might counter-regulate, compensate or prevail over the 
other (Foresti and Motterlini, 1999).
HO-2
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L-Arginii
Hem oproteins
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CO Biliverdin — ► Bilirubin 
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Figure 1.7. Schematic of the potential regulatory interactions between 
HO/CO and NOS/NO systems(adapted from Hartsfield et al., 2002)
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1.14 Carbon Monoxide Releasing Molecules (CO-RMs)
At present four different approaches have been proposed for examining the 
therapeutic potential of CO (Clark et al, 2003): (1) overexpression of HO gene by 
targeted gene transfer (Abraham et al, 2003); (2) direct administration of CO gas 
(Thiemermann et al, 2001; Otterbein et al, 2002);(3) use of prodrugs, such as 
methylene chloride, that are catabolized largely by hepatic enzymes to generate 
CO (Chauveau et a l , 2002); and (4) transport and delivery of CO by means of 
specific CO carriers (Motterlini et al, 2002a; Motterlini et al, 2003). 
Overexpression of HO gene undoubtedly will increase endogenous CO 
generation but unfortunately it will inevitably be associated with over production 
of biliverdin and iron. Direct inhalation of CO, although it has been shown to have 
therapeutic potential, might have problems related to the systemic effects of CO 
on oxygen transport and delivery (Piantadosi et al, 2002; Thiemermann et al, 
2001). Additionally, the therapeutic use of gas mixtures has significant limitations 
such as the difficulty of storing and delivering CO in a controlled and directed 
way (Motterlini et al, 2005). Methylene chloride (MC) is a prodrug which is 
degraded by cytochrome P450 pathway abundant in hepatocytes, to produce CO 
gas (Chauveau et al, 2002). CO produced from methylene degradation has been 
implicated in inhibiting chronic allogeneic aorta rejection, therefore MC therapy 
has been proposed as a new pharmacological approach for CO delivery (Chauveau 
et al, 2002). However, this approach has significant pitfalls. Firstly, to be 
degraded, MC requires adequate liver function which may be compromised as is 
the case during haemorrhagic shock (Chauveau et al, 2002; Chatteijee et al,
2004). Secondly, at low concentration MC degradation appears to be carcinogenic 
in rodents, and at high concentration MC might have carcinogenic effect on
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human (Chauveau et al., 2002). Thirdly, in addition to CO, MC degradation 
produces also CO2  gas (Chauveau et al, 2002).
It has been hypothesised that the discovery of compounds that can carry and exert 
measurable and safe delivery of CO to biological systems undoubtedly would 
facilitate the development of novel pharmaceutical agents suitable for therapeutic 
applications (Motterlini et al., 2002a; Motterlini et al., 2003). This approach could 
offer significant advantages over the previously mentioned approaches (Motterlini 
et al., 2002a; Motterlini et al., 2003). Therefore, our group have focused on 
developing molecules that are capable of carrying and delivering CO under 
appropriate conditions and function as CO-releasing molecules (CO-RMs). The 
first two compounds initially identified and possessing such prerequisites were the 
carbonyl complexes manganese decarbonyl ([Mn2 (CO)io]) and 
tricarbonyldichloruthenium (II) dimer ([Ru(CO) 3  CI2 D , which have been 
subsequently termed CORM-1 and CORM-2, respectively (Motterlini et al., 
2001; Motterlini et al., 2003). A special myoglobin assay designed by Dr 
Motterlini, has proved the ability of these molecules to release measurable and 
controlled levels of CO (Motterlini et al., 2003). Both compounds could convert 
deoxymyoglobin to carboxyhaemoglobin, which indicates that CO was liberated 
from these metal carbonyls. Furthermore, both compounds exerted effects that are 
similar to those mediated by CO gas, including vasorelaxation, attenuation of 
coronary vasoconstriction and suppression of acute hypertension (Motterlini et al., 
2002a; Motterlini et al., 2003). However, these CO-RMs have significant 
drawbacks. Both are soluble only in organic solvent such as DMSO, and CORM-1 
requires light to induce CO donation (Motterlini et al., 2002a; Motterlini et al.,
2003).
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Subsequently, our group made additional progress by synthesising the first 
prototype of a water soluble CO-RM, which was achieved primarily to overcome 
the solubility problems of CORM-1 and CORM-2 (Motterlini et al, 2002b; Clark 
et al, 2003; Motterlini et al, 2003). This compound, 
tricarbonylchloro(glycinato)ruthenium(II), which has been termed CORM-3, 
could be obtained by coordinating the amino acid glycine onto a metal center 
(Motterlini et al, 2002b; Clark et al, 2003; Motterlini et al, 2003). In vitro, ex 
vivo, and in vivo experimental models have demonstrated that CORM-3 can 
rapidly release CO in biological models (Motterlini et al, 2003). Over the last few 
years, CORM-3 has been shown to have many beneficial effects similar to those 
mediated by CO in different experimental models. CORM-3 protected myocardial 
tissues against ischaemia reperfusion injury both ex vivo and in vivo and 
prolonged the survival of cardiac allografts in rats (Clark et al, 2003; Guo et al,
2004). Additionally, CORM-3 protected against cisplatin induced nephrotoxicity 
(in press) and attenuated the inflammatory response elicited by lipopolysaccaride 
in vitro (Sawle et al, 2005b).
In their unrelenting search for compounds that could be safely used as CO-RMs 
in biological systems and eventually as therapeutic agents, our group has 
identified sodium boranocarbonate Na2[HsBC02], later termed CORM-A1, as a 
new water soluble compound that can spontaneously liberate controllable and 
measurable amounts of CO in aqueous solution (Motterlini et al, 2005). Unlike 
CORM-3, CORM-A1 does not contain a transition metal, and its rate of CO 
release, estimated by myoglobin assay, is slower than that of CORM-3. It is worth 
notice that our group has introduced a new amperometric CO sensor, as a novel 
approach for measuring CO liberated from CO-RMs. The slow pattern of CO loss
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from CORM-A1, estimated by myoglobin assay, was confirmed by this CO 
sensor (Motterlini et al., 2005). The differences between CORM-3 and CORM- 
A l, in terms of chemical structure and kinetic of CO liberation, have tempted us 
to further investigate their possible impacts on the pharmacological effects of both 
molecules.
Later on our group has identified a new water soluble CO-releasing molecules, 
with different chemical structure. ([Fe(CO)4 (T|3-C3H4 Me)]BF4 ), which has been 
designated as CORM-319, is an iron containing metal carbonyl molecule, that 
can release CO spontaneously in aqueous solutions (unpublished data from our 
group).
We believe that the identification of new chemicals that can carry and release 
CO may provide significant information for optimizing therapies based on the use 
of this gaseous molecule. In this thesis we extend our knowledge on the 
bioactivity of CO-RMs in vascular tissue by analyzing the vasorelaxing and 
cytotoxic properties of the CO-RMs mentioned above. In addition, a detailed 
comparison between the possible cellular targets of CORM-A1 and CORM-3, 
molecules is also presented.
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1.15 Hypothesis
The hypothesis being tested is whether the CO released from CORM-3, CORM- 
A l, and CORM-319 can induce vasorelaxation of aortic arteries, and to see 
whether the vasorelaxing properties of CORM-3 and CORM-A1, like that of CO 
gas, are mediated by activation of BKca channels and the sGC/cGMP pathway.
1.16 AIMS
The aims of this project are:
• To study the ability of CORM-3, CORM-A1, and CORM-319, to 
spontaneously release CO in a safe and measured way that can induce 
controllable vasorelaxation in precontracted isolated aortic rings.
• To study the cellular mechanisms mediating the vasorelaxing properties of 
CORM-3 and CORM-A1, and to assess the effect imposed by their 
different pattern of CO release on their pharmacological activities.
• To assess the cytotoxic effects of CORM-3, CORM-A1, and CORM-319 
on aortic artery SMCs in vitro.
• To investigate the effect imposed by a small difference in the chemical 
structure of different iron-containing CO-RMs on their vascular activity 
and cytotoxicity in vitro.
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2 Materials and Methods
2.1 Synthesis of Solutions
2.1.1 Synthesis of tricarbonylchloro(glycinato) ruthenium(II) (CORM-3)
Tricarbonylchloro(glycinato)ruthenium(II) ([Ru(CO)3Cl(glycinate)] or CORM-3 
was synthesized as previously described (Clark et al., 2003). CORM-3 was stored 
in closed vials at -20°C and used freshly on the day of the experiments by 
dissolving the compound in distilled water. Inactive CORM-3 (iCORM-3) was 
obtained by leaving CORM-3 in Krebs-Henseleit buffer overnight at room 
temperature. This treatment produced a compound that does not release CO and, 
therefore iCORM-3 was used as negative control for CORM-3 as already reported 
(Clark et al, 2003). Approximately 1 mol of CO per mol of CORM-3 is liberated 
within 10 min after addition to Krebs Henseleit buffer (Clark et al., 2003; Foresti 
et al, 2004). Throughout our project different batches of CORM-3 with the same 
chemical structure but with little difference in their rate of CO release have been 
used.
2.1.2 Synthesis of sodium boranocarbonate (NailHsBCOz]) (CORM-A1) 
CORM-A1 was prepared as previously described by Alberto and co-workers 
(Alberto et al, 2001). Stock solutions of CORM-A1 were freshly prepared before 
the experiments by dissolving the compounds in pure distilled water. It has been 
noticed that acidic pHs significantly accelerate the spontaneous release of CO 
from CORM-A1 (Motterlini et al, 2005). We therefore took advantage of this 
specific property of CORM-A1 and generated an inactive form (iCORM-Al) to 
be used as negative control by initially dissolving CORM-A1 in 0.1 M HC1 and 
then bubbling pure N2  through the solution for 10 min in order to remove the 
residual CO gas. The solution of iCORM-Al was finally adjusted to pH=7.4 and
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tested with the myoglobin assay prior to experiments to verify its inability to 
liberate CO (Motterlini et al, 2005). At pH 7.4 and room temperature the tm  of 
CO release from CORM-A1, assessed by myoglobin assay and amperometric 
sensor, was 21 min (Motterlini et al., 2005).
2.1.3 Synthesis ofCORM-319 ([Fe(COMTf-C3 H4 Me)]BF4)
This compound was prepared using a method previously described (Dieter et al, 
1981; Enders et al., 2001). A stock solution of CORM-319 was prepared freshly 
on the day of experiment and used within one min to preparation. When the rate 
of CO release from CORM-319 was assessed using myoglobin assay it was shown 
to be relatively slow (t\n 22 min) but it was faster (ti/2  1-2 min) when assessed 
using amperometric CO sensor (unpublished data from our group). One mol of 
CO is approximately released by each molecule of CORM-319. CORM-319 is 
rapidly dissociated in distilled water (within 5 min). The inactive form (iCORM- 
319) was prepared by leaving the CORM-319 in distilled water overnight. This 
treatment produced a compound that does not release CO when assessed by 
myoglobin assay (unpublished data from our group).
2.1.4 Synthesis ofCORM-307 ([Fe(CO)3 l(rf-C}H5)])
CORM-307 was synthesised as previously described (Nesmeyanov et al., 1968). 
CORM-307 was dissolved in DMSO and used freshly on the day of experiment. 
When assessed by myoglobin assay, CORM-307 was found to release CO very 
rapidly (ti/2  ~l-2 min) and approximately one mole of CO is released by one mole 
of CORM-307 (unpublished data from our group). The inactive form (iCORM- 
307), which does not release CO and was used as negative control, was prepared 
in DMSO solution and left at least for 48 h to decompose. The iCORM-307 
solution was finally bubbled with a stream of nitrogen to remove any residual CO
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present in the solution (unpublished data from our group).
2.1.5 Synthesis of CORM-308 ([Fe(CO)iBr(rf -C3 H5 )])
CORM-308 was synthesised as previously described (Murdoch et al., 2004). 
CORM-308 was dissolved in DMSO and used freshly on the day of experiment. 
When assessed by myoglobin assay, CORM-308 was found to release CO rapidly 
(ti/2  ~5 min) and approximately one mol of CO is released by one mol of CORM- 
308 (unpublished data from our group). The inactive form (iCORM-308), which 
does not release CO and was used as negative control, was prepared in DMSO 
solution and left at least for 48 h to decompose. The iCORM-308 solution was 
finally bubbled with a stream of nitrogen to remove any residual CO present in the 
solution (unpublished data from our group).
2.1.6 Synthesis ofCORM-314 ([Fe(CO)3 Cl(tf-C 3 Hs)])
CORM-314 was synthesised as previously described (Murdoch et al, 2004). 
CORM-314 was dissolved in DMSO and used freshly on the day of experiment. 
When assessed by myoglobin assay, CORM-314 was found to release CO very 
rapidly (ti/2  ~1 min) and approximately one mol of CO is released by one mol of 
CORM-314 (unpublished data from our group). The inactive form (iCORM-314), 
which does not release CO and was used as negative control, was prepared in 
DMSO solution and left at least 48 h to decompose. The iCORM-314 solution 
was finally bubbled with a stream of nitrogen to remove any residual CO present 
in the solution (unpublished data from our group).
2.2 Preparation of Aortic Rings
Aortic rings preparation was carried out as previously described (Scott et al, 
1996; Foresti et al, 2004). Male Sprague-Dawley rats (300-400g) were killed by 
cervical dislocation and exsanguination. The thoracic aortic artery was extracted
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and immediately stored in cold Krebs Henseleit solution (4°C). After gentle 
flushing with cold Krebs Henseleit solution, the aorta from each animal was 
cleared of surrounding connective tissue and cut into four rings ~2 mm in length. 
Then the aortic rings were carefully mounted between two stainless steel wires in 
18-ml organ baths. The organic baths contained Krebs Henseleit buffer 
(composition in mM) : (NaCl 118, KC1 4.7, KH2P04 1.2, MgS04.7H20  1.2, 
NaHCOs 22, glucose 11, K+ EDTA 0.03, CaCl2 2.5) and the rings were left to 
equilibrate for 1 h before any experiments were conducted. Then the rings were 
contracted with a standard dose of KCL (110 mM) in order to provide an internal 
reference of contraction. Indomethacin (10 pM) was added to the Krebs Henseleit 
buffer to rule out prostaglandins as potential modulators of vascular tone. The 
buffer was aerated with 95% 0 2-5% C 02 and maintained at 37° C. The isolated 
blood vessels were maintained under a resting tension of 2 g. One wire was fixed 
to a metal handle and the other was attached to an isometric force transducer and a 
Grass model 7D polygraph for continuous recording of tension (Figure 2.1).
Force
transducer
Aortic ring
Krebs buffer Organbath
Figure 2.1. Isolated aortic ring model (from Dr Motterlini)
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2.2.1 Aortic ring preparation group (1): vasoactive properties of CORM-3
To establish the potential vasorelaxant effects of CORM-3, aortic rings were 
precontracted with phenylephrine (1 pM) before addition of CORM-3 at different 
concentrations (25-200 pM). CORM-3 was added three times at 6-10 min 
intervals. In another experiment the response of precontracted aortic rings to one 
addition of CORM-3 (100 pM) was monitored over 1 h. Because CO gas has been 
reported to activate guanylate cyclase to increase the production of cGMP 
(Hussain et al., 1997; Nakatsu et al., 2002), additional experiments were 
conducted to examine the involvement of cGMP in the relaxation mediated by 
CORM-3. For this, aortic rings were incubated with the inhibitor of guanylate 
cyclase ODQ (10 pM) 15 min prior to addition of phenylephrine. The effect of 
CORM-3 on vascular tone was also assessed in the presence of the stimulator of 
soluble guanylate cyclase, YC-1 (1 pM), which was incubated 30 min prior to 
addition of phenylephrine. Preliminary experiments were conducted in order to 
identify the concentration of YC-1 that did not significantly affect the response of 
aortic rings to phenylephrine. Indeed, in our experimental model concentrations of 
YC-1 higher than 1 pM reduced the phenylephrine-mediated contraction by 
various degrees. To investigate the possible involvement of nitric oxide (NO) in 
the relaxation elicited by CORM-3, a separate group of experiments was 
performed by treating aortic rings with the NO synthase inhibitor NG-nitro-L- 
arginine-methyl ester (L-NAME, 100 pM) 30 min prior to addition of 
phenylephrine. Finally, CORM-3 was also tested in endothelium-denuded rings. 
For this purpose, the internal lumen of rings was subjected to gentle rubbing with 
a fine wooden stick, and failure to dilate upon addition of acetylcholine was taken 
as a proof of successful endothelium removal.
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2.2.2 Aortic ring preparation group (2): vasoactive properties of CORM-A1
To establish the potential vasorelaxant effects of CORM-A1, aortic rings were 
precontracted with phenylephrine (1 pM) before addition of the compound at 
different concentrations (40-160 pM). The extent of vasorelaxation over one hour 
was determined and compared with the effect produced by one addition of 
CORM-3 (100 pM). In another set of experiments, the inactive form (iCORM- 
A l) and sodium borohydride (NaBfLO were used as negative control to exclude 
the possibility that vasorelaxation was a non-specific effect of boron compounds 
or borate. In addition myoglobin (80 pM) was added simultaneously with CORM- 
A1 (80 pM) to verify the role of CO in mediating the vasoactivity of CORM-A1. 
Additional experiments were conducted to examine the involvement of cGMP in 
relaxation mediated by CORM-A1. For this purpose, ODQ (30 pM), an inhibitor 
of guanylate cyclase, was added simultaneously with CORM-A1 to contracted 
aortic rings. The effect of CORM-A1 on vascular tone was also assessed in the 
presence of a stimulator of soluble guanylate cyclase, YC-1 (1 pM), which was 
added 30 min before phenylephrine. To investigate the possible involvement of 
NO in the relaxation elicited by CORM-A1, a separate group of experiment was 
performed by treating aortic rings with the NO synthase inhibitor NG-nitro-L- 
arginine-methyl ester (L-NAME, 100 pM) 30 min before addition of 
phenylephrine. CORM-A1 was also tested in endothelium-denuded rings. For this, 
the internal lumen of rings was subjected to gentle rubbing with a fine wooden 
stick and failure to dilate upon addition of acetylcholine was taken as a proof of 
successful endothelium removal.
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2.2.3 Aortic ring preparation group (3): assessment of the role of K* channels 
in mediating the vasorelaxing properties of CORM-3 and CORM-A1.
Potassium (K+)channels, which comprise the most sophisticated ion channel 
superfamily in mammalian cells, play an important role in regulating vascular 
tone and mediating the action of a large number of vasoactive agents (Nelson and 
Quayle, 1995; Cao et al., 2002). K+channel inhibitors, which are invaluable for 
investigating the properties and functional role of K+ channels (Olesen et al., 
1994; Nelson and Quayle, 1995), were used to assess the involvement of different 
K+ channels subgroups in mediating the vasorelaxing properties of CORM-3 and 
CORM-A1. For this purpose transverse sections of aortic rings were prepared as 
described above and divided into six groups. Each group was treated with 
different K+ channel subgroup inhibitors for 30-60 min before contracting the 
rings with phenylephrine (1-1.5 pM) then the response of contracted rings to a 
single addition of CORM-A1 (80 pM) or three consecutive additions of CORM-3 
(100 pM) was measured over time as mentioned above. The first group was 
incubated for 60 min with 30 mM of tetraethyammonium (TEA), a nonslective K+ 
channel inhibitor which blocks K c a, K At p , and K y  channels. The second group of 
rings were pretreated with glibenclamide (GLI 10 pM), the K At p  channel inhibitor 
for 30 min, to assess the involvement of K At p  channels. The third group was 
incubated with 1 mM of 4-aminopyridine (4-AP), a selective K y  channel blocker, 
for 30 min. The fourth group was incubated for 60 min with charybdotoxin (100 
nM), the selective blocker of big conductance Ca+2 activated K+ channels ( B K c a 
channels), whereas the fifth group was incubated with apamine (100 nM), the 
selective inhibitor of small conductance Ca activated K+ channels ( S K c a 
channels). Finally, to confirm the possible involvement of both Kca channel
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subtypes in amplifying the signalling effect of CORM-3 and CORM-A1, a sixth 
group of aortic rings was incubated with both apamine (100 nM) and 
charybdotoxin (100 nM) simultaneously for 60 min before contracting the rings 
with phenylephrine.
Knowing that KC1 at high concentration might selectively block K+ channels, in a 
separate set of experiments we tested the ability of CORM-A1 and CORM-3 to 
induce vasorelaxation in high KC1 contracted rings. For this purpose, groups of 
aortic rings were maximally contracted with KC1 (110 mM) solution, and then the 
response of these rings to a single addition of CORM-A1 (80 pM) or three 
additions of CORM-3 (100 pM) was measured over time.
2.2.4 Aortic ring preparation group (4): vasoactive properties of iron- 
containing CO-RMs
The aortic rings were prepared as described above and the extent of 
vasorelaxation by a single addition of CORM319 (12.5-100pM) over one hour 
was monitored in aortic rings precontracted with phenylephrine (1 pM) and 
compared to the effect induced by iCORM-319 (100 pM), the inactive form 
which does not release CO. Similarly, the vasorelaxing properties of single 
addition of DMSO soluble CORM-307, 308 and 314 (100 pM) were also assessed 
and compared to their inactive forms (iCO-RMs). Vasodilatory response was 
expressed as a percentage of the maximum vasoconstriction induced by 
phenylephrine.
23  Cell Culture
The rat aortic smooth muscle cell line A7r5 was obtained from the European 
Collection of Cell Culture (ECCAC-UK) and was used at passages 12-20 
following supplier’s instruction (Lizard et al., 1999; Zahm et al., 2003). Cell
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were grown and passaged in 75 mm2 plastic culture flasks in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10 % fetal bovine serum, 2 mM 
glutamine, 100 U/ml penicillin and 100 pg/ml streptomycin, pH 7.4, in a 
humidified incubator at 37 C° with 5 % CO2 atmosphere. At 60-80 % confluence, 
which was usually reached after 5-6 days, the culture medium was decanted and 
the monolayer of cells was washed with 10 ml PBS and the cells were released 
from culture flasks using 4 ml Trypsin/EDTA solution. Then the cells were 
resuspended in warm medium solution and centrifuged for 5 min. After that the 
harvested cells were seeded in 75 ml flasks with a split ratio of 1:3.
2.4 Alamar Blue Assay
The harvested A7r5 cells from each flask were suspended in medium solution and 
seeded into two 24 well plates (each well contained 1 ml medium solution) for 24 
h. Next day the medium was removed and a new 1 ml of medium containing the 
required concentration of CO-RM under study was added to each well and left in 
the incubator for 24 h. The following day Alamar Blue solution was prepared 
freshly by dissolving 1 part of Alamar Blue to 9 parts of medium solution to have 
10 % Alamar Blue solution (Nakayama et al., 1997; O'Brien et al, 2000). Then 
the medium containing CO-RM treatment was removed from the plates and 0.5 
ml of 10 % Alamar Blue solution was added to each well. The plates were left in 
the incubator for 3 h; during this period the blue colour of the medium gradually 
changed to pink. After that 200 pM from each well were transferred into 96 wells 
plate in order to be read by microplate reader. Alamar Blue assay is based on the 
detection of metabolic activity, particularly of the metabolic chain reaction, of 
living cells utilizing a redox indicator which changes from oxidized (dark blue) 
form to reduced (red) form (O'Brien et al., 2000; Sawle et al., 2005). The extent
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of this conversion which is proportional to cell metabolism, is calculated as the 
difference in absorbance between 570 and 600 mm and expressed as percentage of 
control (Sawle et al., 2005).
2.4.1 Alamar Blue assay group (1): effect o f CORM-3 on aortic SMCs 
viability
Rat aortic smooth muscle cells (A7r5) were cultured as described above. 
Monolayers of A7r5 cells in 24 wells plates were incubated with CORM-3 (25- 
1000 pM) and iCORM-3 (100-1000 pM) solutions for 24 h. Then the cell 
viability was determined in aortic smooth muscle cells using an Alamar Blue 
viability assay kit as described above.
2.4.2 Alamar Blue group (2): effect o f CORM-A1 on aortic SMCs viability 
Rat aortic smooth muscle cells (A7r5) were cultured as described earlier. 
Monolayers of A7r5 cells in 24 well plates were incubated with CORM-A1 (10- 
1000 pM) and iCORM-Al (100-1000 pM) solutions for 24 h. Then the cell 
viability was determined in aortic smooth muscle cells using an Alamar Blue 
viability assay kit as described above.
2.4.3 Alamar Blue assay group (3): effect o f iron-containing CO-RMs on 
aortic SMCs viability.
Rat aortic smooth muscle cells (A7r5) were cultured as previously described. 
Monolayers of A7r5 cells in 24 well plates were divided into four groups. The 
first group was incubated with CORM-319 (10-500pM) and its inactive form 
iCORM-319 (10-500 pM) for 24 h. The other three groups were treated for 24 h 
with increasing concentrations (10-100pM) of active and inactive forms of 
CORM-307, 308 and 314. Then the cell viability was determined using an Alamar 
Blue viability assay kit as described above.
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2.5 Determination of cGMP Levels
Tissue sample purification, reagent preparation and assay method were conducted 
following manufacture’s instructions.
2.5.1 Tissue sample collection
Male Sprague-Dawley rats (300-400g) were killed by cervical dislocation and 
exsanguination. The thoracic aorta was removed and flushed with Krebs-Henseleit 
buffer and immediately stored in cold Krebs-Henseleit buffer. The aorta from 
each animal was cleared from surrounding tissue and allowed to recover for 1 h in 
oxygenated Krebs-Henseleit buffer before treatment with phenylephrine (1 pM). 
Aortas were immediately immersed in liquid nitrogen at -196°C for 8 min 
following one, two or three consecutive bolus additions of CORM-3 (100 pM), 
each addition given at 8 min intervals. This interval was chosen based on the time 
required by aortic rings to reach a stable relaxation upon addition of CORM-3. 
The aortas were stored at -70°C immediately after collection to prevent alteration 
to the cGMP and associated enzymes before analysis.
2.5.2 Tissue sample purification
The frozen tissue was homogenised in cold 6% (w/v) trichloroacetic acid at 2-8°C 
to give a 10% (w/v) homogenate. The homogenate was centrifuged at 2000xg for 
15 minutes at 4°C, then the supernatant was recovered and the pellet was 
discarded. The supernatant was washed four times with five volumes of water 
saturated diethyl ether. The upper ether layer was discarded after each wash. The 
aqueous extract remaining was dried under a stream of nitrogen at 60°C then it 
was stored at -70°C.
2.5.3 Reagent preparation
Five reagents were prepared for this assay. Assay buffer (500 ml) and wash buffer
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(500 ml) were prepared in distilled water. Standard reagent (92.5ml), antibody 
reagent (11ml) and cGMP conjugate (11ml) were prepared in assay buffer. These 
reagents were used to prepare nine working standard Eppendorf tubes (labelled 2, 
4, 8, 16, 32, 64, 128, 256 and 512) according to manufacture instruction 
(Amersham Biosciences) freshly on the day of assay.
2,5.4 Assay method
Assay buffer and working standards were prepared as described above. Eppendorf 
tubes were labelled for zero, standards and unknowns. These tubes were known as 
acetylation tubes. A 96 well microplate was prepared for running of all blanks, 
standards and samples in duplicate. Acetylation reagent was prepared by adding 1 
volume acetic anhydride to 2 volumes of triethylamine. One ml of diluted assay 
buffer was pipetted into zero standard acetylation tube. One ml of each unknown, 
which were prepared earlier, was pipetted into properly labelled acetylation tubes. 
100 pM of acetylation reagent was added to all acetylation tubes containing 
standards and unknowns. 100 pM of antiserum was pipetted into all wells except 
the blank and non-specific binding (NSB) wells. Then starting with the most 
dilute, duplicates of 50 pi aliquots from all acetylation tubes were pipetted into 
appropriate wells. This step was followed by pipetting 150 pi of assay buffer into 
the non-specific binding wells. Then the plate was incubated at 3-5 C° for two 
hours. Two hours later all wells, except the blank, were pipetted with 100 pi 
diluted conjugate and incubated at 3-5 C° for one hour. Then all wells, after 
aspiration and thorough washing, were pipetted with 200 pi of equilibrated 
enzyme substrate and mixed on microplate shaker for 30 min at room 
temperature. Finally the blue colour that developed was read at 630 nm in 
microplate reader.
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2.6 Chemicals
ltf-(l,2,4)oxadiazole(4,3-a)quinoxalin-l-one (ODQ), glibenclamide and 3-(5'- 
hydroxymethyl-2'-furyl)-l-benzylindazole (YC-1) were from Alexis Corporation 
(Nottingham, U.K.). Alamar Blue viability assay kits were purchased from 
Serotec Inc, Kidlington, Oxford, UK. CORM-3 was synthesised and supplied by 
Professor Brian Mann and co-workers, Department of Chemistry, University of 
Sheffield, Sheffield, UK. CORM-A1 was supplied by Dr Roger Alberto, 
Department of Chemistry, University of Zurich, Switzerland. All other chemicals 
used in the study were from Sigma, unless otherwise specified.
2.7 Statistics
Vasodilatory response was expressed as a percentage of the vasoconstriction 
induced by phenylephrine. Statistical analysis was performed using two-away 
Anova combined with Bonferroni test. Differences were considered to be 
significant at P< 0.05. Statistical analysis of the cell viability was performing 
using one-way Anova combined with Bonferroni test. Differences were 
considered to be significant at P< 0.05.
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3 VASOACTIVE PROPERTIES OF CORM-3
Tricarbonylchloro(glycinato)ruthenium(II), which has been termed CORM-3, is a 
pharmacologically active water-soluble metal carbonyl complex, which was 
obtained by coordinating glycine onto the metal center as shown below 
(Motterlini et al., 2003; Foresti etal., 2004).
T r i c a r b o n y l c h l o r o ( g l y c i n  a t o )  r u t h e n i u m  (II) 
C O R M - 3
Graph 3.1A. Chemical structure of CORM-3 (adapted from Motterlini et al.,
2003)
CORM-3 releases CO in vitro, ex vivo and in vivo biological models (Motterlini et 
al.f 2003) and has been reported to have protective effects against ischaemia- 
perfusion injury in rats and cardiac allograft rejection in mice (Clark et al., 2003). 
Further more, CORM-3 has been shown to attenuate inflammatory response 
elicited by lipopolysaccharide in murine macrophages (Sawle et al., 2005a). 
These results prompted us to further investigate the vasoactive properties of 
CORM-3. For this purpose we investigated the vasorelaxing effect of CORM-3 
on an ex vivo model of isolated aortic rings. In addition we tried to explore the 
possible mechanisms that might mediate the CORM-3-induced vasorelaxation on 
aortic rings. Among different proposed pathways we focused on soluble guanylate
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cyclase (sGC)/cyclic guanosine monophosphate (cGMP) pathway as a possible 
target for CORM-3. The role of endothelium and nitric oxide gas (NO) in 
mediating the vasorelaxing activities of CORM-3 was also investigated in this 
project. Finally we did not forget to assess the effect of CORM-3 on aortic smooth 
muscle cells (SMCs) viability in vitro to rule out any toxic effects for CORM-3 on 
vascular SMCs.
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3.1 Material and Methods
3.1.1 Preparation of CORM-3 solution
CORM-3 was synthesized as previously described (Clark et al., 2003; Motterlini 
et al, 2003). CORM-3 was freshly prepared before the experiments by dissolving 
the compound in distilled water. Inactive CORM-3 (iCORM-3) was obtained by 
leaving CORM-3 in Krebs-Henseleit buffer overnight at room temperature. This 
treatment produced a compound that does not release CO and therefore, iCORM-3 
was used as a negative control to assess the direct involvement of CO in the 
pharmacological actions of CORM-3 (Clark et al., 2003; Foresti et al., 2004). It 
was reported that around 1 mol of CO per 1 mol of CORM-3 is liberated within 
10 min after addition to Krebs-Henseleit buffer (Clark et al, 2003; Foresti et al, 
2004).
3.1.2 Aortic ring preparations
Transverse sections of aortic rings were prepared from adult Sprague-Dawley rats 
(300-400 g) and suspended under 2 g tension in oxygenated Krebs-Henseleit 
buffer as previously described in Materials and Methods (Chapter 2). To establish 
the potential vasorelaxant effects of CORM-3, aortic rings were precontracted 
with phenylephrine (1 pM) before addition of CORM-3 at different concentrations 
(25-200 pM). CORM-3 was added three times at 6-10 min intervals. In another 
experiment the response of precontracted aortic rings to one addition of CORM-3 
(100 pM) was monitored over 1 h. Additional experiments were conducted to 
examine the involvement of cGMP in the relaxation mediated by CORM-3. For 
this purpose, aortic rings were incubated with the inhibitor of guanylate cyclase 
ODQ (10 pM) 15 min prior to addition of phenylephrine. The effect of CORM-3
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on vascular tone was also assessed in the presence of the stimulator of soluble 
guanylate cyclase, YC-1 (1 pM), which was incubated 30 min prior to addition of 
phenylephrine. Preliminary experiments were conducted in order to identify the 
concentration of YC-1 that did not significantly affect the response of aortic rings 
to phenylephrine. Indeed, in our experimental model concentrations of YC-1 
higher than 1 pM reduced the phenylephrine-mediated contraction by various 
degrees. To investigate the possible involvement of nitric oxide (NO) in the 
relaxation elicited by CORM-3, a separate group of experiments was performed 
by treating aortic rings with the NO synthase inhibitor NG-nitro-L-arginine-methyl 
ester (L-NAME, 100 pM) 30 min prior to addition of phenylephrine. Finally, 
CORM-3 was also tested in endothelium-denuded rings. For this purpose, the 
internal lumen of rings was subjected to gentle rubbing with a fine wooden stick, 
and failure to dilate upon addition of acetylcholine was taken as a proof of 
successful endothelium removal.
3.1.3 Determination of aortic cGMP levels
Aortas were collected and allowed to recover for 1 h in oxygenated 
Krebs-Henseleit buffer before treatment with CORM-3. Aortas were freezed- 
clamped 8  min following one, two or three consecutive bolus additions of CORM- 
3 (100 pM), each addition given at 8  min intervals. This interval was chosen 
based on the time required by aortic rings to reach a stable relaxation upon 
addition of CORM-3. Levels of cGMP were measured in aortic tissue extracts 
using a commercial ELISA kit (Amersham) following the manufacturers' 
instructions. Four aortas per group were used for the assay. cGMP levels were 
expressed as fmol mg' 1 of aortic tissue.
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3.1.4 Cell viability assay
Rat aortic smooth muscle cells (A7r5) were cultured as previously described in 
Materials and Methods (Chapter 2). Monolayers of A7r5 cells in 24 wells plates 
were incubated with CORM-3 (25-1000 pM) and iCORM-3 (100-1000 pM) 
solutions for 24 h. Then the cell viability was determined in aortic smooth muscle 
cells using an Alamar Blue assay kit and carried out according to the 
manufacturer’s instructions (Serotec, UK) as previously explained in Material and 
Methods.
3.1.5 Statistical analysis
Vasodilatory response was expressed as percentage of the vasoconstriction 
induced by phenylephrine. Statistical analysis was performed using one-way and 
two-way ANOVA combined with Bonferroni test. Differences were considered to 
be significant at P<0.05.
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3.2 Results
3,2.1 Effect of CORM-3 on vascular tone in vitro
Figure 3.1 shows that CORM3 induced a concentration-dependent vasorelaxation 
on precontracted aortic rings. The vasorelaxing response to first addition of 
CORM-3 (100 pM) was 36.5 % increased to 47.8 % and 52.7 % after second and 
third additions respectively. The relaxation induced by 200 pM CORM-3 did not 
differ significantly from that induced by 100 pM (44.4 vs. 36.5 % after first 
addition respectively). In contrast, iCORM-3 (100 pM) did not elicit evident 
relaxation, demonstrating that CO released from CORM-3 is the factor involved in 
the modulation of vessel tone. The vasorelaxing response to one addition of 
CORM-3 (100 pM) reached the maximum within 10 min and remained sustained 
without recontraction over one hour (Figure 3.2).
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Figure 3-1. Effect of CORM-3 on vascular tone.
This graph shows the vasodilatory response of aortic rings subjected to three 
consecutive bolus additions of CORM-3 at different concentrations (25-200 pM). 
iCORM-3 (100 pM), the negative control, did not cause any evident relaxation. 
Vasodilation is expressed as the percentage of maximal precontraction. Data 
represent the mean ±s.e.m. of 6 - 8  independent experiments. *P< 0.05 compared to 
iCORM-3.
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Figure 3.2. Effect of CORM-3 on vascular tone.
The response of aortic rings precontracted with phenylephrine (1 pM) to one 
addition of 100 pM CORM-3 was monitored over one hour. CORM-3 induced 
significant and sustained vasorelaxation on precontracted rings. Vasodilation is 
expressed as the percentage of maximal precontraction. Data represent the mean 
±s.e.m. of 5-6 independent experiments. *P< 0.05 compared to phenylephrine.
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3.2.2 Involvement of the sGC/cGMP pathway in mediating the vasorelaxing 
effect of CORM-3
The sGC/cGMP pathway has been reported to play an important role in mediating 
the vasorelaxing properties of externally applied or internally produced CO 
(Hussain et al., 1997; Wang et al., 1997a). In this study, the vascular relaxation 
induced by CORM-3 was markedly attenuated by the sGC inhibitor (ODQ 10 
pM) (Figures 3.3). Interestingly, the inhibitory effect of ODQ was partially lost 
following the third addition of CORM-3. In the presence of the sGC activator, 
YC-1, the vasorelaxing properties of CORM-3 was significantly intensified at all 
the CORM-3 concentrations tested (Figures 3.4), further supporting the evidence 
for a direct contribution of cGMP in conducting the vasoactivity of CO. 
Consistent with the fact that ODQ was able to reduce the vasorelaxing effect of 
CORM-3, cGMP levels in aortic tissues were found to be elevated following the 
first and second addition of CORM-3 (100 pM) (Figure 3.5). cGMP was 
significantly augmented from a basal level of 0.26±0.03 (control group, CON) to 
1.23±0.3 and 0.97±0.4 fmol mg- 1  tissue (P<0.05) after the first and second 
addition of CORM-3, respectively. In contrast, addition of a third bolus of 
CORM-3 did not change cGMP levels compared to control (0.27±0.02 fmol mg- 1  
tissue).
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Figure 3-3. Vasorelaxing effect of CORM-3 in the presence of ODQ.
This graph shows the vasodilatory response of aortic rings subjected to three 
consecutive bolus additions of CORM-3 in the presence of ODQ (10 pM). ODQ 
was added to the water bath 15 min prior to the addition of phenylephrine. ODQ 
significantly attenuated the vasorelaxing effect of CORM-3. Dilatation is 
expressed as percentage of precontraction. Data represent the mean±s.e.m. of 6 - 8  
independent experiments. *P<0.05 compared to 100 pM CORM-3 alone.
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Figure 3.4. YC-1 potentiates CORM-3-induced vasorelaxation.
This graph shows the vasodilatory response of aortic rings subjected to three 
consecutive bolus additions of CORM-3 (25 and 100 pM) in the presence of 1 pM 
YC-1. As shown (a and b) the presence of YC-1 potentiated the vasodilatory 
effect of CORM-3 at both concentrations. Data represent the mean ± s.e.m. of 6 - 8  
independent experiments. *P<0.05 compared to CORM-3 alone.
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Figure 3.5. cGMP levels in aortas treated with CORM-3.
Aortas were extracted and subjected to the same treatments with CORM-3 as for 
measurement of isometric tension. At 8 min after the first, second or third addition 
of CORM-3 (100 pM), aortas were frozen and subsequently processed for cGMP 
assay. Control aortas (CON) were treated with vehicle (water). Data represent the 
mean ± s.e.m. of four different aortas per group. *P<0.05 compared to control.
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3.2.3 Effect of CORM-3 on vascular tone of aortic rings pretreated with a NO 
synthase inhibitor or endothelium-denuded rings
To assess the impact of intact endothelium on CORM-3 vasoactivity, CORM-3 
was tested in endothelium-denuded rings. Intriguingly, removal of the endothelial 
layer completely abolished the relaxation elicited by 100 pM CORM-3, and a 
small relaxation was only obtained with higher concentrations of CORM-3 (200- 
400 pM) (Figure 3.6). These findings have prompted us to investigate whether 
endothelium-derived NO has a role in mediating the vasorelaxing effect of 
CORM-3. Interestingly, preincubation of aortic rings with the NO synthase 
inhibitor, L-NAME, significantly reduced the CORM-3-induced vasorelaxation. 
For example, following the first addition, CORM-3 elicited around 37% relaxation 
but the presence of L-NAME decreased the extent of relaxation to 5% (P<0.05). 
Under these conditions, relaxation could be elicited by using much higher 
concentrations of CORM-3 (200 or 400 pM) (Figure 3.7). Taken together, these 
data suggest that endothelium-derived factors, including NO, may interact with 
CORM-3 and potentiate its pharmacological activities.
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Figure 3.6. Removal of the endothelium reduces CORM-3-mediated dilatory 
response.
The endothelium of aortic rings was gently removed (E ) as described in Methods 
and the response to three consecutive bolus additions of CORM-3 at different 
concentrations (100, 200 and 400 pM) was compared to that of intact rings E+. 
The absence of the endothelium markedly reduced CORM-3-mediated 
vasodilation and higher CORM-3 concentration were required to produce 
relaxation. Data represent the mean ± s.e.m. of 6-8 independent experiments. *P 
<0.05 compared to 100 pM CORM-3 in intact endothelium.
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Figure 3.7. Blockade of NO production reduces CORM-3-mediated dilatory 
response.
Aortic rings were incubated with the inhibitor of the NO synthase pathway L- 
NAME (100 pM) for 30 min prior to contraction with phenylephrine. L-NAME 
markedly prevented relaxation caused by 100 pM CORM-3, and higher 
concentration of CORM-3 (200-400 pM) were required to induce dilatation in the 
presence of L-NAME. Data represent the mean ± s.e.m. of 6-8 independent 
experiments. *P <0.05 compared to 100 pM CORM-3 alone.
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3.2.4 Effect o f CORM-3 on SMCs viability
Because CORM-3 contains ruthenium which is a heavy metal and has a potential 
toxic effect, we assessed the effect of CORM-3 on cultured aortic SMCs in vitro. 
We found that up to 500 pM, CORM-3 had little effect on SMCs viability (Figure 
3.8). Additions at higher concentration (1000 pM) of both CORM-3 and iCORM- 
3 resulted in markedly depressed viability of cells. This finding points toward the 
role of chemical components of CORM-3, especially the transitional metal 
ruthenium, rather than released CO in mediating this toxic effect.
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Figure 3.8. Effect of CORM-3 on cell viability.
Aortic SMCs (A7r5) were treated with increasing concentrations of CORM-3 (25- 
1000 pM) and iCORM-3 (100-1000 pM) for 24 h and the change in cell viability 
was assessed using Alamar Blue technique. As shown in figure (a) CORM-3 up to 
500 pM had no significant toxic effect on SMCs. At higher concentration (1000 
pM) CORM-3 induced considerable loss of cell viability. Figure (b) shows that 
the inactive form iCORM-3 was slightly less toxic than CORM-3. Data represent 
the mean ± s.e.m. of 6-12 independent experiments. *P<0.05 compared to control.
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3.3 Discussion
The current project demonstrates the vasorelaxant properties of CORM-3, a 
newly synthesized CO-RM that has been designed to render it water soluble by 
coordinating the amino acid glycine, a biologically compatible ligand , onto the 
metal centre (Motterlini et al., 2003; Clark et al., 2003). Undoubtedly, the water 
solubility is a significant evolution in the design of CORM-3 as the more water- 
soluble the drugs are, the better their absorption and bioavailability when they are 
administrated orally (McFarland et al., 2003; Berger et al., 2004). In contrast the 
previously identified CO-RMs were only DMSO soluble, posing reasonable 
doubts about the potential use of these compounds as therapeutic medicines in 
future. We found that CORM-3 induced concentration-dependant vasorelaxation 
of precontracted aortic rings and this effect was clear starting at 25 pM CORM-3. 
The inactive form of the compound, iCORM-3, which does not release CO 
according to the myoglobin assay, did not induce vasorelaxation. These findings 
point toward CO liberated from CORM-3 as the responsible factor for the 
significant decrease in vascular tone observed in our model of isolated aortic 
rings. Furthermore, the pattern of vasorelaxation elicited by CORM-3 might 
reflect its kinetics of CO liberation according to the myoglobin assay. The finding 
that the half life of CO is around 5 min might explain the significant decrease in 
vascular tone that happened within 10 min from administration of CORM-3 into 
organic baths.
The presence of ODQ, a sGC inhibitor, partially attenuated the vasorelaxation of 
aortic rings induced by CORM-3. This finding indicates that sGC/cGMP is a 
possible cellular mediator of CORM-3-induced vasorelaxation. The role of 
sGC/cGMP pathway was further supported by elevated cGMP levels measured in
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aortic tissues following the addition of CORM- 3. Our data accord with previous 
studies in which it has been proposed that the sGC/cGMP cellular pathway is the 
cellular target of endogenously produced or externally applied CO (Hussain et al, 
1997; Wang et al 1997a; Nakatsu et al, 2002). In addition, the finding that YC-1, 
which has been reported to promote the stimulatory effect of CO on pure sGC, 
remarkably potentiated the vasorelaxing properties of CORM-3, strongly supports 
the role played by sGC/cGMP pathway. In the presence of YC-1 lower 
concentrations of CORM-3 were needed to elicit significant vasorelaxation. 
Similar findings have been observed when external CO was combined with YC- 
1 (McLaughlin et al, 2000). Therefore, the combination of CORM-3 and YC-1 
might have important therapeutic application in vascular diseases.
A remarkable finding of the current study is that the vasorelaxation induced by 
CORM-3 was significantly reduced in endothelium-denuded rings or in rings 
pretreated with L-NAME, a NO synthase blocker. There are three possible 
reasons for this effect. Firstly, NO, alone or combined with other unidentified 
substances produced in the endothelium, synergises with or facilitates the 
vasorelaxing effect of CO released from CORM-3. Secondly, CO released from 
CORM-3 induces release of NO from endothelial storage pools which in turn 
relaxes the aortic ring as formerly suggested in a study conducted on renal 
resistance arteries (Thorup et al, 1999). However, the optimal concentration of 
CO needed to stimulate maximum release of NO in renal arteries was 10 nM, 
which is much lower than that liberated from 100 pM CORM-3, assuming that 
one mole of CO is released by each mole CORM-3 according to myoglobin assay 
(Clark et al, 2003; Foresti et al, 2004). Indeed, the higher the concentrations of 
CO applied to renal arteries, the less NO release was detected (Thorup et al,
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1999). Therefore, the vasorelaxing effect of CORM-3 is unlikely to be solely due 
to stimulation of NO release. Thirdly, NO formed in endothelium might form 
stable complexes with ruthenium, as previously suggested (Mosi et al, 2002; 
Marmion et al, 2004), and weaken the bond between carbonyl groups and the 
transition metal of CORM-3. As a result, CO is easily released from CORM-3 to 
induce vasorelaxation. The last hypothesis is the most relevant as ruthenium has a 
strong affinity for NO and has been proposed as a new therapeutic strategy to 
scavenge NO in some pathological conditions (Mosi et al, 2002; Marmion et al,
2004).
Another important finding in this study is that CORM-3 at concentrations as high 
as 500 pM had no notable toxic effect on aortic SMCs. This means that CORM-3 
at concentrations that cause significant vasorelaxation (50-200 pM) is relatively 
safe to SMCs in vitro. This fact undoubtedly will encourage us to go further in our 
journey toward finding the optimal CORM-3 concentrations that can safely 
modulate vascular tone in vivo. At high concentration of 1000 pM both CORM-3 
and iCORM-3 induced a significant loss in SMCs viability, this finding points 
towards the role of the chemical structure of CORM-3, particularly its heavy 
metal backbone, rather than released CO as mediating these toxic effects.
In conclusion, our study shows that CORM-3 delivers CO and exerts rapid 
endothelium-dependant vasorelaxation ex vivo. It appears that the sGC/cGMP 
pathway and NO produced from endothelium layer play roles in mediating 
CORM-3-induced vasorelaxation. In addition our study shows that CORM-3 at 
concentrations (50-200 pM) that induce significant vasorelaxation ex vivo had no 
notable toxic effect on aortic SMCs viability in vitro. Our findings support the 
idea that water-soluble metal carbonyls could be utilized as prototypic chemicals
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in the development of pharmacologically active compounds capable of delivering 
CO for the control of vascular functions and prevention of hypertension.
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4 Vasoactive Properties of CORM-A1
Sodium boranocarbonate Na2  [H3 BCO2 ], which has been designated CORM-A1, 
is a newly identified water soluble carbon monoxide releasing molecule. Unlike 
CORM-3, CORM-A1 does not contain a transition metal but a boron atom to 
which a carboxyl group (COO ) is covalently bound (Motterlini et al., 2005) 
(Figure 4.1A). Another important difference between COM-A1 and CORM-3 is 
the kinetic of CO release from these water soluble molecules. While CORM-3 has 
been shown to release CO rapidly (within 1-5 min), CORM-A1 has a slower 
pattern of CO release at physiological pH ~ 21 min) (Motterlini et al., 2005).
Figure 4.1A. Chemical structure of sodium boranocarbonate (CORM-A1) 
(adapted from Motterlini et al., 2005).
In this project we studied the vasoactive properties of CORM-A1 and compared it 
to that elicited by CORM-3. For this purpose the aortic ring preparation model 
was used to assess the vasorelaxing properties of CORM-A1 on precontracted 
rings. Furthermore we dedicated a significant part of this study to explore
2- 2 N a+
H
H
H
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underlying mechanisms that might mediate the vascular activities of CORM-A1. 
In particular we focused on the soluble guanylyl cyclase (sGC)/cyclic guanosine 
monophosphate (cGMP) pathway as a potential cellular target. In addition the role 
of nitric oxide (NO) and the vascular endothelium layer in mediating CORM-A1 
induced vasorelaxation was investigated. Finally we studied the effect of CORM- 
A 1 on cultured aortic smooth muscle cell viability to rule out any toxic effect on 
smooth muscle cells.
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4.1 Materials and Methods
4.1.1 Preparation of solutions
CORM-A1 and CORM-3 were prepared as previously described (Alberto et al., 
2001; Clark et al., 2003). Stock solutions of CORM-A1 and CORM-3 were 
freshly prepared before the experiments by dissolving the compounds in distilled 
water. When assessed by a myoglobin assay or by an amperometric CO sensor, 
CORM-A1 has been shown to release CO slowly (lm  ~ 21 min) compared to 
CORM-3 (tj/ 2  1-5 min) (Motterlini et al., 2005). It has been noticed that acidic pH 
significantly accelerated the spontaneous release of CO from CORM-A1. 
Therefore we took advantage of this specific property of CORM-A1 and 
generated a CO-depleted inactive form (iCORM-Al) to be used as negative 
control by initially dissolving CORM-A1 in 0.1 M HC1 and then bubbling pure N2  
through the solution for 10 min in order to remove the residual CO gas. The 
solution of iCORM-Al, which is probably predominantly sodium borate, was 
finally adjusted to pH 7.4 and tested with the myoglobin assay to verify its 
inability to liberate CO (Alberto et al., 2001; Motterlini et al., 2005).
4.1.2 Aortic ring preparation
Transverse ring sections prepared from aortas of male adult Sprague Dawley rats 
(300-400 g) were suspended under 2 g tension in oxygenated Krebs Henseleit 
buffer as previously described in Materials and Methods (Chapter 2). To establish 
the potential vasorelaxant effects of CORM-A1, aortic rings were precontracted 
with phenylephrine (1 pM) before addition of the compound at different 
concentrations (40-160 pM). The extent of vasorelaxation over one hour was 
determined and compared with the effect produced by one addition of CORM-3 
(100 pM). In another set of experiments, the inactive form (iCORM-Al) and
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sodium borohydride (NaBR*) were used as negative control to exclude the 
possibility that vasorelaxation was a non-specific effect of boron compounds or 
borate. In addition myoglobin (80 pM) was added simultaneously with CORM- 
A1 (80 pM) to verify the role of CO in mediating the vasoactivity of CORM-A1. 
Because CO gas has been reported to activate guanylate cyclase to increase the 
production of cGMP (Hussain et al., 1997; Nakatsu et al., 2002), additional 
experiments were conducted to examine the involvement of cGMP in relaxation 
mediated by CORM-A1. For this, ODQ (30 pM), an inhibitor of guanylate 
cyclase, was added simultaneously with CORM-A1 to contracted aortic rings. The 
effect of CORM-A1 on vascular tone was also assessed in the presence of a 
stimulator of soluble guanylate cyclase, YC-1 (1 pM), which was added 30 min 
before phenylephrine. To investigate the possible involvement of NO in the 
relaxation elicited by CORM-A1, a separate group of experiments were 
performed by treating aortic rings with the NO synthase inhibitor N -nitro-L- 
arginine-methyl ester (L-NAME, 100 pM) 30 min before addition of 
phenylephrine. CORM-A1 was also tested in endothelium-denuded rings. For this, 
the internal lumen of rings was subjected to gentle rubbing with a fine wooden 
stick and failure to dilate upon addition of acetylcholine was taken as a proof of 
successful endothelium removal.
4.1.3 Cell viability assay
Rat aortic smooth muscle cells (A7r5) were cultured as previously described in 
Materials and Methods (Chapter 2). Monolayers of A7r5 cells in 24 wells plates
were incubated with CORM-A1 (10-1000 pM) solutions for 24 h. The effect of 
higher concentrations of CORM-A1 (100-1000 pM) were compared with similar 
concentrations of iCORM-Al. Then the cell viability was determined in aortic
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smooth muscle cells using an Alamar Blue assay kit and carried out according to 
the manufacturer’s instructions (Serotec, UK) as previously explained in Material 
and Methods.
4.1.4 Statistical analysis
Vasodilatory responses were expressed as a percentage of the vasoconstriction 
induced by phenylephrine. Statistical analysis was performed using one-way and 
two-way ANOVA combined with Bonferroni test. Differences were considered to 
be significant at P<0.05.
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4.2 Results
4.2.1 Vasodilatory effects o f CORM-A1 in isolated aortic rings 
Figure 4.1 shows the response of aortic rings pre-contracted with phenylephrine 
(Phe) to a single addition of CORM-3 (100 pM) or CORM-A1 (80 pM). As 
shown in this figure, CORM-3 induced rapid relaxation compared to CORM-A1 
which caused a profound but more gradual reduction in the vascular tension. 
Specifically, CORM-A1 promoted a gradual relaxation which was maximal (96%) 
30 min following administration of the molecule to the organ bath whereas 
CORM-3 elicited more than 50% relaxation within 5-10 min. Pre-contracted 
isolated vessels were also treated with increasing concentrations of CORM-A1 
(40, 80 and 160 pM) and changes in vascular tone were recorded over one hour 
(Figure 4.2). It can be observed that CORM-A1 elicited a significant relaxation 
over time in a concentration-dependent manner. For example, the extent of 
vasodilatation mediated by the three concentrations of CORM-A1 after 10 min 
was as follows: 21.0±2.3% with 40 pM CORM-A1, 40.2±3.4% with 80 pM 
CORM-A1 and 74.9±1.8% with 160 pM CORM-A1. The maximal relaxation of 
aortic rings was reached 30 min following addition of CORM-A1; the rings 
spontaneously re-contracted again thereafter but no vasorelaxation was observed 
if a new addition of CORM-A1 was added immediately after re-contraction (data 
not shown). The inactive form (iCORM-Al), which did not release CO, and 
sodium borohydride (NaBFLO, which was used as an additional negative control to 
exclude any effect of boron on vessel tone, failed to induce any relaxation of pre­
contracted aortic rings (Figure 4.3). Furthermore, the addition of myoglobin (80 
pM) to the organ bath markedly reduced the vasorelaxation induced by CORM- 
A1 (Figure 4.4). Taken together, the current results indicate that CO liberated
111
IJCL CHAPTER 4
from CORM-A1 is directly responsible for the observed vascular effect.
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Figure 4.1. Effects of CORM-A1 and CORM-3 on vascular tone.
This graph compares the vasodilatory response of precontracted rings to one 
addition of CORM-3 (100 , ' 3  CORM-A1 (80 pM) over one hour. CORM-3 
induced rapid vasorelaxation which reached a maximum within 10 min whereas 
CORM-A 1 induced a gradual pattern of vasorelaxation that reached a maximum 
after 30 min then the aortic rings recontracted spontaneously. Vasodilatation is 
expressed as percentage of maximal precontraction. Data represent the mean ± 
s.e.m. of 6-8 independent experiments. *P<0.05 compared to CORM-3 100 pM.
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Figure 4.2. Effect of CORM-A 1 on vascular tone.
This graph shows the vasodilatory response of precontracted aortic rings to three 
different concentrations of CORM-A 1 (40, 80, and 160 pM). CORM-A 1 caused 
significant relaxation over time in a concentrated-dependent manner. 
Vasodilatation is expressed as percentage of maximal precontraction. Data 
represent the mean ± s.e.m. of 6-8 independent experiments. *P<0.05 compared to 
CORM-A 1 40 pM.
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Figure 4.3. Effect of CORM-A 1 on vascular tone
This graph shows the vasodilatory effects of 80 pM CORM-A 1 on precontracted 
aortic rings compared to 80 pM iCORM-Al and 80 pM sodium borohydride 
(NaBH4). CORM-A 1 induced a gradual and profound vasorelaxation, whereas 
iCORM-Al and NaBH4 were ineffective. Vasodilatation is expressed as 
percentage of maximal precontraction. Data represent the mean ± s.e.m. of 6-8 
independent experiments. *P<0.05 compared to decomposed CORM-A 1 80pM.
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Figure 4.4. Myoglobin reduces CORM-A1 induced vasorelaxation.
Myoglobin 80 pM was added simultaneously with 80 pM CORM-A 1 to 
precontracted isolated aortic rings. Myoglobin significantly reduced the CORM- 
A1-induced vasorelaxation. Vasodilatation is expressed as percentage of maximal 
precontraction. Data represent the mean ± s.e.m. of 6-8 independent experiments. 
*P< 0.05 compared to CORM-A 1 80 pM.
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4.2.2 CO-mediated vasorelaxation by CORM-A1: possible mechanisms of 
action
In this study, the vasoactivity of CORM-A 1 was partially attenuated in the 
presence of a guanylate cyclase blocker (ODQ, 30 pM) (Figure 4.5). 
Additionally, when aortic rings were pre-incubated with YC-1, which is known to 
sensitize guanylate cyclase to activation by CO (Friebe et al., 1996; Friebe et al, 
1998), the vasorelaxing properties of CORM-A 1 were significantly potentiated at 
all concentrations tested (Figure 4.6). For example, 20 pM CORMA-1 caused 
15.4±5.1% relaxation after 30 min but a more pronounced relaxation response 
(66.7±6.0%, p<0.01) was detected after pre-treatment of vessels with YC-1 (1 
pM). Control vessels pre-treated with YC-1 alone and contracted with 
phenylephrine also exhibited a degree of relaxation over time (25.8±2.5% after 30 
min). Interestingly, the rings treated with CORM-A 1 in combination with YC-1 
did not spontaneously re-contract after reaching the maximal relaxation. 
Collectively, these data sustain the role of guanylate cyclase in mediating the 
vasorelaxing properties of CORM-A 1.
CORM-A 1 was also tested in endothelium-denuded rings to examine the 
contribution of endothelium in CORM-A 1-mediated vasorelaxation (Figure 4.7). 
Interestingly, absence of endothelium had no effect on CORM-A 1 vasoactivity. 
Aortic rings were also pre-incubated with NO synthase inhibitor (L-NAME), to 
assess the involvement of NO in mediating the vasorelaxing properties of CORM- 
A l. Apart from an initial 17±2.4% reduction of the vasorelaxing effect of CORM- 
A l, in the first 10 min, the presence of L-NAME did not significantly change the 
response to CORM-A 1 thereafter (Figure 4.8). Taken together, these results 
suggest that NO and/or factors derived from the endothelium barely contribute to
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the vasodilatory response to CORM-A 1.
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Figure 4.5. Inhibition of sGC pathway reduces CORMA-mediated
vasorelaxation.
ODQ (30 pM) was added simultaneously with 80 pM CORM-A 1 to
precontracted isolated aortic rings. ODQ reduced the CORM-A 1-mediated 
vasorelaxation. Vasodilatation is expressed as percentage of maximal
precontraction. Data represent the mean ± s.e.m. of 10-12 independent
experiments. *P<0.05 compared to CORM-A 1 80 pM.
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Figure 4.6. YC-1 potentiates CORM-A1-induced vasorelaxation.
Rings were incubated with 1 \iM YC-1 30 min prior to addition of phenylephrine. 
Different concentrations of CORM-A 1 (1, 10 and 20 pM) were added. YC-1 
significantly potentiated the vasodilatory effects of all CORM-A 1 concentrations. 
Vasodilatation is expressed as percentage of maximal precontraction. Data 
represent the mean ± s.e.m. of 6-8 independent experiments. *P<0.05 compared to 
CORM-A 1 20 pM.
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Figure 4.7. CORM-A 1 induces endothelium independent vasorelaxation.
CORM-A 1 (80 nM) was added to endothelium denuded aortic rings (E ) and 
endothelium intact aortic rings (E+). CORM-A 1 induced endothelium-independent 
vasorelaxation. Vasodilatation is expressed as percentage of maximal 
precontraction. Data represent the mean ± s.e.m. of 6-8 independent experiments. 
*P<0.05 compared to CORM-A 1 80 \iM E+.
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Figure 4.8. NO synthase inhibitor L-NAME does not affect CORM-A1- 
mediated vasorelaxation.
Aortic rings were incubated with 100 jaM L-NAME 30 min prior to the addition 
of phenylephrine. Apart from mild inhibition at 10 min, L-NAME did not affect 
CORM-A 1-induced vasorelaxation. Vasodilatation is expressed as percentage of 
maximal precontraction. Data represent the mean ± s.e.m. of 6-8 independent 
experiments. *P<0.05 compared to CORM-A 1 80 pM alone.
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4.2.3 Effect o f C0RM-A1 on SMCs viability
The effect of CORM-A 1 on aortic SMCs (A7r5 cell line) was assessed using the 
Alamar Blue technique. We found that even at high concentration (1000 pM), 
CORM-A 1 had no noticeable effect on aortic SMCs viability (Figure 4.9). 
Similarly, the inactive form iCORM-Al up to 500 pM had no significant 
inhibitory effect on aortic SMCs metabolism but at higher concentration (1000 
pM) it induced significant suppression of SMCs metabolism (39±2.9 %) 
compared to CORM-A 1 (13.1±6.1pM) at the same concentration.
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Figure 4.9. Effect of CORM-A 1 on cell viability.
Aortic SMCs (A7r5) were treated with increasing concentrations of CORM-A 1 
(10-1000 pM) and iCORM-Al (100-1000 pM) for 24 h and the change in cell 
viability was assessed using Alamar Blue technique. As shown in figure (a) 
CORM-A 1 up to 1000 pM had no noticeable toxic effect on SMCs. Figure (b) 
shows that the inactive form iCORM-Al up to 500 pM had no effect on cell 
viability but at 1000 pM it was more toxic than CORM-A 1. Data represent the 
mean ± s.e.m. of 6-12 independent experiments. *P<0.05 compared to control.
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4.3 Discussion
In the current study, we represent findings on sodium boranocarbonate 
(Na2 [H3BCC>2 ] as a newly identified CO-RM that spontaneously releases CO with 
a different pattern compared to the ruthenium-based carbonyl CORM-3. When the 
rate of CO release was assessed by myoglobin assay it was found that CORM-A1 
has a slower pattern of CO liberation compared to CORM-3 (Clark et al., 2003; 
Motterlini et al., 2005). Indeed, it is known from our recent work that the release 
of CO from CORM-3 ([Ru(CO)3Cl(glycinate)]) in biological systems occurs very 
rapidly (within 1-5 min) (Clark et al., 2003; Foresti et a l , 2004); as a 
consequence, CORM-3 elicits a correspondingly rapid relaxation in isolated 
vessels. In the case of CORM-A1, its half-life at physiological pH and 
temperature is approximately 21 min (Motterlini et al., 2005). In line with this 
slower release, CORM-A-1 added to isolated aortic rings pre-contracted with 
phenylephrine promoted a gradual and sustained vasorelaxation that was maximal 
after 30 min, whereas CORM-3 caused a profound relaxation within 5-10 min 
after addition to the organ bath. In the current study there is ample evidence which 
points toward the role of CO in mediating the vasorelaxing properties of CORM- 
A l. Firstly, the inactive form, (iCORM-Al), which does not release CO when 
assessed by either myoglobin assay or CO sensor, could not elicit any 
vasorelaxation. Secondly, when precontracted aortic rings were treated with a 
single addition of NaBHj (80 pM), which was used as another negative control to 
verify any possible contribution of boron in the bioactivity mediated by CORM- 
A1 (Motterlini et al., 2005), no significant change in vascular tone was detected. 
Thirdly, myoglobin, a CO scavenger, significantly reduced the extent of 
vasodilatation exerted by CORM-A1, confirming the direct involvement of CO in
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the observed biological effects.
An interesting finding in our result is the recontraction that followed CORM-A1- 
induced relaxation in aortic rings. Almost all aortic rings treated with CORM-A1 
(40-160 pM) elicited spontaneous significant recontraction after around 40 min 
from adding CORM-A1 to the organ bath. The mechanisms underlying this 
contraction are not obvious and possible explanations include: (1) CORM-A1 
compound might have intrinsic vasoconstrictor property but CO-induced 
vasorelaxation suppresses this effect and once the CO effect disappears from the 
system this vasoconstrictive mechanism re-asserts itself; (2) the slow pattern of 
CO release from CORM-A1 might activate other vasoconstriction mechanisms 
which start to elicit their actions after 40 min from adding CORM-A1 to organ 
bath or when the CO effect is completed; (3) it might simply be physical recoil of 
aortic rings as a response to the gradual vasorelaxation. In preliminary 
experiments CORM-A1 (80 pM) failed to induce relaxation in spontaneously 
recontracted aortic rings previously treated with the same concentration of 
CORM-A1. Interestingly, higher concentration of CORM-A1 (160 pM) or 
another vasorelaxing factor (CORM-3 100 pM) was needed to elicit 
vasorelaxation. The possible explanation for this observation is that either CO 
RM-A1 or its released CO might desensitize the cellular receptors that mediate the 
vascular activities of CORM-A1, therefore higher concentrations or other 
vasodilators are needed to activate such receptors.
The presence of YC-1, which is a well-known benzylindazole derivative that 
activates the soluble guanylate cyclase (sGC)/cGMP pathway, markedly amplified 
the extent of vasodilatation caused by CORM-A1 (at concentrations as low as 1
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pM) in isolated aortas. Furthermore, the sGC inhibitor (ODQ), mildly reversed the 
vasorelaxation of aortic rings induced by CORM-A1. Taken together, these 
findings indicate that sGC played a role in mediating the vasorelaxing properties 
of CORM-A1. Interestingly, CORM-A1 in combination with YC-1 did not result 
in recontraction as opposed to CORM-A1 alone. YC-1 might prolong the 
pharmacological action of CORM-A1 or influence vasoconstrictor mechanisms. 
Therefore, we believe that, like CORM-3, a combination of CORM-A1 and YC-1 
might have important therapeutic applications in vascular diseases. A remarkable 
finding of the current study is that absence of endothelium or inhibition of NO 
synthase activity by L-NAME, failed to prevent the vasorelaxing effects of 
CORM-A1. These results suggest that the pharmacological action of CO released 
from CORM-A1 is independent of the endothelial function.
Another important finding of this study is that CORM-A1 up to concentrations as 
high as 1000 pM had no noticeable negative effect on aortic SMCs viability. At 
1000 pM CORM-A1 induced only 13.1±6.1 % suppression of cell metabolism 
compared to 43.9±6.1 % induced by CORM-3. The relative safety of CORM-A1 
on cultured cells will undoubtedly encourage us to go further in our long journey 
to design effective carbon monoxide releasing molecules that can be used safely 
on in vitro, ex vivo and in vivo experimental models. The current results show that 
up to 500 pM, the inactive form (iCORM-Al) had similar effect on SMCs 
viability to that elicited by its active form but at higher concentration iCORM-Al 
induced more suppression on cell metabolism (29.0±2.8 %) than CORM-A1 
(13.1 ±6.1 %). This result does not accord with the result obtained with CORM-3 
where the active form was more toxic than the inactive form at higher 
concentrations. The difference in kinetics of CO release from these CO-RMs
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might explain the discrepancy between their effects on SMCs viability at high 
concentration.
To sum up, the current results show that the water soluble sodium 
boranocarbonate molecule (CORM-A1), promotes gradual endothelium- 
independent vasorelaxation which reflects its gradual pattern of CO release 
compared to CORM-3. This vasorelaxation is partially mediated by activation of 
soluble guanylate cyclase and it appears that NO has little or no role in mediating 
such effect. In addition, CORM-A1 even at high concentrations has no remarkable 
inhibitory effect on cultured aortic SMCs viability. Our data highlight the effect of 
CO release kinetics from different CO-RMs on their pharmacological actions. 
Taken together, these data show that CORM-A1 is another example of carbon 
monoxide releasing molecules that can be further modified to be utilized as 
pharmacologically active compounds capable of delivering CO for the control of 
vascular functions and prevention of hypertension.
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5 The role of K+ channels in regulating vasorelaxing 
properties of water-soluble carbon monoxide releasing 
molecules, CORM-3 and CORM-A1.
Potassium (K+) channels are groups of integral membrane proteins that 
selectively transport K+ across the cell membrane (Korn and Trapani, 2005). They 
have been found in all mammalian cells and have diverse functions in both 
excitable and non excitable cells. In fact K+ channels are more sophisticated than 
any other ion channel super family found in mammalian cells (Cao et al., 2002). 
In arterial smooth muscle cells almost every physiological vasoconstrictor and 
vasodilator has been shown to modulate one type or another of K+ channels 
(Standen and Quayle, 1998). In general most vasoconstrictors and vasodilators 
have multiple pathways of action and among these pathways, K+ channels 
contribute to regulate membrane potential and vascular contractile tone (Standen 
and Quayle, 1998). It is well known that activation of K+ channels in arterial 
smooth muscle cells (SMCs) induces vasodilatation and lowers blood pressure, 
whereas inhibition of these channels leads to vasoconstriction (Nelson and Quayle 
1995). At least four K+ channels subgroups have been identified in vascular SMCs 
(Nelson and Quayle 1995; Standen and Quayle 1998; Korovkina and England 
2002b; Jackson et al., 2005): The first one is Ca+2 activated K + (K c a) channels 
which respond to change in intracellular Ca+2 to regulate intrinsic tone in small 
arteries. It has been proposed that any rise of intravascular pressure through 
membrane depolarization and elevation of intracellular calcium activates Kca 
channels. Activation of Kca leads to K+ efflux, which counteract membrane 
depolarization and vasoconstriction (Brayden and Nelson 1992). K c a channels are 
divided into three groups: big conductance (BKca), intermediate conductance
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(IKca) and small conductance (SKca) channels. The second K+ channels subgroup 
is voltage dependant K+ (Kv) channels which respond to depolarization stimuli. 
Activation of Kv channels causes efflux of K+ ions, which leads to membrane 
hyperpolarization and maintains the resting membrane potential at -40 to - 60 mV 
under physiological situations (Cao et al., 2002). The third subgroup is inward 
rectifier K+ (Kir) channels which appear to mediate external K+-induced 
hyperpolarization and dilatation of resistance arteries (Nelson and Quayle, 1995). 
Finally the fourth subgroup is ATP sensitive K+ ( K a t p )  channels which is 
sensitive to some molecules produced from cellular energy metabolism. Among 
these molecules, nucleotide phosphates (ATP and ADP) are the most common 
(Zhuo et al., 2005). The decrease of intracellular ATP leads to opening of the 
K a t p  channels, which will induce vasodilatation and increase blood flow into 
organs. In vascular SMCs the most abundant K+ channels are BKca and Kv 
channels (Korovkina and England, 2002b).
The role of K+ channels in endothelial cells (EC) is not as well understood as that 
in SMCs. K c a ,  Kv, K a t p  and Kir channels have all been identified in endothelial 
cells (Coleman et al., 2004). In contrast to SMCs, IKca and SKca are abundant in 
EC and it appears that these channels play essential roles in production of 
endothelium-derived hyperpolarizing factor (EDHF) which travels through 
myoendothelial gap junctions to SMCs to induce hyperpolarization and 
vasorelaxation (Coleman et al., 2004).
Among different K+ channel subgroups in vascular SMCs, Kca channel subgroups 
have been supposed to be mediators for carbon monoxide (CO)-induced 
vasorelaxation (Wang et al., 1997b; Zhang et al., 2001a; Wang and Wu 2003; Xi 
et al., 2004). CO appears to modify BKca directly by increasing its sensitivity to
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calcium (Ca2+) ions. In coronary artery, chronic CO exposure has been found to 
enhance 4-aminopyridine (4-AP) current in isolated coronary myocytes and 
because 4-AP, at low concentration, is a general blocker of Kv channels the effect 
of CO on Ky was suggested (Barbe et al., 2002b).
The present study was designed to investigate the potential role of different K+ 
subfamilies in mediating CORMA1 and CORM-3-induced vasorelaxation. For 
this purpose aortic rings were pre-treated with some known K+ channel inhibitors 
before adding CO-RMs and the vascular tone was measured using aortic ring 
preparation model.
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5.1 Material and Methods
5.1.1 Aortic ring preparation
Transverse sections of aortic rings have been prepared as previously described in 
Materials and Methods (Chapter 2). To establish the role of K+ channel subgroups 
in mediating CORM-A1 and CORM-3-induced vasorelaxation, the aortic rings 
were divided into six groups. Each group was treated with different K+ channel 
subgroup inhibitors for 30-60 min before contracting the rings with phenylephrine 
(1-1.5 pM). The response of contracted rings to a single addition of CORM-A1 
(80 pM) or three consecutive additions of CORM-3 (100 pM) was then measured 
over time as described before in Materials and Methods (Chapter 2). The first 
group was incubated with 30 mM tetraethyammonium (TEA), a nonslective K+ 
channel inhibitor, for 60 min. The second group of rings were pretreated with 10 
pM glibenclamide (GLI), a K a t p  channel inhibitor, for 30 min. The third group 
was incubated with 1 mM of 4-aminopyridine (4-AP), a Kv channel inhibitor, for 
30 min. The fourth group of rings was pretreated with 100 nM charybdotoxin 
(CHB), a BKca channel inhibitor, for 60 min. The fifth group was incubated with 
100 nM apamine (APA), a SKcafor 60 min. Finally the sixth group was incubated 
with both apamine (100 nM) and charybdotoxin (100 nM) simultaneously for 60 
min before contract the rings with phenylephrine.
In another set of experiments the ability of CORM-A1 and CORM-3 to induce 
vasorelaxation in high KC1 contracted rings was assessed. For this purpose a 
group of aortic rings was contracted with high KC1 (110 mM) solution then the 
response of these rings to single addition of CORM-A1 (80 pM) or three addition 
of CORM-3 (100 pM) was measured over time.
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5.1.2 Statistical analysis
Vasodilatory responses were expressed as a percentage of the vasoconstriction 
induced by phenylephrine or KC1. Statistical analysis was performed using two- 
way ANOVA combined with Bonferroni test. Differences were considered to be 
significant at P<0.05.
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5.2.1 Effect o f potassium channel blockers on CO-RMs-induced 
vasorelaxation
TEA is a non selective inhibitor of most K+ channel subgroups. At 10 mM 
concentration which was reported to inhibit K At p , K v , K c a channels (Qiu and 
Quilley 2001; Nelson and Quayle 1995) TEA failed to affect the vasorelaxing 
properties of CORM-3 (preliminary results). However, at 30 pM it completely 
reversed the CORM-3-induced vasorelaxation of phenylephrine contracted rings 
(Figure 5.1a) and also significantly attenuated CORM-A1-induced vasorelaxation 
(Figure 5.1b). These findings indicate that K+ channels play a role in mediating 
the vasorelaxing effect of CORM-3 and CORM-A1.
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Figure 5.1A. Nonselective K+ channel blocker, tetraethylammonium (TEA), 
reversed CORM-3-mediated vasorelaxation.
Rings were incubated with 30 mM tetraethylammonium (TEA) 60 min prior to the 
addition of phenylephrine. TEA completely reversed CORM-3-mediated 
vasorelaxation. Vasodilatation is expressed as percentage of maximal 
precontraction. Data represent the mean s.e.m. of 6-8 independent experiments. 
*P<0.05 compared to CORM-3 (100 pM) alone.
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Figure 5.1B. Nonselective K+ channel blocker, tetraethylammonium(TEA), 
attenuated CORMA1-mediated vasorelaxation.
Rings were incubated with 30 mM tetraethylammonium (TEA) 60 min prior to the 
addition of phenylephrine. TEA significantly attenuated CORM-A1 -mediated 
vasorelaxation. Vasodilatation is expressed as percentage of maximal 
precontraction. Data represent the mean s.e.m. of 6-8 independent experiments. 
*P<0.05 compared to CORMA1 (80 pM) alone.
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5 . 2 . 2  Effect o f K a t p  channel inhibitor on CO-RMs induced vasorelaxation.
After establishing the role of K+ channels in mediating the vasorelaxation induced 
by both the CO-RMs under study, the next step was to determine the K+ channel 
subgroups involved in this action. For this purpose the rings were incubated with 
10 pM of the selective K atp channels blocker, glibenclamide (G L I) (Quayle, 
Nelson, and Standen 1997b; Zhuo et al, 2005). G L I significantly inhibited the 
vasorelaxing effect of CORM-3 (Figure 5.2A). For instance, a third addition of 
CORM-3 induced only 21.5 % relaxation of contracted aortic rings pre-treated 
with glibenclamide compared to 52.7 % reduction induced by CORM-3 in control 
rings. On the other hand incubating the aortic rings with glibenclamide had no 
effect on the CORM-A1-induced vasorelaxation (Figure 5.2B). These results 
indicate that vascular K atp channels are cellular targets for the CORM-3 but not 
CORM-A1.
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Figure 5.2A. K At p  channel blocker, glibenclamide, attenuated CORM-3- 
mediated vasorelaxation.
Rings were incubated with 10 pM glibenclamide (GLI) 30 min prior to the 
addition of phenylephrine. Glibenclamide attenuated CORM-3-mediated 
vasorelaxation. Vasodilatation is expressed as percentage of maximal 
precontraction. Data represent the mean s.e.m. of 6-8 independent experiments. 
*P<0.05 compared to CORM-3 (100 pM) alone.
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Figure 5.2B. K At p  channel blocker, glibenclamide, did not affect CORM-A1- 
mediated vasorelaxation.
Rings were incubated with 10 pM glibenclamide (GLI) 30 min prior to the 
addition of phenylephrine. Glibenclamide did not affect CORM-A1-mediated 
vasorelaxation. Vasodilatation is expressed as percentage of maximal 
precontraction. Data represent the mean s.e.m. of 6-8 independent experiments. 
*P<0.05 compared to CORM-A1 (80 pM) alone.
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5.2.3 The role of Ky channels in mediating the vasorelaxing properties of 
CO-RMs.
The role of K y  channels in mediating the vasorelaxing properties of CORM-3 and 
CORM-A1 was assessed in the current study. 4-aminopyridine (4-AP) is perhaps 
the most selective known inhibitor of K v  in vascular smooth muscle cells (Nelson 
and Quayle, 1995). Therefore, aortic rings were pre-treated with 4-AP for 30 min 
before contracting the vessels with phenylephrine. In contrast to glibenclamide, 
the 4-AP significantly attenuated the vascular activity of CORM-A1 but had no 
effect on CORM-3. The maximum vasorelaxation induced by CORM-A1 was 
reduced by 45.4 % from 80.7 % to 35.3 % in the presence of 4-AP. These results 
show that each of these CO-RMs target different K + channel subgroups.
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Figure 5.3A. Ky channel blocker, 4-aminopyrydine, did not affect CORM-3- 
mediated vasorelaxation.
Rings were incubated with ImM 4-aminopyridine (4-AP) 30 min prior to the 
addition of phenylephrine. 4-AP did not affect CORM-3-mediated vasorelaxation. 
Vasodilatation is expressed as percentage of maximal precontraction. Data 
represent the mean s.e.m. of 6-8 independent experiments. *P<0.05 compared to 
CORM-3 (100 pM) alone.
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Figure 5.3B. Ky channel blocker, 4-aminopyrydine, reduced CORM-A1- 
mediated vasorelaxation.
Rings were incubated with ImM 4-aminopyridine (4-AP) 30 min prior to the 
addition of phenylephrine. 4-AP significantly reduced CORM-A1-mediated 
vasorelaxation. Vasodilatation is expressed as percentage of maximal 
precontraction. Data represent the mean s.e.m. of 6-8 independent experiments. 
*P<0.05 compared to CORM-A1 (80 pM) alone.
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5.2.4 The role o f Kca channels in mediating the vasorelaxing properties o f CO- 
RMs
After confirming the role of K a t p  a n d  K v  in mediating the vascular effect of 
CORM-3 and CORM-A1 respectively, we tested the possible involvement of Kca 
channels. For this, aortic rings were treated with charybdotoxin (100 nM), the 
BKca channel inhibitor (Garcia et al., 1995) (Figure 5.4A and B), and apamine 
(100 nM), the SKca channels blocker (Vergara et al., 1998; Coghlan, Carroll, and 
Gopalakrishnan 2001) (Figure 5.5A and B), for one hour before contracting the 
rings with phenylephrine. Charybdotoxin and apamine separately or together 
(figure 5.6A and B) had no significant effects on the vasorelaxing effect induced 
by CORM-3 or CORM-A1. These finding indicate that Kca channel subgroups 
have no significant role in mediating the vasorelaxing action of the CO-RMs 
tested in this study.
141
W L CHAPTER 5
- a - C H B
—  C H B  +  C 0 - R M 3  
C O R M - 3
125n
100
O 75-
o
co
•*->co
o
50-
25-
10 2 3 4
Additions
Figure 5.4A. BKca channel blocker, charybdotoxin, mildly attenuated 
CORM-3-mediated vasorelaxation.
Rings were incubated with 100 nM charybdotoxin (CHB) 60 min prior to the 
addition of phenylephrine. CHB elicited mild effect on CORM-3-mediated 
vasorelaxation. Vasodilatation is expressed as percentage of maximal 
precontraction. Data represent the mean s.e.m. of 6-8 independent experiments. 
*P<0.05 compared to CORM-3 (100 (xM) alone.
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Figure 5.4B. BKca channel blocker, charybdotoxin, did not affect CORM-A1- 
mediated vasorelaxation.
Rings were incubated with 100 nM charybdotoxin (CHB) 60 min prior to the 
addition of phenylephrine. CHB did not affect CORM-A1-mediated 
vasorelaxation. Vasodilatation is expressed as percentage of maximal 
precontraction. Data represent the mean s.e.m. of 6-8 independent experiments. 
*P<0.05 compared to CORM-A1 (80 pM) alone.
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Figure 5.5A. SKCa channel blocker, apamine, did not affect CORM-3- 
mediated vasorelaxation.
Rings were incubated with 100 nM apamine (APA) 60 min prior to the addition of 
phenylephrine. APA did not affect CORM-3-mediated vasorelaxation. 
Vasodilatation is expressed as percentage of maximal precontraction. Data 
represent the mean s.e.m. of 6-8 independent experiments. *P<0.05 compared to 
CORM-3 (100 pM) alone.
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Figure 5.5B. SKCa channel blocker, apamine, did not affect CORM-A1- 
induced vasorelaxation.
Rings were incubated with 100 nM apamine (APA) 60 min prior to the addition of 
phenylephrine. APA did not affect CORM-A1 mediated vasorelaxation. 
Vasodilatation is expressed as percentage of maximal precontraction. Data 
represent the mean s.e.m. of 6-8 independent experiments. *P<0.05 compared to 
CORM-A1 (80 pM) alone.
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Figure 5.6A. Combination of SKca and BKCa has insignificant effect on 
CORM-3-induced vasorelaxation.
Rings were incubated with both 100 nM apamine (APA) and 100 nM 
charybdotoxin (CHB) 60 min prior to addition of phenylephrine. Combination of 
APA and CHB had no significant effect on CORM-3-induced vasorelaxation. 
Vasodilatation is expressed as percentage of maximal precontraction. Data 
represent the mean s.e.m. of 6-8 independent experiments. *P<0.05 compared to 
CORM-3 (100 pM) alone.
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Figure 5.6B. Combination of SKca and BKca has insignificant effects on 
CORM-Al-induced vasorelaxation.
Rings were incubated with both 100 nM apamine (APA) and 100 nM 
charybdotoxin (CHB) 60 min prior to addition of Phe. Combination of APA and 
CHB has no effect on CORMA1-induced vasorelaxation. Vasodilatation is 
expressed as percentage of maximal precontraction. Data represent the mean 
s.e.m. of 6-8 independent experiments. *P<0.05 compared to CORM-A1 (80 pM) 
alone.
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5.2.5 Effect o f CO-RMs on high K*-contracted rings
At high external K+, cell membrane potential and Ek are very close together thus 
preventing any membrane hyperpolarization and relaxation to K+ channel openers 
(Nelson and Quayle, 1995). Here, CORM-3 (100 pM), which has remarkable 
relaxing effect on aortic rings precontracted with phenylephrine, failed to induce 
significant relaxation in high KC1 (110 mM) contracted rings (Figure 5.7A). 
Although the potency of relaxation induced by CORM-A1 in high KCL 
contracted rings was similar to that induced in the rings precontracted with 
phenylephrine, the maximum vasorelaxing effect of CORM-A1 was delayed from 
-30 min in phenylephrine treated rings to -50 min in high K+ contracted rings 
(Figure 5.7B). This data confirm the involvement of K+ channels in mediating the 
vasorelaxing activity of CORM-3 and CORM-A1.
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Figure 5.7A. CORM-3 has little effect on high KC1 contracted rings.
Rings were precontracted with KC1 (110 mM) prior to CORM-3 (100 pM) 
addition. CORM-3 failed to induce significant relaxation in KCL contracted rings. 
The vasorelaxing effect of CORM-3 (100 pM) on KCL precontracted rings were 
compared to the effect induced by same concentration of CORM-3 on Phe 
precontracted rings. Vasodilatation is expressed as percentage of maximal 
precontraction. Data represent the mean s.e.m. of 6-8 independent experiments. 
*P<0.05 compared to CORM-3 (KCL contraction).
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Figure 5.7B. High KC1 delayed CORM-A1-induced vasorelaxation.
Rings were precontracted with KC1 (110 mM) prior to CORM-A1 addition. 
CORM-A1 induced significant vasorelaxation in KC1 pretreated rings but the 
maximum vasorelaxation was delayed to around 50 min after adding CORM-A1. 
Vasodilatation is expressed as percentage of maximal precontraction. Data 
represent the mean ±s.e.m. of 6-8 independent experiments. *P<0.05 compared to 
CORM-A1 (KCL contraction).
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5.3 Discussion
K+ channels have multiple functions in vascular tissues. Among these functions is 
regulation of vascular tone by providing a repolarizing current to counteract and 
balance vasoconstrictive actions (Korovkina and England, 2002b). BKcahas been 
proposed as the main cellular target for endogenously formed or externally 
applied CO (Wang et al., 1997b). Few studies have reported that CO might 
activate Kv, K Atp> and SK ca channels in coronary artery (Barbe et al., 2002b; 
Barbe et al., 2002c).
In this study we investigated the potential role of K+ channels in mediating 
CORM-3 and CORM-A1 vascular activities. The results of this study show that 
K+ channels participate in mediating CORM-3 and CORM-A1-induced 
vasorelaxation. However, it appears that the two CO-RMs target different K+ 
channel subgroups, and possibly through different mechanisms. The failure of 
CORM-3 to relax rings precontracted with high KC1 points toward the possible 
involvement of K+ channels in mediating CORM-3-induced vasorelaxation. 
Furthermore, the fact that TEA, which is a nonslective inhibitor of various K+ 
channels, completely reversed the CORM-3-induced vasorelaxation confirms the 
role of K+ channels in mediating CORM-3-induced vasorelaxation. In the current 
results, the ability of TEA to moderately attenuate the vasorelaxing effect of 
CORMA1, also points toward the role of K+ channels in mediating CORM-A1 
vascular activities. Although high KC1 did not prevent CORM-A1-induced 
vasorelaxation, it delayed its maximum vasorelaxation (from after 30 min in Phe 
precontracted rings to after 50 min in KC1 precontracted rings) which indicate that 
K+ channels might mediate the first part of CORM-A1 -induced vasorelaxation.
The present results show that among different K+ channel subgroups, KAtp
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channels play an important role in mediating the vasorelaxing properties of 
CORM-3. CO released from CORM-3 may activate soluble guanylate cyclase 
enzyme which increase intracellular cGMP. Elevation of intracellular cGMP 
either activates cGMP dependent protein kinase (PKG) or cross activates cAMP- 
dependant protein kinase (PKA) to stimulate K atp channels (Brayden et al., 2002; 
Standen and Quayle, 1998). Although glibenclamide was the only specific K+ 
channel subgroup blocker that attenuated CORM-3-induced vasorelaxation this 
finding does not completely exclude the roles of other K+ channel subfamilies for 
two weighty reasons. Firstly glibenclamide only moderately attenuated CORM-3- 
induced vasorelaxation, whereas TEA and high KC1 reversed it completely or 
significantly (P< 0.05) respectively. Secondly TEA as mentioned before is a 
nonselective blocker of K+ channels which can at different concentrations (lower 
than those used in this study) induce partial block of other K+ channel subtypes 
such as Ky and Kca channels (Nelson et al., 1990). B K c a channels might be 
another mediator of CORM-3-induced vasorelaxation because charybdotoxin in 
the present results showed some inhibitory effect on the vasorelaxing activity of 
CORM-3 (it decreased the maximum vasorelaxation after third addition of 
CORM-3 from 70% to 52%) and this possibility is supported by a reported direct 
effect of CO on Kca in vascular SMCs (Wang et al., 1997b). However, the 
inhibitory effect of charybdotoxin on CORM-3 was not statistically significant 
(P< 0.05). In addition, a combination of charybdotoxin and apamine potentiated, 
instead of attenuating, the CORM-3-induced vasorelaxation. Therefore the 
possible role of Kca in mediating CORM-3-induced vasorelaxation is undermined. 
The other possibility that can explain the gap between the complete and partial 
inhibition of TEA and glibenclamide respectively is that the different K+ channels
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subgroups might interact comprehensively to mediate the vasorelaxing activities 
of CORM-3. This interaction might reflect the sophistication and diversity of K+ 
channels.
The interaction between K+ channels and CORM-A1 seems to be less complex as 
both TEA and 4-AP, elicited similar partial inhibition on CORM-A1-induced 
vasorelaxation and both TEA and high KC1 delayed the maximum vasorelaxation 
induced by CORM-A1. These findings point toward the role of Kv channels in 
mediating the first part of CORM-A1-induced vasorelaxation. CO released by 
CORM-A1 might activate Kv channels directly or indirectly through elevation of 
intracellular cGMP level since cGMP has been suggested to partially participate 
in activating Kv channels (Satake and Shibata, 1997).
Our current results do not support other reported results which accentuate the role 
of Kca in mediating CO-induced vasorelaxation (Kodama et al., 1997; Wang et 
a l , 1997a; Kodama et al., 1997; Wang and Wu 2003; Xi et a l, 2004). There are 
some possible explanations for this difference between our results and those 
presented in other studies. Firstly, although the findings of other studies confirm 
the role of B K ca channels, they did not rule out the role of vascular K v, K atp 
channels as targets for CO activity. Secondly, the expression of different K + 
channel subgroups is highly dependant on the tissue type and developmental age 
(Cao et al, 2002; Nelson and Quayle, 1995; Tang and Wang, 2001; Archer et al, 
1996). Accordingly, the K v  and K Atp not Kca channels might be the dominant 
subgroups in male adult Sprague Dawley rats examined in this study. Thirdly, the 
pattern of CO delivery to vascular tissue might explain the variation regarding the 
role of K+ channel subtypes between our results and those published by other 
groups. Supporting this hypothesis it has been reported that the effect elicited by
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external CO was different from the endogenously produced CO (Hristov et al., 
2004; Naik and Walker, 2003). Additionally, the different patterns of CO release 
from CORM-3 and CORM-A1 (fast versus slow) might explain the difference in 
their cellular target. It seems that CO released rapidly from CORM-3 activates 
K a t p  channel subtypes whereas CO liberated slowly from CORM-A1 preferred 
Kv channels.
Taken together, the present data indicate that K+ channels play a role in CORM- 
A1 and CORM-3-induced vasorelaxation mainly through activation of Kv and 
K a t p  channels respectively. It also shows that the kinetics of CO release from 
different CO-RMs might affect their pharmacological activities.
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6 The Vascular Properties of Iron-Containing Carbon 
Monoxide-Releasing Molecules (CO-RMs)
In this chapter we continued our persistent search for molecules that can be safely 
used as carbon monoxide releasing molecules (CO-RMs) in biological systems. 
Therefore we have identified a new iron containing metal carbonyl molecule, here 
termed CORM-319 as another promising water soluble molecule that can release 
CO spontaneously in aqueous solutions and could be used safely for timed and 
measurable CO delivery into vascular tissue. Using an amperometric CO sensor, 
CORM-319 was found to have a fast pattern of CO release in physiological 
solutions (unpublished data from our group). Using aortic ring preparations we 
studied the vasorelaxing properties of CORM-319 and compared it to another 
three DMSO soluble CO-RMs. These CO-RMs, termed CORM-307, CORM-308 
and CORM-314, are also iron containing metal carbonyls and have very similar 
chemical structures to CORM-319 as shown below.
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Figure 6.1A. Chemical structure of iron-containing CO-RMs (unpublished 
data from our group).
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The only difference between these CO-RMs is the halide (I, Br or Cl) which 
coordinates in trans position to one of the CO groups bound to the metal center. In 
this project, using Alamar Blue technique, we also assessed the effect of iron 
containing CO-RMs on smooth muscle cell (SMCs) viability to see whether the 
difference in chemical structure has significant impact on their toxicity.
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6.1 Materials and Methods
6.1.1 Preparation of solutions
CORM-307, 308, 314 and 319 were prepared as previously described Materials 
and Methods (Chapter 2). Stock solutions of CORM-319 (in distilled water) and 
CORM307, CORM-308 and CORM-314 (in DMSO) were prepared fresh and 
used within one min from preparation. The inactive form of CORM-319 (iCORM- 
319) was obtained by leaving CORM-319 in distilled water overnight at room 
temperature. The inactive forms of the other CO-RMs (iCO-RMs) were obtained 
by leaving them in DMSO for at least 48 h at room temperature. The iCO-RMs 
solutions were finally bubbled with a stream of nitrogen to remove any residual 
CO present in the solution. This inactivation process produced compounds that 
did not release CO. The solutions of iCO-RMs were tested with the myoglobin 
assay prior to experiments to verify its inability to liberate CO (unpublished data 
from our group).
6.1.2 Cell viability
Rat aortic smooth muscle cells (A7r5) were cultured as previously described in 
Materials and Methods (Chapter 2). Monolayers of A7r5 cells in 24 wells plates
were divided into four groups. The first group was incubated with CORM-319 
(10-500pM) and its inactive form iCORM-319 (10-500pM) for 24 h. The other 
three groups were treated for 24 h with increasing concentrations (KMOOpM) of 
active and inactive forms of CORM-307, 308 and 314. Then the cell viability was 
determined in the SMCs using an Alamar Blue assay kit and carried out according 
to the manufacturer’s instructions (Serotec, UK) as previously explained in 
Materials and Methods.
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6.1.3 Aortic ring preparation
Transverse sections of aortic rings were prepared from adult Sprague-Dawley rats 
(300-400 g) and suspended under 2 g tension in oxygenated Krebs-Henseleit 
buffer as previously described in Materials and Methods (Chapter 2). The extent 
of vasorelaxation over one hour elicited by a single addition of CORM319 (12.5- 
100 pM) was monitored in aortic rings precontracted with phenylephrine (1 pM) 
and compared to the effect produced by iCORM-319 (100 pM). The vasorelaxing 
properties of a single addition of DMSO soluble CO-RMs (100 pM) was also 
assessed and compared to their inactive forms (iCO-RMs). The vasodilatory 
response was expressed as percentage of the vasoconstriction induced by 
phenylephrine.
6.1.4 Statistical analysis
Statistical analysis was performed using one-way and two-way ANOVA 
combined with Bonferroni test. Differences were considered to be significant at 
p<0.05.
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6.2 Results
6.2.1 Vasorelaxing properties o f iron-containing CO-RMs
Pre-contracted aortic rings were treated with increasing concentrations of water 
soluble CORM-319 (12.5, 50 and 100 pM) and vasorelaxation was measured at 
different time points. CORM-319 induced fast and concentration-dependant 
vasorelaxation in phenylephrine contracted rings (Figure 6.1). The maximum 
vasorelaxation mediated by CORM-319 was reached after 10 min; this was 
quantified as 19.5+5.8 % at 12.5 pM, 36.4+6.8 % at 50 pM and 57.1+2.7 at 100 
pM. On the other hand, iCORM-319 at 100 pM elicited only slight relaxation 
8.8+6.2 % indicating that CO release from CORM-319 is the factor involved in 
the modulation of vascular tone. To a certain extent the vasorelaxing properties of 
the DMSO soluble CO-RMs were different. For instance, iCORM-307 at 100 pM 
produced very similar vasorelaxing pattern compared to its active form CORM- 
307 at the same concentration (Figure 6.2). Both of them elicited gradual and 
progressive vasorelaxation that reached the maximum 60 min after adding the 
CO-RMs to the organ bath. Therefore, the vasorelaxation induced on the aortic 
rings cannot be contributed only to CO released from CORM-307. The 
vasorelaxing patterns of CORM-308 and CORM-314 were slightly different to 
that obtained with CORM-307. CORM-308 and 314 elicited gradual and 
progressive vasorelaxation which reached maximum after 60 min, whereas their 
inactive forms induced relatively weaker vasorelaxation which reached maximum 
after 10 min and remained more or less stable over the next 50 min (Figure 6.3 
and 6.4).
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Figure 6.1. Effect of CORM-319 on vascular tone.
This graph shows the vasodilatory response of precontracted aortic rings to three 
different concentrations of CORM-319 (12.5, 50, and 100 pM). CORM-319 
caused significant relaxation over time in a concentrated-dependent manner. 
Conversely, iCORM-319 the negative control elicited mild vasorelaxation. 
Vasodilatation is expressed as percentage of maximal precontraction. Data 
represent the mean ± s.e.m. of 5-6 independent experiments. *P<0.05 compared to 
iCORM-319 100 pM.
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Figure 6.2. Effect of CORM-307 on vascular tone.
This graph shows the vasodilatory response of precontracted aortic rings to a 
single addition of CORM-307 (100 pM). CORM-307 caused significant 
relaxation over time in the contracted rings. iCORM-307 the negative control 
elicited similar pattern of vasorelaxation. Vasodilatation is expressed as 
percentage of maximal precontraction. Data represent the mean ± s.e.m. of 5-6 
independent experiments. *P<0.05 compared to iCORM-307 100 pM.
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Figure 6.3. Effect of CORM-308 on vascular tone.
This graph shows the vasodilatory response of precontracted aortic rings to a 
single addition of CORM-308 (100 jxM). CORM-308 caused significant 
relaxation over time in the contracted rings. iCORM-308 the negative control 
elicited weaker vasorelaxation pattern that remain stable over time. Vasodilatation 
is expressed as percentage of maximal precontraction. Data represent the mean ± 
s.e.m. of 5-6 independent experiments. *P<0.05 compared to iCORM-308 100 
pM.
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Figure 6.4. Effect of CORM-314 on vascular tone.
This graph shows the vasodilatory response of precontracted aortic rings to a 
single addition of CORM-314 (100 pM). CORM-314 caused significant 
progressive relaxation which reached maximum after 60 min. iCORM-314 the 
negative control elicited weaker vasorelaxation pattern compared to its active 
form. Vasodilatation is expressed as percentage of maximal precontraction. Data 
represent the mean ± s.e.m. of 5-6 independent experiments. *P<0.05 compared to 
iCORM-314 100 pM.
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6.2.2 Effect o f iron containing CO-RMs on SMCs viability 
The effect of iron containing CO-RMs on cell viability was examined on rat aortic 
smooth muscle cells (A7r5). After 24 h incubation all DMSO soluble CO-RMs 
tested in this study caused complete cell loss at concentrations as low as 10 pM 
(Figure 6.6, 6.7 and 6.8). On the other hand water soluble CORM-319 at 
increasing concentration (10, 50 and 100 pM) was significantly less toxic than the 
other CO-RMs (Figure 6.5). The cell viability of SMCs treated with 100 pM 
CORM-319 for 24 h was 58.8 % whereas other iron containing CO-RMs induced 
100 % loss of SMCs viability at the same concentration. It is worthy of notice that 
at a higher concentration (500 pM) CORM-319 caused almost complete loss of 
cell viability. Compared to CORM-319, the inactive form iCORM319 was 
significantly less toxic especially at higher concentrations. For instance the 
viability rate of SMCs treated with 500 pM iCORM-319 was 60.8 % compared to 
0.79 5% in the cells treated with same concentration of CORM-319 (Figure 6.5). 
Generally inactive forms of CORM-307, 308 and 314 are less toxic than their 
active forms especially at low concentrations (10- 50 pM). These findings point 
toward a role for released CO in mediating the toxic effect of iron containing CO- 
RMs.
164
CHAPTER 6
CORM-319 
iCORM-319
125
100
>  7? 
£  2
S  c
03 O
>  °  
=  O
o  ^
50 100
(MM)
Figure 6.5. Effect of CORM-319 on aortic SMCs viability.
This graph compares the effect of CORM-319 (10-500 pM) and its inactive form 
iCORM-319 on A7r5 cell line viability. As shown in this graph the toxicity of 
CORM-319 increased with rise in concentrations and reached maximum at 500 
pM. the inactive form iCORM-319 was relatively less toxic than CORM-319 
especially at high concentrations. Data represent the mean ± s.e.m. of 4-6 
independent experiments. *P<0.05 compared to CORM-319 (0 pM). +P<0.05 
compared to related concentration of iCORM-319.
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Figure 6.6. Effect of CORM-307 on aortic SMCs viability.
This graph compares the effect of CORM-307 and its inactive form iCORM-307 
on A7r5 cell line viability. CORM-307 induced complete loss cell viability at 10 
pM. iCORM-307 was less toxic than CORM-307 at all tested concentrations. 
Data represent the mean ± s.e.m. of 4-6 independent experiments. *P<0.05 
compared to related concentration of iCORM-307.
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Figure 6.7. Effect of CORM-308 on aortic SMCs viability.
This graph compares the effect of CORM-308 and its inactive form iCORM-308 
on A7r5 cell line viability. CORM-308 induced almost complete loss cell viability 
at 10 pM and its inactive form iCORM-308 had also significant toxic effect 
especially at high concentrations. Data represent the mean ± s.e.m. of 4-6 
independent experiments. *P<0.05 compared to related concentration of iCORM- 
308.
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Figure 6.8. Effect of CORM-314 on aortic SMCs viability.
This graph compares the effect of CORM-314 and its inactive form iCORM-314 
on A7r5 cell line. CORM-314 induced complete loss cell viability at 10 pM. 
iCORM-314 had also significant toxic effect especially at high concentrations. 
Data represent the mean ± s.e.m. of 4-6 independent experiments. *P<0.05 
compared to related concentration of iCORM-314.
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6.3 Discussion
The discovery of new CO-RMs with different chemical characteristics that allow 
the fine modulation of CO release has been proposed to offer more flexibility 
both in terms of cellular targeting and effective therapeutic applications 
(Motterlini et al., 2005). Therefore the discovery of new water soluble iron 
containing CO-RM here termed CORM-319 can be considered as an important 
step toward achieving this target. Although CORM-319 released CO relatively 
slowly when assessed by the myoglobin assay, it has been shown to have a fast 
pattern of CO release when assessed by amperometric CO sensor (ti/2 ~ 1 min) 
(unpublished data from our supervisor). In fact we do not know exactly the 
causes that underlie the discrepancy between the rates of CO released from 
CORM-319 assessed by myoglobin assay from that assessed by CO electrode 
(see Appendix). However we think that the chemical structure of CORM-319 
might play a role in developing these differences. CORM-319 is iron based and it 
is possible that an interaction between iron and the myoglobin happened and this 
interaction might decrease the affinity of myoglobin for CO. Therefore, the rate 
of carbonmonoxyglobin formation was relatively slow compared to that obtained 
by CO electrode. On the other hand, CORM-3 hardly released any CO when 
assessed by CO electrode. Similarly the chemical structure of CORM-3 might 
underlie this discrepancy. We think that the ruthenium backbone of CORM-3 
might precipitate on the CO electrode and decrease the available space for CO 
reading. Thus the rate of CO release assessed by CO electrode was not 
comparable to that evaluated by the myoglobin assay. Interestingly, CORM-A1, a 
very pure salt that does not contain iron or heavy metal, had similar patterns of
169
UCL CHAPTER 6
CO release when assessed by either myoglobin assay or CO electrode. Based on 
these findings, it is sensible to conclude that the chemical structure of a given 
CO-RM should be considered in interpreting data from different CO measuring 
techniques. Therefore we think the CO electrode assay is the best available assay 
to assess the rate of CO release from CORM-319, whereas myoglobin assay is 
the appropriate assay to evaluate the rate of CO liberated from CORM-3. For 
CORM-A1, a pure salt, both assays will have similar results. Thus the fast pattern 
of CO release detected by amperometric CO sensor might explain the 
vasorelaxing properties of CORM-319 on precontracted aortic rings. At 
increasing concentrations (12.5, 50 and 100 pM) CORM-319 elicited fast 
vasorelaxation that reached a maximum after 10 min. Since 100 pM iCORM-319 
elicited only slight and significantly less relaxation these data indicate that CO 
released from CORM-319 is responsible for the observed effect.
Although DMSO soluble CORM-307 induced significant progressive relaxation 
in contracted aortic rings, this vasorelaxation cannot be attributed only to the 
released CO as the inactive form iCORM-307 elicited a similar pattern of 
relaxation. The other two DMSO soluble molecules CORM308 and CORM-314 
elicited gradual and progressive significant vasorelaxation and their inactive 
forms also induced vasorelaxation but it was milder than that elicited by their 
active forms. The difference in vasorelaxing scale between the active and inactive 
forms might point toward a partial role played by CO released from CORM-308 
and 314 in augmenting the vasorelaxing properties of these molecules. However, 
the vasorelaxation induced in contracted rings might be due to damage of aortic 
SMCs as both CORM-308 and 314 caused a complete loss of SMCs viability at 
concentrations as low as 10 pM.
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The current SMCs viability results revealed that water soluble CORM-319 is the 
least toxic molecule among all the iron containing CO-RMs examined in this 
project. Using the Alamar Blue technique, all DMSO soluble CO-RMs induced 
complete loss of SMCs viability at 10 pM concentration, whereas 84.5 % of the 
cells treated with the same concentration of CORM-319 remained alive after 24 h. 
However, the toxicity of CORM-319 increased with rising concentrations. For 
example, CORM-319 induced only 41.2 % decrease in cell viability at 100 pM 
but at 500 pM it induced almost complete loss of cell viability. Another 
interesting finding in our results is that iCORM-319 was significantly less toxic 
than its active form especially at high concentrations (100-500 pM). This finding 
suggests that CO released from high concentrations of CORM319 have potential 
toxic effects on aortic SMCs. Similarly it seems that the CO bound to other iron 
containing CO-RMs plays an important role in boosting their cytotoxicity. 
Bearing in mind that one mol of CORM-319 releases one mol of CO, which is the 
same amount released by one mol from any other water insoluble CO-RMs, it 
seems that the toxicity of a released CO gas can be significantly affected by the 
chemical structure of the CO releasing molecule. That might explains the low 
toxic effect exerted by CO released from 10 pM CORM-319 compared to same 
concentration of CORM-307. Additionally it might explain the different effects 
on SMC imposed by CORM-3 and CORM-319, which are both water soluble and 
appear to have similar patterns of CO release.
In summary, our current results show that CORM-319 which is a new water 
soluble iron containing metal carbonyl is a promising compound that can 
spontaneously deliver CO into vascular tissues. Compared to other water 
insoluble iron containing CO-RMs tested in this study, CORM-319 elicits
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concentration-dependant vasorelaxation at concentrations that are relatively safe 
to aortic SMCs. Our data suggest that CO released from this iron carbonyl 
complex is responsible for the observed vasorelaxation. It also suggests that CO 
released from CORM-319 at high concentrations (100-500 pM) might have 
negative effects on aortic SMCs viability.
Furthermore our current data reveal that the small difference in the chemical 
structure between CORM-319 and the other iron based CO-RMs tested in this 
project has a great impact on their vascular activities.
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7 General Discussion
7.1 Assessment of Methodology
An ex vivo model of aortic ring preparations was used in this project to assess the 
vasorelaxing properties of CO-RMs. In fact isolated vessel preparations have been 
extensively used to examine changes in contractile tension in blood vessels in 
response to various vasoconstricting and vasodilating compound (Jones et al, 
1986; Karaki et al., 1987; Calderone et al., 1996). Many advantages tempted us to 
use this model. Firstly, because the blood vessels are examined in vitro, the 
environment of the vessels can be accurately regulated, whereas many parameters 
can affect the result of in vivo studies (Jones et al., 1986; Karaki et al., 1987). 
Secondly, the concentration of drugs that are added to the bathing medium to 
which the vessels is exposed can be accurately established. Thirdly, in contrast to 
isolated aortic zig-zag or helical strip preparations, the isolated ring technique 
usually conserves the endothelial layer (Pual et al, 1988; Calderone et al., 1996). 
Fourthly, with proper training, the ring preparation is simple to prepare and to 
mount on hooks for recording tension. However, convincing criticism has also 
been directed against this ex vivo model. Firstly, it may be difficult to assess the 
effect of drugs working on presynaptic mechanisms using this preparation (Karaki 
et al., 1987). Therefore, the effect of adrenergic compounds with potential 
vasodilating effects can not be assessed using this technique (Karaki et al, 1987). 
Secondly, the response of isolated blood vessels towards some agent varies 
according to the type of blood vessel and species examined (Jones et al., 1986; 
Karaki et al, 1987; Calderone et a l, 1996). These variations can be attributed to 
the complexity of vascular SMC architecture. Thirdly, though this model has been 
widely employed, there is no unanimous consensus that the physiology of isolated
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blood vessels mimics that of in vivo vessels (Jones et al., 1986). However, 
despites these disadvantages, isolated blood vessel models have provided us with 
very useful results; and in most cases the response of isolated vessels qualitatively 
reflected the response of the blood vessels in vivo (Jones et al., 1986).
In the current project three consecutive additions of CORM-3 were used to assess 
the vasoactive properties of CORM-3 because the vasorelaxing pattern induced by 
CORM-3 usually reached a plateau after 6-8 min. Therefore, second and third 
additions were added to have an accumulative effect of CORM-3. The rings were 
monitored for 8 min after the last addition. On the other hand, only one addition 
of CORM-A1 was used to assess the vasoactivity of CORM-A1 because one 
addition of CORM-A1 was enough to induce almost complete reversal of 
contraction induced by phenylephrine, therefore there was no need to make extra 
additions of CORM-A1. It is worth notice that CORM-A1 was introduced to our 
laboratory around 6 months after CORM-3. The recontraction of aortic rings that 
follow the vasorelaxation induced by CORM-A1 prompted us to monitor the 
effect of CORM-A1 for one hour until the recontraction reach a plateau. Similarly 
we ran a group of experiments (Figure 3.2) to assess the response of 
precontracted aortic rings to one addition of CORM-3 (100 |xM) over one hour. 
The vasorelaxing effect of exogenous CO was not assessed in the present study 
because in our opinion it is difficult to precisely control the amount of CO gas that 
is added to biological preparations. Many studies, analysed in Introduction 
(Chapter 1), have demonstrated the vasorelaxing effect of exogenous CO gas in 
different vascular beds. However, there has been a lack of agreement among 
scientist about the real concentrations of CO gas in physiological buffers. Many 
studies have reported the discrepancy between the calculated concentrations and
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real concentrations measured in experimental buffers. For example in a study 
conducted on cerebral arteries it was demonstrated that the measurable 
concentrations of CO in their experimental models were around 99% less than the 
expected concentrations (Komuro et al., 2001). In another study the concentration 
of CO in the buffer was 50% less than the theoretical one (Marks et al., 2002a). 
Therefore we thought that use of external CO gas would complicate instead of 
clarifying our results.
In the present study, the Alamar Blue technique was used to assess aortic SMCs 
viability in vitro. The one step Alamar Blue assay, which is an indicator of 
mitochondrial metabolic activity, particularly of the metabolic chain reaction, has 
gained popularity as a simple technique to assess the cytotoxiciy of different 
compounds (Nakayama et al., 1997; O'Brien et al., 2000; Miret et al., 2005). It is 
very simple, extremely stable, fast, and least toxic to the cells, accurate and 
sensitive assay providing certain precaution are taken (Nakayama et al., 1997; 
O'Brien et al., 2000; Miret et al., 2005). However, the density of cells examined, 
Alamar Blue dye concentration, incubation time, and the interaction between the 
dye and the compound to be used, can all affect the result of the assay (O'Brien et 
al., 2000; Nakayama et al., 1997). In fact more sensitive assays to evaluate cell 
viability through different pathways have now been introduced, and combinations 
of different assays for different aspects of cell death has been proposed as the best 
way to assess the cytotoxicity of a given compound (Miret et al., 2005). However, 
despite its drawbacks, Alarm Blue assay remains a useful indicator for drug 
toxicity (O'Brien et al., 2000).
7.2 Assessment of the Pharmacological Tools Used in This Study
One major problem in pharmacological research is the insufficient specificity of
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the tools of the trade (Cao et al, 2002). The selective inhibitors used in this study 
to assess the cellular pathways targeted by CORM-3 and CORM-A1 are no 
exception. ODQ, (IH-[l,2,4]oxadiazolo[4,3-a]quinoxaline-l-one), was identified 
by Garthwaite and colleagues, around ten years ago, and considered as first potent 
and selective inhibitor of soluble guanylate cyclase, that does not affect either NO 
nor NO synthase (NOS) activity (Garthwaite et al., 1995). Since that time, ODQ 
has been extensively used as the most selective sGC inhibitor (Cao et al., 2002). 
However, Feelisch and colleagues have shown that ODQ lacks specificity for sGC 
and interferes with other heme proteins such as cytochrome P-450 and NOS 
(Feelisch et al., 1999). Therefore, the authors suggested that particular caution 
should be taken when assessing any vasodilators that might be affected by NOS 
activity (Feelisch et al., 1999). Bearing in mind that in our studies vasorelaxation 
of aortic rings by 100 pM CORM-3 was completely inhibited by L-NAME, the 
NOS inhibitor, and ODQ significantly inhibited the vasorelaxation induced by the 
same concentration of CORM-3, an important question emerged; was the 
inhibitory effect of ODQ on CORM-3 due to cross inhibition of NOS activity? In 
order to rule out this possibility and support the role of cGMP in mediating the 
CORM-3-induced vasorelaxation we tested the direct effect of CORM-3 on 
cGMP production in aortic tissue extracts. CORM-3 significantly increased the 
cGMP production, especially after first and second additions, which correlates 
with the maximum inhibitory effect of ODQ on the vasorelaxation of aortic rings 
after first and second additions of CORM-3. Therefore these results confirm the 
role of the sGC/cGMP pathway in mediating vasorelaxation induced by CORM-3. 
As our results showed that CORM-A1 action was independent of endothelium or 
NOS activity, ODQ was considered an appropriate pharmacological tool to
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confirm the involvement of sGC/cGMP pathway in mediating the vasorelaxing 
effect of CORM-A1.
YC-1 is another pharmacological tool used in this project to verify the 
contribution of sGC/cGMP to CORM-3 or CORM-A1 vascular activity. Several 
reports have described YC-1 as directly activating sGC in vascular SMC and 
platelets (Ko et al., 1994; Friebe et al., 1996; Mulsch et al., 1997). It has been 
widly used as a pharmacological tool to activate sGC/cGMP pathway in cultured 
cells or isolated tissues (Chun et al, 2004). However, YC-1 was shown to have 
cGMP-independent inhibitory effects on Kv and Kca channels in cultured pituitary 
gland cells (Wu et a l, 2000). These results have been expected to confuse the 
interpretation of studies which use YC-1 specifically as an activator of sGC (Wu 
et a l, 2000). This expectation does not seem to apply to our results for two 
reasons: 1) inhibition of Kv and Kca channels depolarizes the vascular wall and 
induces vasoconstriction, which was not the case in our system, where incubating 
the aortic rings with YC-1 attenuated the vasoconstriction induced by 
phenylephrine; 2) YC-1 potentiated the vasorelaxing properties of CORM-3 and 
CORM-A1. Therefore, it is sensible to conclude that the synergistic effect of YC- 
1 with CORM-3 and CORM-A1 was mainly due to activation of sGC/cGMP 
system not to inhibition of Kv and Kca channels. Taken together, we believe we 
can safely say that ODQ and YC-1 were the proper pharmacological tools to 
examine the involvement of sGC/cGMP in mediating the vasorelaxing properties 
of CORM-3 and CORM-A1.
Potassium (K+) channels are perhaps more sophisticated than any other ionic 
channels in vascular SMCs (Cao et al, 2002). K+ channel inhibitors have 
provided us with invaluable information about the properties and functions of K+
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channels (Olesen et al., 1994; Nelson and Quayle, 1995).
Charybdotoxin (ChTX), a minor component of scorpion venom, reversibly blocks 
big conductance calcium-activated K + channels (B K c a) (Miller et al., 1985). 
Charybdotoxin and other Kca inhibitors successors have provided us with unique 
tools not only to investigate the functional role of K + channels but also to develop 
the molecular pharmacology of these channels (Garcia et al, 1995). Although it 
has been shown to block some other K + channels in other tissues, charybdotoxin 
appears to be selective for the Kca channels in arterial SMCs (Nelson and Quayle, 
1995). Charybdotoxin was also reported to inhibit intermediate conductance Kca 
channels (IK ca) (Nelson and Quayle, 1995). However, IK ca do not seem to be 
involved in SM contractile functions. Instead it was suggested to be involved in 
non-excitable functions such as regulation of SMC growth (Neylon et a l, 1999). 
Therefore, we think that charybdotoxin was a proper choice to investigate the 
involvement of BKca in conducting the vasorelaxing properties of CORM-3 and 
CORM-A1.
The functional role of small conductance Kca Channel (SKca) was also assessed in 
this study. Three different subtypes of SKcahave been cloned and identified, SKI, 
SK2, and SK3 (Vergara et a l, 1998; Coghlan et a l, 2001; Liegeois et a l, 2003). 
In fact SKca is classified pharmacologically according to their sensitivity to 
venom toxin apamin, into apamin sensitive and apamin insensitive SKca channels 
(Vergara et al, 1998; Bond et al, 1999; Coghlan et a l, 2001). SK2 and SK3 are 
apamin sensitive, whereas SKI seems to be apamin insensitive (Kohler et a l, 
1996; Vergara et a l, 1998; Coghlan et a l, 2001). The localization and function of 
SKI in vascular tissue is not clear. However, apamin alone or in combination with 
charybdotoxin, has been reported to inhibit arterial relaxations to various
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vasodilators, such as acetylcholine, and L-citrulline in numerous vascular beds 
(Ruiz and Tejerina 1998; Qiu and Quilley 2001). Therefore, in the light of 
available information regarding the SKca channels, apamin remains a reasonable 
choice to study the possible role for SKca in mediating the vasorelaxing properties 
of the CORM-3 and CORM-A1.
Voltage-dependant potassium channels (Kv), widely expressed in vascular tissue, 
are the most sophisticated K+channels subgroup (Cao et al., 2002; Korovkina and 
England, 2002b). 4-aminopyridine (4-AP) is considered the most selective known 
blocker of Kv channels in vascular smooth muscle cells (Nelson and Quayle, 
1995). Therefore, 4-AP has been used to differentiate Kv currents from Kca 
currents, which are also stimulated by membrane depolarization (Nelson and 
Quayle, 1995). 4-AP sensitive Kv channels have been identified in all vascular 
smooth muscle tissues investigated to date (Cole et al, 1996). However 4-AP 
insensitive Kv channels have been identified in some vascular SMCs (Cao et al., 
2002). In rat aortic artery Kv2.1 channel, which is Kv channel subtype sensitive to 
millimolar concentrations of 4-AP, was reported to play an important role in the 
regulation of contractility of rat aorta (Tammaro et al., 2004). Hence, we think 
that 4-AP was essential to assess the involvement of Kv channels in 
vasorelaxation induced by the tested CO-RMs. One of the pitfalls of 4-AP is that 
it might cross inhibit ATP dependant K+ channels ( K a t p )  in vascular tissue 
(Nelson and Quayle, 1995). However, the failure of 4-AP to affect the 
vasorelaxing properties of CORM-3, which was attenuated by K a t p  channel 
inhibition, points toward the absence of a significant inhibitory role of the 4-AP 
on K a t p  in our system.
Arterial K atp channels, the last K + channel subgroup to be examined in this study,
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are important regulators of vascular tone (Sampson et al., 2004). They form a 
focal point for signalling by many modulators of vascular smooth muscle tone 
(Sampson et al., 2004). The K At p  channel is a hetero-octamer comprising two 
subunits: the pore-forming subunit Kir6.x (Kir6.1 or Kir6.2) and the regulatory 
subunit sulfonylurea receptor SUR (SUR1, SUR2A, or SUR2B) (Seino et al., 
1999; Cao et al., 2002; Zhuo et al., 2005). K a t p  channels are inhibited by 
glibenclamide, the oral hypoglycaemic sulfonylurea drug (Nelson and Quayle, 
1995; Quayle et al., 1997b; Sobey et al., 2001; Jackson et al., 2005). 
Glibenclamide appears to be selective for K At p  channels and does not block other 
ion channels (Nelson and Quayle, 1995). However, the affinities of the SUR1, 
SUR2A, and SUR2B to glibenclamide are different (Cao et al., 2002; Zhuo et al., 
2005). It was reported that SUR1 subunit binds glibenclamide with a dissociation 
constant (K<j) around 1 nM, while the Kd of SUR2A subunit is 1.2 pM (Cao et al., 
2002). Therefore, the concentration of glibenclamide used in this study (10 pM), 
would inhibit all SUR subunits.
T etrae thy lam m onium  (TEA) is a  non selective K+ channel b locker u sed  to  
p robe  s tru c tu re  and  functions of K+ ch an n e ls  (S ansom  et al., 2 0 0 2 ; Korn and
Trapani 2005). The TEA can induce a half block of Kca, KATp, and Kv channels at
concentrations ranged from 0.2 to 10 mM (Nelson and Quayle, 1995; Cao et al.,
2002). Therefore, the TEA concentration (30 mM) used in this study would inhibit
all the above mentioned K channels subtypes.
In the current study, TEA completely reversed the CORM-3-induced 
vasorelaxation of aortic rings, whereas glibenclamide partially reversed it, and the 
other K+ channel subtypes inhibitors had no significant effect on CORM-3. There 
are three possibilities for this discrepancy between the effect of TEA and
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glibenclamide. Firstly, the presence of unidentified TEA sensitive K+ channel 
subtypes in aortic SMCs that are not sensitive to the inhibitors used in this study. 
Secondly, the presence of other ion channels or cellular pathways that is sensitive 
to TEA. Thirdly, Kv or Kca channels might provide alternative pathways to 
CORM-3 when K a t p  is blocked. Therefore, once TEA blocked K At p , K v , and K c a  
channels simultaneously, the vasorelaxing effect of CORM-3 was completely 
abolished. On the other hand the interaction between CORM-A1 and K+ channels 
was less complex, as both TEA and 4-AP induced similar partial inhibition of 
CORM-A1- induced vasorelaxation. This suggests the Kv to be the only K+ 
channel subtype targeted by CORM-A1.
Taken together the current results showed that both sGC and K a t p  channels are 
involved in mediating the vasorelaxing properties of CORM-3, whereas sGC and 
Kv channels are involved in that of CORM-A1. The question is how CO-RMs can 
interact with these cellular pathways to induce their actions?
CORM-3, through its released CO, might bind the haem moiety of sGC enzyme 
to induce a four to six fold increase in its activity (Stone and Marietta 1994; 
Kharitonov et al., 1995). sGC catalyzes the conversion of GTP to cGMP which in 
turn stimulates a cascade of reactions ended by smooth muscle cell relaxation 
(Stone and Marietta 1994; Kharitonov et al., 1995; Sharma and Magde 1999). 
CORM-3 can modify K At p  channels either directly or indirectly. Like many other 
identified K a t p  channel openers, CORM-3 might interact with the SUR subunit of 
K a t p  channels (Lawson et al., 2000; Coghlan et al., 2001; Mannhold et al., 2004; 
Moreau et al., 2005). Indeed, SUR within the channel complex provides a major 
pharmaceutical target as it bind many drugs, K a t p  channel openers and blockers, 
capable of up-or down- regulating channel activity (Lawson et al., 2000;
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Mannhold et al., 2004; Moreau et al., 2005). Therefore, CORM-3 might bind 
directly to SUR subunit to activate the channel. Alternatively, CORM-3 might 
indirectly modify K a t p  channels through increased cGMP production which is 
associated with increase in K a t p  channels activity (Kubo et al., 1994; Miyoshi et 
al., 1994; Murphy and Brayden 1995). cGMP, through the subsequent activation 
of protein kinase G (PKG), can influence K At p  channels activity directly, or 
indirectly through cross-activation of protein kinase A (PKA) (Quayle et al., 
1997a; Standen and Quayle, 1998).
In contrast to K At p  channels which have been the most widely explored of the K+ 
channels in terms of their therapeutic potential, there have been relatively few 
reports of the modulation of Kv channels by vasodilator agents in systemic 
vascular smooth muscle (Standen and Quayle 1998; Coghlan et al., 2001). The 
cGMP stimulation has been associated with acetylcholine induced Kv channels 
activation (Satake et al., 1997). In addition it was also reported that 
phosphorylation by PKA, enhance the Kv channel current in vascular smooth 
muscle cells (Aiello et al., 1995; Aiello et al., 1998). In the light of these findings, 
CORM-A1 can activate Kv channels through activation of the cGMP/ PKG 
pathway which might phosphorylate the channel protein directly, or indirectly by 
cross activation of the cAMP/PKA pathway (Aiello et al., 1995; Aiello et al., 
1998). Alternatively, CORM-A1, independent of cGMP, might directly interact 
with Kv channels through mechanisms yet to be defined.
In conclusion, knowing that there is no drug which acts with exclusive specificity, 
and in the light of published studies, we believe we have justified and confirmed 
the importance of compounds used in this study to assess the involvement of 
sGC/cGMP pathway and K+ channels in mediating the vasorelaxing properties of
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CORM-3 and CORM-A1. The current results have shown that sGC is a cellular 
target for both CORM-3 and CORM-A1, whereas each CO-RM activates different 
K + channel subtypes. CORM-3 and CORM-A1 activated K a t p , and K v  channels 
respectively. Each CO-RM might modulate each subunit directly or indirectly 
through sGC/cGMP pathway activation.
7.3 Comparison between the vascular activity elicited by water soluble CO- 
RMs and the CO delivered by other methods
The attitude toward CO has changed dramatically over the last two decades from 
nothing but silent killer to a gas with diverse biological activity and therapeutic 
potential (Johnson et al., 1999; Morse and Choi, 2002). HO enzyme which 
catalyzes the endogenous formation of CO from heme molecules has been 
expressed in almost all life forms, ranging from prokaryotic bacteria and fungi to 
plants and human (Wagener et a l , 2003). Actually, there are no enzymes 
identified to date that are affected by so numerous stimuli of diverse nature as is 
HO-1, the inducible form of HO (Maines et al., 1997). The CO, endogenously 
derived or exogenously applied, is involved in cellular signalling in 
cardiovascular, gastrointestinal, liver, respiratory, inflammatory and nervous 
system (Wang et al., 1997a; Zakhary et al., 1997; Goda et al., 1998; Otterbein et 
al., 2002; Gibbons and Farrugia, 2004). In both systemic and pulmonary 
circulation CO plays an important role in regulating vascular tone under 
physiological and pathological conditions (Wang et al., 1998; Villamor et al., 
2000; Zhao et al., 2002). It attenuates vasoconstriction responses and induces 
vasodilatation of diverse blood vessels with different diameters and from different 
species through different mechanisms. Among different mechanisms proposed to 
elucidate the vasorelaxing properties of CO, activation of sGC/cGMP pathway
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and BKca channels have received significant interest (Wang et al., 1998; Zhang et 
al, 2001b; Zhao et al, 2002; Morse and Choi, 2005). However, despite the 
progress made in understanding the pathophysiological and therapeutic potential 
of CO over the last two decades, it remains incomparable to that of NO gas which 
has been extensively investigated and found its way into clinical practice to treat 
diverse pathological conditions (Moncada and Higgs 1995; Cohen et al, 1999; 
Motterlini et a l, 2002b). The experimental studies on NO have been largely 
facilitated by the development of a wide variety of organic compounds that 
spontaneously release NO and can be easily acquired to produce physiological or 
pathophysiological functions of NO (Feelisch et al, 1998; Ignarro et al, 2002; 
Motterlini et a l, 2003). Undoubtedly, discovery of similar compounds that can 
carry and deliver CO into vascular tissue in safe, measured and controllable way 
will extend our understanding of the chemistry of CO, its interaction with 
intracellular targets, and its importance in physiology and medicine (Motterlini et 
al, 2002b; Motterlini et al, 2003). Recently, Dr Motterlini has discovered the 
ability of some transitional metal carbonyl compounds to release CO into 
physiological solutions. These compounds have been termed CO-releasing 
molecules (CO-RMs) (Motterlini et a l, 2001; Motterlini et a l, 2002a). 
Dimanganese decarbonyl (CORM-1) and tricarbonyldichloro ruthenium (II) dimer 
(CORM-2), proved to be pharmacologically active with functional effects that are 
similar to CO gas, particularly vasorelaxation and suppression of acute 
hypertension. However both molecules are soluble only in an organic solvent such 
as DMSO, and CORM-1 requires light to induce CO release which raises justified 
doubts about their application in vivo. Water solubility is of great importance to 
drugs and there is a universal desire in drug discovery to increase water solubility
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or to decrease hydrophobicity (Berger et al., 2004). Generally the more water- 
soluble the drugs are, the better their bioavailability when they are administrated 
orally (McFarland et al, 2003; Berger et al., 2004). Therefore, it is an advantage 
in designing new drugs to be able to estimate their solubility before their 
preparation as potential new compounds might be removed from consideration if 
their predicted solubility makes them hopeless candidates (McFarland et al., 2003; 
Berger et al., 2004). For these reasons our group intensified their work to discover 
new water soluble CO-RMs that overcome the solubility problem of the first 
generation of CO-RMs. As a result, CORM-3, CORM-A1, and CORM-319, three 
structurally different water soluble CO releasing molecules have been identified 
and produced (Foresti et al., 2004; Motterlini et al, 2005). 
Tricarbonylchloro(glycinato) ruthenium(II) (CORM-3) is a ruthenium based metal 
carbonyl complex that has been shown to spontaneously and relatively rapidly 
release CO into biological buffers (ti/ 2  —1-5 min) (Foresti et al., 2004). Sodium 
boranocarbonate Na2  [H3 BCO2 ] (CORM-A1) is another water soluble molecule 
that releases CO spontaneously into physiological solutions (Motterlini et al., 
2005). However, the rate of CO release from CORM-A1 is slower than that from 
CORM-3 (ti/2 ~ 2  1 min) (Motterlini et al., 2005). The last molecule in this group is 
iron based ([Fe(CO)4 (T|3 -C3H4 Me)]BF4 ) (CORM-319) which quickly releases CO 
into physiological solutions (ti/2  ~ 1 min) when assessed by amperometric CO 
sensor (unpublished data from our group).
In the study presented here we tested the hypothesis that water soluble CORM-3, 
CORM-A1, and CORM-319, like CO, can elicit vasorelaxation in precontracted 
aortic rings. Additionally, we also tried to confirm the hypothesis that CORM-3 
and CORM-A1 mediate their vasorelaxation through activation of sGC/cGMP and
185
UCL GENERAL DISCUSSION
or BKca channels. The results of this project substantiate the first part of this 
hypothesis as all CO-RMs tested in this study induced concentration dependant 
vasorelaxation. However, the mechanisms by which CORM-3 and CORM-A1 
function do not fit completely with our hypothesis. Both of them activated the 
sGC/cGMP pathway but Kv and K At p  channels, not B K c a ,  were the cellular 
targets of CORM-A1 and CORM-3 respectively.
The current results indicate that CO liberated from these molecules is responsible 
for their vasorelaxing effect as the inactive forms (iCO-RMs), which do not 
release CO, did not have any significant effect on vascular tone. Additionally, 
CORM-3 and CORM-319 which have a fast pattern of CO release induced rapid 
vasorelaxation which reached a maximum within 10 min, whereas CORM-A1 
which has a slower pattern of CO release elicited gradual relaxation which 
reached maximum after around 30 min. These findings show that the vasorelaxing 
pattern of the tested CO-RMs reflects their kinetics of CO release.
In this study we showed that similar to HO-derived or externally applied CO gas, 
both CORM-3 and CORM-A1 activate sGC which in turn catalyzed the 
production of cGMP, an important intracellular second messenger that mediates 
the relaxation of vascular smooth muscle cells. On the other hand, the absence of 
a significant role for BKca channels in our project, does not agree with other 
studies elsewhere which reported that CO, either endogenously produced or 
externally applied, primarily targets BKca channels in vascular tissue (Wang et al., 
1997a; Wang et al., 1997b; Naik and Walker, 2003; Wang and Wu, 2003; Dubuis 
et al., 2005 ; Jaggar et al., 2005). There are three possible explanations for this 
discrepancy between our results and these studies. Firstly, although the findings of 
other studies confirm the role of BKca channels, they did not rule out the role of
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vascular K v, K Atp channels as target for CO activity. Secondly, it is well known 
that different K+ channel subtype expression and dominance is highly tissue 
specific (Nelson and Quayle, 1995; Coghlan et al. 2001; Cao et al., 2002; Jackson 
et al., 2005). Furthermore, the expression and function of various K+ channel 
subtypes in the same cultured vascular cells might vary in response to in vitro 
culture conditions (Tang and Wang, 2001). For example BKca current is 
predominant whereas Kv current is a minor component of total outward K+ 
current in freshly dissociated cultured SMCs of rat tail artery. In contrast the Kv 
current was found to the predominant in the same cells after 24 hours incubation 
(Tang and Wang, 2001). Therefore, the role played by BKca channels in mediating 
the vasorelaxing properties of CO in rat tail artery, mesenteric artery and 
pulmonary arteries might reflect the predominance of this K+ channels subtype in 
these vascular bed. Regarding aortic arteries, at least in male Wistar rats. Kv 
channels not charybdotoxin-sensitive channels were shown to play an important 
role in the regulation of excitability and contractility of rat aorta (Tammaro et al., 
2004). Therefore, the activation of K v and K atp channels by CORM-A1 and 
CORM-3 respectively in isolated rings of adult male Sprague Dawley rats might 
be a reflection of the expression and function of these channels in aortic SMCs. 
Generally speaking, K + channels are the most diverse and sophisticated ion 
channels in mammalian cells and their role in mediating the effect of vasorelaxing 
or vasoconstricting agents should be analysed carefully (Cao et al., 2002; 
Mannhold et al., 2004; Tammaro et al., 2004).
Lastly, the pattern of CO delivery to vascular tissue might explain the variation 
regarding the role of K+ channel subtypes between our results and those published 
by other groups. Additionally it might explain the difference between the
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mechanisms of action between CORM-3 and CORM-A1. Here, we tested the 
vascular action of CO gas delivered by water soluble CO-releasing molecules 
while the others assessed the effect of HO-derived or externally applied CO gas. It 
is noteworthy that different effects and mechanisms of action were reported 
between endogenously formed and externally applied CO gas (Naik and Walker, 
2003; Hristov et al., 2004). For example endogenous CO derived from HHL, the 
HO substrate, elicited sGC independent vasorelaxation in mesenteric arterioles, 
whereas exogenous CO-induced vasorelaxation was sGC dependant (Naik and 
Walker 2003). Interestingly, iberiotoxin, the BKca blocker, attenuated the 
vasorelaxing effect of both endogenous and exogenous CO. In another study 
conducted on isolated smooth muscle cells of portal vein, both hemin, the HO 
substrate, and external CO had similar effects, both increased Kca current, 
although hemin was significantly more potent than CO (Hristov et al., 2004). 
Inexplicably, the effect of external CO was sGC dependant, whereas hemin effect 
was sGC independent. Furthermore iron administration or chelating activate or 
suppresses Kca channels respectively. Therefore, it was concluded that the 
stimulatory effect of hemin on Kca was not due to CO production (Hristov et al., 
2004). These two studies confirm that the methods of CO delivery into vascular 
tissue could affect its pharmacological action. Hence, the pattern of CO release by 
CORM-3 and CORM-A1 (fast versus slow) might explain the difference in their 
cellular target. For unknown reasons which need further clarification, it seems that 
CO released rapidly from CORM-3 activates K a t p  channel subtypes whereas CO 
liberated slowly from CORM-A1 preferred Kv channels. Indeed we do not know 
why the fast pattern of CO release activates K a t p  channels, whereas slow pattern 
stimulates the other K + channel subgroup. Physical, electrochemical, or unknown
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mechanisms might lie behind this effect. Surely, a lot of work is needed to 
understand this effect; however we think that this sophisticated work is beyond 
the scope of this thesis.
Another important finding of our study is that CORM-3 and CORM-A1 at 
concentrations higher than those which induced maximum vasorelaxation have no 
toxic effect on cultured aortic SMCs. This result could help to design effective 
carbon monoxide releasing molecules that can be used safely in vivo and clinical 
practice. Such molecules might be of great value to treat diverse vascular diseases 
such as hypertension, coronary heart disease, cerebral and peripheral vascular 
disease. Although CORM-319 elicited mild damage at 50 pM which induced 
moderate vasorelaxation ex vivo, it induced remarkable cytotoxicity at 100 pM 
and completely destroyed the cultured aortic SMCs at 500 pM. However, CORM- 
319 is notably safe if compared with other iron containing CO-RMs tested in this 
project. These water insoluble molecules which have very similar chemical 
structure to CORM-319, completely damaged aortic SMCs at concentrations as 
low as 10 pM. The water insolubility and extreme toxicity of these CO-RMs show 
how a minor difference in the chemical structure of iron containing CO-RMs has 
great impact on their pharmacological activity.
Another important finding in the study presented here is that the toxicity level of a 
given concentration of CO is highly dependant on the chemical structure of the 
releasing molecules. For example, when 500 pM CORM-319 was applied to 
cultured SMCs, it induced around 100 % loss of cell viability, while only 40% 
damage was imposed by iCORM-319, the inactive form which does not release 
CO. This means that the 500 pM of CO gas released by CORM-319 is likely 
responsible for this immense toxicity. However, 500 pM of CORM-A1 which
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release the same amount of CO, had insignificant effect on the cell viability. 
These findings highlight the great importance of developing various CO releasing 
molecules with various structures (ruthenium, boron, or iron based) in 
understanding the biochemical aspects of CO.
In conclusion, our study leads us to substantiate the hypothesis that the water 
soluble CORM-3, CORM-A1 and CORM-319 can induce vasorelaxation of 
precontracted aortic rings, and this effect is most likely mediated through their 
released CO gas. Both CORM-3 and CORM-A1 stimulate the sGC/cGMP 
pathway. However, unlike HO derived or exogenously applied CO gas, CORM-3 
activates K a t p  channel subtypes whereas CORM-A1 activates Kv subtypes. 
Additionally, the data presented here demonstrate the great impact imposed by the 
kinetic of CO release and change in chemical structure on the pharmacological 
activity of CO-RMs. Finally, these results also show that the CORM-3 and 
CORM-A1 are relatively safe when applied to cultured aortic SMCs at 
concentrations higher than those which induced significant vasorelaxation. If this 
safety is supported by further in vitro and in vivo toxicological screening, CORM- 
3 and CORM-A1 might be of great therapeutic value as vasorelaxing drugs. On 
the other hand, the noticeable toxicity of CORM-319 at 100 pM might raise 
questions about its future as an optimal medicine. A modification on the chemical 
structure of CORM-319 might resolve any potential cytotoxicity.
7.4 Conclusions, Reflections and Future Perspectives
CO is an important regulator of vascular tone under both physiological and 
pathological conditions. Therefore, the pharmaceutical modulation of vascular CO 
levels has been speculated to be of great importance in treating vascular disease 
(Morse and Choi, 2005; Abraham and Kappas, 2005). In this project we
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confirmed that the water soluble CORM-3, and CORM-A1 molecules meet the 
criteria of pharmacological active CO carriers that can spontaneously and safely 
release CO into physiological solutions to modulate vascular tone. Undoubtedly, 
the water solubility of these CO-RMs is of great pharmaceutical advantage over 
the first generation of CO-RMs which were soluble only in organic solvents. Our 
attempt to diversify the collection of CO-RMs that have a variety of chemical 
structure (ruthenium, boron, or iron based) and patterns of CO release (fast vs. 
slow release) will help to elucidate the biochemical characteristics of CO, and the 
cellular targets that are responsive to CO and will facilitate the therapeutic 
delivery of CO.
The current work is a significant step in a long journey started when endogenous 
production of CO was discovered for the first time and will be completed by 
optimal therapeutic application of CO in vascular and other diseases, such as 
hypertension and coronary artery disease. The involvement of K+ channels and 
other ion channels or cellular pathways need to be further examined in other 
vascular beds and through additional techniques, for example patch-clamp 
technique. The efficacy, tissue distribution and elimination of the CO-RMs 
presented in this study must be examined in different animal species in vivo. Last 
but not least, comprehensive toxicological studies are essential to approach 
optimal therapeutic concentrations of this gas with a bad history.
Whether the molecules presented in this study in their current shape reach the 
hospital bedside or not, we deeply believe that they are a breakthrough in the 
biomedical field of CO and will provide the base for many other studies 
investigating the biology of CO.
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9 APPENDIX
The pattern of CO released from CORM-319, CORM-3 and CORM-A1 was 
assessed using an amperometric CO sensor (Figure 9.1, 9.4) and myoglobin assay 
(Figure 9.2, 9.3 and 9.5). As mentioned in the text the chemical structure of a 
tested CO-RM should be considered in interpreting the results of any applied 
assay. For example, CORM-319 has a fast pattern of CO release when assessed by 
CO sensor (Figure 9.1), whereas it has a slower pattern of CO release when 
assessed by the myoglobin assay (Figure 9.2). In contrast, CORM-3 hardly 
release any CO when assessed by CO sensor (data not shown), while it had a fast 
pattern of CO liberation when tested by myoglobin assay (Figure 9.3). CORM- 
A1 which is a very pure salt, has similar kinetics of CO release whether measured 
by CO sensor (Figure 9.4) or myoglobin assay (Figure 9.5).
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Figure 9.1 Quantification of CO liberated from CORM-319 using CO 
electrode (from Sandip Bains).
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Figure 9.2 Quantification of CO liberated from CORM-319 using the 
myoglobin assay (from Dr Philip Swale).
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Figure 9.3 Quantification of CO liberated from CORM-3 using myoglobin 
assay (from Dr Philip Swale).
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Figure 9.4 Quantification of CO liberated from CORM-A1 using an 
amperometric CO sensor (from Sandip Bains).
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Figure 9.5 Quantification of CO liberated from CORM-A1 using a 
myoglobin assay (from Dr Philip Sawle).
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